



EMORY UNIVERSITY AND ITS SUBSIDIARIES

Independent Auditors' Reports as Required by the Uniform
Guidance and State of Georgia and Related Information

Year Ended August 31, 2021

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements – Years ended August 31, 2021 and 2020	3
Notes to Consolidated Financial Statements	8
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	37
Supplementary Schedules	
Supplementary Schedule of Expenditures of Federal Awards	39
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	67
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	68
Uniform Guidance Reports	
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards	71
Schedule of Findings and Questioned Costs	74



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees
Emory University:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statements of financial position as of August 31, 2021 and 2020, the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Emory University and its subsidiaries as of August 31, 2021 and 2020, and the changes in their net assets and their cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.



Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 20, 2021 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Atlanta, Georgia
December 20, 2021

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

AUGUST 31, 2021 AND 2020 (Dollars in thousands)

	August 31, 2021	August 31, 2020
ASSETS:		
Cash and cash equivalents	\$ 1,265,377	\$ 1,368,050
Patient accounts receivable, net	607,687	555,349
Student accounts receivable, net	18,616	81,136
Loans receivable, net	18,441	20,783
Contributions receivable, net	180,994	160,429
Other receivables, net	244,847	249,025
Prepaid expenses, deferred charges, and other assets	446,291	446,925
Investments	11,630,104	8,778,088
Interests in perpetual funds held by others	1,848,427	1,670,377
Operating lease right-of-use assets	182,372	212,499
Property and equipment, net	4,015,749	3,629,700
Total assets	\$ 20,458,905	\$ 17,172,361
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 1,001,352	\$ 799,140
CARES Act accrued liabilities	345,829	575,762
Deferred revenue	393,435	326,377
Interest payable	40,843	28,735
Liability for derivative instruments	211,164	270,976
Bonds and notes payable	2,526,137	2,562,915
Accrued liabilities for benefit obligations and professional liabilities	693,038	730,455
Operating lease liabilities	186,260	214,354
Finance lease liabilities	17,624	17,846
Funds held in trust for others	1,239,045	911,138
Annuities payable	15,843	14,677
Government advances for federal loan programs	16,719	19,494
Asset retirement obligations	85,833	82,615
Total liabilities	6,773,122	6,554,484
Net assets without donor restrictions, controlled by Emory	5,495,749	4,355,032
Net assets without donor restrictions related to noncontrolling interests	139,764	104,470
Total net assets without donor restrictions	5,635,513	4,459,502
Net assets with donor restrictions	8,050,270	6,158,375
Total net assets	13,685,783	10,617,877
TOTAL LIABILITIES AND NET ASSETS	\$ 20,458,905	\$ 17,172,361

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF ACTIVITIES

YEAR ENDED AUGUST 31, 2021 (WITH SUMMARIZED COMPARATIVE INFORMATION FOR 2020) (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2021	Total August 31, 2020
OPERATING REVENUE				
Tuition and fees, net of scholarship allowance	\$ 416,618	-	\$ 416,618	\$ 455,077
Sales and services of auxiliary enterprises, net of scholarship allowance	37,715	-	37,715	62,364
Endowment spending distribution	206,255	-	206,255	204,034
Distribution from perpetual funds	40,418	-	40,418	38,797
Other investment income designated for current operations	58,316	-	58,316	59,934
Gifts and contributions for current use	57,704	40,615	98,319	112,473
Grants and contracts	590,964	-	590,964	513,925
Indirect cost recoveries	171,885	-	171,885	153,399
Net patient service revenue	4,803,785	-	4,803,785	4,191,037
Medical services	325,027	-	325,027	254,180
Independent operations	12,519	-	12,519	13,001
Other revenue	613,913	-	613,913	379,438
Net assets released from restrictions	41,581	(18,153)	23,428	14,797
Total operating revenue	7,376,700	22,462	7,399,162	6,452,456
OPERATING EXPENSES				
Salaries	3,601,666	-	3,601,666	3,367,132
Fringe benefits	799,598	-	799,598	714,223
Student financial aid	28,678	-	28,678	27,302
Other operating expenses	2,347,090	-	2,347,090	2,100,859
Interest on indebtedness	74,959	-	74,959	72,764
Depreciation and amortization	315,406	-	315,406	303,345
Total operating expenses	7,167,397	-	7,167,397	6,585,625
NET OPERATING ACTIVITIES	209,303	22,462	231,765	(133,169)
NONOPERATING ACTIVITIES, NET				
Investment return in excess of spending distribution for current operations	853,975	1,424,990	2,278,965	637,866
Change in undistributed income from perpetual funds held by others	-	250,749	250,749	(37,422)
Gifts and contributions for capital and long-term investment	12,786	203,741	216,527	77,316
Other losses	(4,359)	-	(4,359)	(4,042)
Gain on defeasance of debt	-	-	-	4,386
Change in fair value of derivative instruments	59,812	-	59,812	(32,864)
Net periodic benefit cost other than service cost	(669)	-	(669)	(7,720)
Changes in pension and other postretirement obligations	65,336	-	65,336	17,715
Other nonoperating items, net	(18,546)	11,754	(6,792)	(3,416)
Net assets released from restrictions	(1,627)	(21,801)	(23,428)	(14,797)
Total nonoperating activities, net	966,708	1,869,433	2,836,141	637,022
CHANGE IN NET ASSETS	1,176,011	1,891,895	3,067,906	503,853
Less change in net assets related to noncontrolling interests	35,294	-	35,294	(2,910)
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ 1,140,717	1,891,895	\$ 3,032,612	\$ 506,763

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENT OF ACTIVITIES

YEAR ENDED AUGUST 31, 2020 (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2020
OPERATING REVENUE			
Tuition and fees, net of scholarship allowance	\$ 455,077	-	\$ 455,077
Sales and services of auxiliary enterprises, net of scholarship allowance	62,364	-	62,364
Endowment spending distribution	204,034	-	204,034
Distribution from perpetual funds	38,797	-	38,797
Other investment income designated for current operations	59,931	3	59,934
Gifts and contributions for current use	64,853	47,620	112,473
Grants and contracts	513,925	-	513,925
Indirect cost recoveries	153,399	-	153,399
Net patient service revenue	4,191,037	-	4,191,037
Medical services	254,180	-	254,180
Independent operations	13,001	-	13,001
Other revenue	379,438	-	379,438
Net assets released from restrictions	48,166	(33,369)	14,797
Total operating revenue	6,438,202	14,254	6,452,456
OPERATING EXPENSES			
Salaries	3,367,132	-	3,367,132
Fringe benefits	714,223	-	714,223
Student financial aid	27,302	-	27,302
Other operating expenses	2,100,859	-	2,100,859
Interest on indebtedness	72,764	-	72,764
Depreciation and amortization	303,345	-	303,345
Total operating expenses	6,585,625	-	6,585,625
NET OPERATING ACTIVITIES	(147,423)	14,254	(133,169)
NONOPERATING ACTIVITIES, NET			
Investment return in excess of spending distribution for current operations	305,197	332,669	637,866
Change in undistributed income from perpetual funds held by others	-	(37,422)	(37,422)
Gifts and contributions for capital and long-term investment	22,146	55,170	77,316
Other losses	(4,042)	-	(4,042)
Gain on defeasance of debt	4,386	-	4,386
Change in fair value of derivative instruments	(32,864)	-	(32,864)
Net periodic benefit cost other than service cost	(7,720)	-	(7,720)
Changes in pension and other postretirement obligations	17,715	-	17,715
Other nonoperating items, net	(2,176)	(1,240)	(3,416)
Net assets released from restrictions	5,000	(19,797)	(14,797)
Total nonoperating activities, net	307,642	329,380	637,022
CHANGE IN NET ASSETS	160,219	343,634	503,853
Less change in net assets related to noncontrolling interests	(2,910)	-	(2,910)
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ 163,129	343,634	\$ 506,763

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2021 AND 2020 (Dollars in thousands)

	August 31, 2021	August 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ 3,067,906	\$ 503,853
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:		
Contributions and pledge payments restricted for long-term investment and capital projects	(185,734)	(74,923)
Contributions of donated securities	(29,418)	-
Proceeds from sale of donated securities	24,664	-
Net realized and unrealized gains on investments	(2,901,679)	(970,091)
Loss on disposal of property and equipment	4,406	4,095
(Gain) loss on interests in perpetual funds held by others	(250,749)	37,422
Gain on defeasance of debt	-	(4,386)
Depreciation and amortization	311,480	298,987
Amortization of bond premiums and issuance costs	(19,953)	(5,591)
Amortization of right-of-use assets	41,749	46,033
Change in pension and other postretirement	(64,667)	(9,995)
Change in fair value of derivative instruments	(59,812)	32,864
Change in operating assets:		
Accounts and other receivables, net	14,360	(167,428)
Contributions receivable for operations	(39,232)	9,181
Prepaid expenses, deferred charges, and other assets	(53,957)	(69,413)
Change in operating liabilities:		
Accounts payable, accrued liabilities, and interest payable	186,854	68,343
CARES Act accrued liabilities	(229,933)	575,762
Asset retirement obligations	3,218	3,519
Accrued liabilities for benefit obligations and professional liabilities	27,250	88,326
Lease liabilities, net	(36,467)	(38,707)
Deferred revenue	67,058	(14,069)
Net cash (used in) provided by operating activities	(122,656)	313,782
CASH FLOWS FROM INVESTING ACTIVITIES:		
Disbursements for loans to students	(1,903)	(2,899)
Repayment of loans from students	4,245	4,076
Proceeds from sales and maturities of investments	3,142,187	7,327,933
Purchases of investments	(3,074,681)	(6,857,730)
Purchases of property, plant, and equipment	(676,349)	(417,158)
Increase in funds held in trust for others	327,907	84,475
Net cash (used in) provided by investing activities	\$ (278,594)	\$ 138,697

(Continued)

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2021 AND 2020 (Dollars in thousands)

	August 31, 2021	August 31, 2020
CASH FLOWS FROM FINANCING ACTIVITIES:		
Contributions and pledge payments restricted for long-term investment and capital projects	\$ 277,100	\$ 148,882
Proceeds from sale of donated securities restricted for long-term investment and capital projects	4,754	-
Proceeds from bonds payable	-	1,535,171
Principal repayments of bonds payable	(16,769)	(938,336)
Payments on finance lease obligations	(1,591)	(4,087)
Change in annuities payable	1,166	(610)
Debt issuance costs	(56)	(4,003)
Change in government advances for federal loan programs	(2,775)	2,856
Borrowings on line of credit	-	275,000
Repayments on line of credit	-	(275,000)
Net cash provided by financing activities	261,829	739,873
Net change in cash, cash equivalents, and restricted cash	(139,421)	1,192,352
Cash, cash equivalents, and restricted cash at beginning of year	1,467,313	274,961
Cash, cash equivalents, and restricted cash at end of year (Note 2a)	\$ 1,327,892	\$ 1,467,313
Supplemental disclosures:		
Cash paid for interest	\$ 93,715	\$ 67,868
Accrued liabilities for property, plant, and equipment purchases	40,225	12,759

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

(1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research, and healthcare facilities to support its mission. Emory provides educational services to approximately 8,200 undergraduate students and 7,700 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare System (Emory Healthcare), Emory Medical Care Foundation, and Emory Innovations, LLC.

Emory Healthcare consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), Emory Saint Joseph's Hospital (ESJH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Rehabilitation Hospital (ERH), DeKalb Medical Center, Inc. (DMC), Decatur Health Resources, Inc. (DHR), DeKalb Medical Center Foundation (DMCF), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), and Clifton Casualty Insurance Company, Ltd. (CCIC). EUH, EUHM, EJCH, ESJH, ERH, DMC, and DHR are sometimes referred to herein, collectively, as “the Hospitals.”

The consolidated financial statements include the University and all other entities in which Emory has significant financial interest and control. All significant interentity accounts and transactions have been eliminated in consolidation.

(2) Summary of Significant Accounting Policies

The following significant accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenue, gains, and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations.

Net assets with donor restrictions – Net assets that are subject to donor-imposed stipulations that will or may be met either by actions of the University and/or the passage of time. These net assets include donor-restricted endowments, unconditional pledges, split-interest agreements, and interests in perpetual trusts held by others. Generally, the donors of these assets permit the University to use all, or part, of the income earned and net appreciation on related investments for general or specific purposes.

Revenue is reported as increases in net assets without donor restrictions unless its use is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications among the applicable classes of net assets.

The University considers the following items to be nonoperating activities: gifts and contributions for capital and long-term investment and the related net assets released from restrictions, investment return in excess of spending distribution for current operations, change in fair value of derivative instruments, pension- and postretirement-related changes and net periodic benefit cost other than service cost, and other activities, net.

(a) Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist primarily of bank balances and short-term money market mutual funds and treasury bills with original maturities generally 90 days or less that are not invested as part of the long-term investments. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes. Restricted cash consists of cash on hand that is restricted for a specific purpose under various capital financing arrangements or cash held for others and, therefore, not available to Emory for immediate or general business use. Restricted cash appears separately from the cash and cash equivalents on the University's consolidated statements of financial position.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The following table is a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying consolidated statements of financial position to the amounts shown in the accompanying consolidated statements of cash flows as of August 31 (in thousands):

	2021	2020
Cash and cash equivalents	\$ 1,265,377	\$ 1,368,050
Restricted cash included in investments	31,205	13,362
Restricted cash included in prepaid expenses, deferred charges, and other assets	31,310	85,901
Total cash, cash equivalents, and restricted cash	\$ 1,327,892	\$ 1,467,313

Fiscal year 2021 cash, cash equivalents, and restricted cash decreased primarily as a result of moving funds to long-term investments.

(b) Contributions Receivable, Net

Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is provided based on management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

(c) Loans Receivable, Net

Emory-funded loans to students are carried at estimated net realizable value. Loans receivable from students under certain government loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to federal direct loans (which are not reported in the consolidated financial statements), loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing, and Health Professions Student Loan Programs.

(d) Other Receivables, Net

Other receivables are recorded at net realizable value and include receivables under grants and contracts, medical services provided to other organizations, and losses recoverable from reinsurers.

(e) Investments

Investments are reported at fair value. Investments in securities and listed funds are valued using quoted prices in active markets if available; otherwise, if the market is inactive, fair value is

determined by the University in accordance with its valuation policy.

Investments in alternative investment fund structures are valued using the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if (a) the underlying investment manager's calculation of NAV is fair value based and (b) the University does not currently have plans to sell the investment for an amount different from NAV. Valuations provided by the general partners and investment managers are evaluated by the Emory Investment Management Office and are believed to present reasonable estimates of fair value at August 31, 2021 and 2020.

Investments are exposed to several risks, which may include (but are not limited to) interest rate, liquidity, currency, market, and credit risks. The University attempts to manage these risks through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions, though it is at least reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the University's consolidated financial statements.

Investment transactions are accounted for on the trade-date basis. Dividend income is recognized on the ex-dividend date, and interest income is recognized on the accrual basis. Investment return, including realized and unrealized gains and losses, is recognized when earned and reported in the consolidated statements of activities net of external and direct internal investment expenses. Investment return, if restricted, is reported in the consolidated statements of activities as increases or decreases in net assets with donor restrictions until amounts have been appropriated and the donor-imposed or statutory time restrictions have been satisfied.

(f) Fair Value Measurements

Fair value measurements reflected in the consolidated financial statements represent the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants at the measurement date. GAAP provides a hierarchy that prioritizes the inputs to fair value measurements based on the extent to which inputs to valuation techniques are observable in the marketplace. The hierarchy assigns a higher priority to observable inputs that reflect verifiable information obtained from independent sources and a lower priority to unobservable inputs that would reflect the University's assumptions about how market participants would value an asset or liability based on the best information available. Fair value

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

measurements must maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured and reported at fair value are classified and disclosed within one of the following categories:

Level 1 – Valuations for assets and liabilities traded in active exchange markets as of the reporting date; valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

Level 2 – Valuations are determined through direct or indirect observations other than quoted market prices. The types of investments in Level 2 include certain positions in which the University is a unit of account holder within a fund or account that holds underlying assets that are traded in active exchange markets with readily available pricing.

Level 3 – Valuations for assets and liabilities that are unobservable and derived from other valuation methodologies, including discounted cash flow models and similar techniques, and not based on market exchange, dealer, or broker-traded transactions; Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

(g) Split-Interest Agreements

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenue is recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

(h) Interests in Perpetual Funds Held by Others

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' net assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in beneficial interest in perpetual funds and as contribution revenue at the date such funds are established. The largest fund of this type primarily holds shares of common stock of The Coca-Cola Company. The carrying value of Emory's interest in such perpetual funds is adjusted annually for changes in fair value.

(i) Property and Equipment, Net

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years, land improvements and infrastructure – 5 to 40 years, movable equipment – 3 to 20 years, fixed equipment – 3 to 30 years, software and enterprise systems – 3 to 10 years, leasehold improvements – term of the lease, and library books – 10 years. Certain assets totaling \$119.2 million and \$114.9 million, such as art, museum assets, and rare books, are included in property and equipment, net as of August 31, 2021 and 2020, respectively, but are not depreciated.

Property and equipment are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized only if the carrying amount of a long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. There were no asset impairments for fiscal years 2021 or 2020.

(j) Net Tuition and Fees

Tuition and fees revenue is derived from degree programs and continuing education programs. Most undergraduate students receive institutional financial aid based upon academic promise and demonstrated financial need. Graduate students often receive tuition support in connection with research assistant, teaching assistant, and fellowship appointments. Student financial aid provided by the University for tuition and fees is reflected as a reduction of tuition and fees revenue from published rates.

(k) Health Insurance Plan

The University is self-insured for employee and student health insurance costs, with losses insured in excess of a maximum amount on both a per claim and annual aggregate claim amount. The self-insurance liability is based on claims filed and an estimate of claims incurred but not yet reported. Self-insurance claims are reported as net of insurance premiums collected from employees and students.

(l) Gifts and Contributions Revenue

Contributions, including unconditional promises to give, are recognized as revenue in the period received. Unconditional promises to give, with payments due in future periods, are

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

recorded as increases in net assets with donor restrictions at the estimated present value of future cash flows, net of an allowance for uncollectible pledges. Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift.

Donor-restricted contributions are reported as revenue with donor restrictions, which increases this net asset class. If the donor stipulation is met in the year of the gift, the contribution is reflected in net assets without donor restrictions. Restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional; that is, when the barriers on which they depend are met.

(m) Grants and Contracts Revenue and Indirect Cost Recoveries

Funding from the federal government, corporations, or private foundations (sponsors) is recorded as grants and contracts revenue when it is for a specified activity with a defined budget, period of performance, and scope of work undertaken by the University. The agreement with the sponsor may take the form of a contract, grant, or cooperative agreement and is generally in direct support of the University's mission. Revenue is recognized when services are rendered, milestones are met, or qualifying expenses are incurred as specified in the terms and conditions of the agreements, not necessarily when payments are received. Unearned revenue results when cash is received from sponsors in advance of revenue being earned. Unearned revenue is recorded as a liability (deferred revenue) until it is earned. Amounts recorded in grants and contracts receivable are for services rendered or expenditures incurred in advance of the receipt of funds.

Indirect cost recoveries are based on negotiated rates with grantor agencies and represent recoveries of facilities and administrative costs incurred under grant and contract agreements.

(n) Patient Accounts Receivable and Concentrations

Patient accounts receivable are reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations.

Emory Healthcare analyzes contractually due amounts and provides an allowance for implicit price concessions. Accounts receivable are written off after collection efforts have been undertaken in accordance with Emory's policies.

The mix of net receivables from patients and third-party payors for the years ended August 31 is as follows:

	2021	2020
Managed care and other third-party payors	58%	55%
Medicare	31	31
Medicaid	4	8
Patients	7	6
	100%	100%

(o) Sales and Services of Auxiliary Enterprises and Independent Operations

An auxiliary enterprise is a nonacademic entity that exists predominantly to furnish goods and services to students, faculty, and staff. Auxiliary enterprises include residential halls, a bookstore, and parking operations. Fee charges are directly related to the costs of services provided.

Sales and services of auxiliary enterprises, net of scholarship allowance has been significantly impacted by COVID-19. In response to the pandemic and the national emergency declared in March 2020, the University closed its residential buildings for the remainder of the spring 2020 semester and issued refunds to its students for the unearned portion of housing and parking fees. Auxiliary enterprises experienced further decline in revenue, primarily due to residential building closures for fall of 2020, and the reduced number of students for the spring 2021 semester when the University's campuses opened.

Independent operations are activities that are solely owned and/or controlled by the University but are unrelated or independent of its mission. Independent operations include an externally managed conference center, hotel, and a fitness center. Fee charges are based on market rates for the services provided.

(p) Leases

The University determines whether an arrangement is a lease (operating or finance) at inception by evaluating whether the contract conveys the right to use an identified asset and whether Emory obtains substantially all of the economic benefits from and has the right to control the asset. Right-of-use (ROU) assets represent the University's right to use an underlying asset for the lease term and lease liabilities represent the University's obligation to make lease payments arising from the lease.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

Operating and finance lease ROU assets and liabilities are recognized at the lease commencement date based on present value of the lease payments over the lease term discounted using the interest rate implicit in the lease agreement or Emory's relevant incremental borrowing rate. The University's current discount rates range from 0.3% to 4.5% depending on the term of the arrangement.

(q) Income Taxes

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code of 1986, as amended (the Code), and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The University is, however, subject to federal and state income tax on unrelated business income.

The Tax Cuts and Job Acts (the Act) imposes an excise tax on net investment income and excess compensation for certain organizations and established rules for calculating unrelated business income. Based on reasonable estimates under the current regulatory guidance on the Act, Emory has recognized current and deferred tax liabilities aggregating \$34.6 million as of August 31, 2021 and \$4.5 million as of August 31, 2020. The University also has a net operating loss carryforward related to unrelated business income aggregating \$133.7 million, for which a valuation allowance is recorded as of August 31, 2021.

The University regularly evaluates its tax positions and as of August 31, 2021 and 2020, there were no material uncertain tax positions.

(r) Derivative Instruments

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments in order to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value and included in investments. Changes in the fair value of investment-related derivative instruments are included in investment return in excess of spending distribution for current operations on the consolidated statements of activities. The University also utilizes interest swap agreements to hedge interest rate market exposure of variable rate debt. The difference between amounts paid and received under such agreements is reported in interest expense. Changes in the fair value of these swap agreements are recognized as nonoperating activities in the consolidated statements of activities.

(s) Pension and Postretirement Benefit Plans

The University recognizes the funded status of its defined-benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in net assets without donor restrictions.

(t) COVID-19 Pandemic

In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. The COVID-19 pandemic has resulted in financial loss, stress, and hardship for many.

In 2020 and 2021, the Coronavirus Aid, Relief and Economic Security Act (CARES), the Coronavirus Response and Relief Supplemental Appropriations Act (CRRSAA), and the American Rescue Plan (ARP), (collectively, the Acts) were enacted and signed into law to provide emergency grants to help individuals and businesses affected by the pandemic. Under the provisions of the CARES Act, Emory Healthcare received approximately \$219.1 million in provider relief funds (PRF) from the Department of Health and Human Services (HHS) for both general and targeted distributions. Such funding was accounted for as a conditional contribution and recorded as refundable advances in CARES Act accrued liabilities in the consolidated statement of financial position as of August 31, 2020. According to HHS guidance released during fiscal year 2021, Emory Healthcare determined that the underlying conditions of the grant had been met and recognized the \$219.1 million as other revenue in the accompanying consolidated statement of activities for the year ended August 31, 2021.

During fiscal year 2020, Emory Healthcare also received approximately \$285.2 million in advance payments, that must be repaid, through the Centers for Medicare & Medicaid Services (CMS) COVID-19 Accelerated and Advance Payments (CAAP) Program to provide necessary funds when there is a disruption in claims submissions and processing or in circumstances such as a national emergency or natural disasters in order to accelerate cash flow to impacted healthcare providers. Repayment of outstanding CAAP amounts began in April 2021 and will occur monthly over a 29-month period to end in August 2023. As of August 31, 2021, CMS had recouped approximately \$64.0 million of advanced payments received by Emory Healthcare. As such, approximately \$221.2 million and \$285.2 million, respectively, is reflected in CARES Act accrued liabilities in the accompanying 2021 and 2020 consolidated statements of financial position.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

Through August 31, 2021, the Department of Education awarded \$39.5 million in Higher Education Emergency Relief Funds (HEERF) to the University under the Acts, of which \$33.9 million was approved for payment to Emory and \$21.5 million was received as of August 31, 2021. The University distributed \$9.8 million to students and allocated \$11.7 million to qualifying COVID-related expenses in fiscal year 2021. Emory recognized Grants and contracts revenue of \$11.6 million related to these expenditures, while \$9.9 million was included in CARES Act accrued liabilities in the accompanying 2021 consolidated statement of financial position.

The CARES Act allows employers to defer deposits and payments of the employer's share of Social Security taxes incurred between March 27, 2020 and December 31, 2020. As of August 31, 2021 and 2020, Emory has deferred payments of \$114.7 million and \$67.4 million, respectively, of employer taxes that are included in CARES Act accrued liabilities in the accompanying consolidated statements of financial position. Fifty percent of the deferred payments must be paid by December 31, 2021, with the remainder by December 31, 2022.

(u) New Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, *Fair Value Measurement: Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)*. ASU No. 2018-13 eliminates, modifies, and adds certain disclosures on fair value measurements. ASU No. 2018-13 is effective for fiscal periods beginning after December 15, 2019. The University has adopted the ASU for the year ended August 31, 2021. The impact of adopting the new guidance was not significant to the University's consolidated financial statements.

(v) Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires that management make estimates and assumptions affecting the reported amounts of assets, liabilities, revenue, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for price concessions for medical services, reserves for employee and student healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities.

(w) Conflict of Interest Policies

University trustees, directors, principal officers, and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members.

When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. The written conflict of interest policy for the University requires, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest.

(x) Investments in Joint Ventures

Emory accounts for its investments in joint ventures over which it has significant influence but not a controlling interest, using the equity method. Investments in joint ventures are generally included in investments in the accompanying consolidated statements of financial position. Regarding investments in which Emory has guaranteed obligations of a joint venture or is otherwise committed to provide further financial support for the joint venture for additional losses in excess of Emory's contributed capital, estimated obligations to the related unconsolidated joint venture are included in accounts payable and accrued liabilities in the accompanying consolidated statements of financial position.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

(3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	2021	2020
UNCONDITIONAL PROMISES EXPECTED TO BE COLLECTED IN:		
Less than one year	\$ 76,980	\$ 122,430
One year to five years	118,402	42,804
Over five years	1,229	4,787
Gross contributions receivable	196,611	170,021
Less:		
Allowance for uncollectible amounts	(10,243)	(4,861)
Discount to present value	(5,374)	(4,731)
Contributions receivable, net	\$ 180,994	\$ 160,429

At August 31, 2021 and 2020, the five largest outstanding donor pledge balances represented 71% and 74%, respectively, of Emory’s gross contribution receivables. Contribution receivables are discounted at rates ranging from 3.5% to 4.3%.

As of August 31, 2021, the University had received bequest intentions and conditional promises of approximately \$53.6 million. These intentions to give are not recognized as assets or revenue and, if received, will generally be restricted for purposes stipulated by the donor.

(4) Revenue from Contracts with Students and Sponsors

(a) Contracts

The University recognizes revenue, when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the University expects to receive in exchange for those goods or services.

(b) Contract Balances

Accounts receivable are recorded only when the University’s right to consideration is unconditional (i.e., the contract is noncancelable – generally after the expiration of a student withdrawal period).

Deferred revenue relates to payments received in advance of performance under contracts with customers. Emory invoices customers (i.e., students) for education and residential services and customers transfer consideration before the University has transferred promised goods or services to its customers. At each reporting date, Emory records all prepayment amounts associated with educational services that have not yet been delivered as deferred revenue.

The University records accounts receivable and related contract liabilities for noncancelable contracts with customers when there is a right to consideration.

(c) Significant Judgments

Emory applies the portfolio approach to educational and residential services (room and board) and to patient services due to the large volume of similar contracts and similar customer classes.

Emory considers education and residential service as separate and distinct performance obligations. Since students receive instruction and housing concurrently during the academic term, they simultaneously receive and use all the benefits that Emory provides in the performance of the contracts. Therefore, the performance obligations associated with academic programs are satisfied over time and revenue recognized as the related services are performed.

Tuition and fees are recognized in the fiscal year in which the academic programs and residential services are provided. Revenue is reflected in the consolidated statements of activities for the portion that is completed by the end of the fiscal year. The remaining performance obligation that will be completed in the following fiscal year remains a liability on the consolidated statements of financial position.

Emory provides institutionally funded grants and scholarships to students, who either demonstrate financial need or qualify academically, as a form of price reduction up to and equal to amounts owed by students to the University. Institutional resources provided in excess of amounts owed by the students to Emory are recorded as scholarship expenses. Students receive Title IV financial aid, state funds, and employer reimbursements. Emory accounts for the payment as a third-party payment on behalf of an identified customer to an existing exchange transaction, and therefore, the grant or loan amount does not reduce the transaction price.

Auxiliary enterprises revenue includes revenue from residential services, parking operations, bookstore, conference services, and other miscellaneous activities. Within auxiliary enterprises, Emory considers parking service agreements to be distinct performance obligations that are billed to students in advance and payments due prior to the start of each academic term. Prepayments are reflected on the consolidated statements of financial position as deferred revenue and recognized as revenue ratably over the period during which the parking services are rendered. Sales of goods within auxiliary enterprises generally

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

occur as a point of sale transaction, and the revenue is recognized as the sale occurs. Any discounts are factored into the selling price at the point of sale.

Emory considers revenue from clinical trial agreements to be exchange transactions where revenue is recognized as services are performed, billed, and the University has contractual right to consideration. Revenue related to clinical trial agreements included in grants and contracts revenue in the consolidated statements of activities for the years ended August 31, 2021 and 2020 totaled \$57.5 million and \$54.6 million, respectively.

The University recognizes revenue from nonrefundable, up-front fees allocated to a license at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the University recognizes revenue when the related sales occur.

The University has contractual agreements with Grady Memorial Hospital where practicing interns and medical residents of the Emory School of Medicine receive clinical training and faculty provide teaching, medical care, and hospitalization services. The School of Medicine is reimbursed for expenses incurred for interns and medical residents based on the costs for labor and reimbursed for the faculty teaching, administrative, and clinical services based on the number of interns and residents trained and time spent performing clinical and administrative services. Medical services revenue is recognized as services are performed and the customer receives and uses the benefits of the services.

The University also has affiliation and administrative services agreements with Children's Healthcare of Atlanta and the Emory + Children's Pediatric Institute, where it provides various administrative services. Revenue is recorded as other revenue in the consolidated statements of activities as the University satisfies the performance obligation over time. The customer simultaneously receives and consumes the benefits as the University performs.

(d) Disaggregation of Student Revenue

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2021 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 407,437	17,730	425,167
Graduate and professional programs	327,774	340	328,114
Total at published rates	735,211	18,070	753,281
Less institutional aid for undergraduate programs	(158,755)	(3,984)	(162,739)
Less institutional aid for graduate and professional programs	(167,801)	(103)	(167,904)
Tuition and fees and auxiliary enterprises, net of institutional aid	408,655	13,983	422,638
Other academic programs	7,963	-	7,963
Total tuition and fees and auxiliary enterprises	\$ 416,618	13,983	430,601

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2020 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 439,894	38,450	478,344
Graduate and professional programs	317,229	910	318,139
Total at published rates	757,123	39,360	796,483
Less institutional aid for undergraduate programs	(162,077)	(5,755)	(167,832)
Less institutional aid for graduate and professional programs	(157,328)	(181)	(157,509)
Tuition and fees and auxiliary enterprises, net of institutional aid	437,718	33,424	471,142
Other academic programs	17,359	3,010	20,369
Total tuition and fees and auxiliary enterprises	\$ 455,077	36,434	491,511

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

(5) Grants and Contracts

The University receives grants and contracts revenue from federal, state, corporate, and private sources. If resource providers do not receive commensurate benefit (only indirect benefit because the research findings serve the general public) in exchange and the results are maintained and can be used by the University, such grants and contracts are considered contributions.

Most Emory nonexchange, sponsored research agreements are conditional contributions as the agreements include both a right of return or release of assets and a barrier that Emory must overcome to be entitled to the consideration. These agreements become unconditional as barriers are satisfied. The University recognizes revenue associated with these sponsored agreements as qualifying allowable expenses are incurred or a measurable performance-related barrier is achieved in accordance with the terms and conditions of the agreements. Conditional contributions are recognized as deferred revenue if assets are transferred in advance or not recognized at all until the conditions have been substantially met or explicitly waived by the sponsoring entity, at which point the contributions are recognized as unconditional. Conditional agreements with sponsor-imposed restrictions that expire simultaneously with the satisfaction of the specified conditions are reported as net assets without donor restrictions.

The following table presents Emory's sources of grants and contracts revenue (including indirect cost recoveries) for the years ended August 31 (in thousands):

	2021		2020	
	Grants	Contracts	Grants	Contracts
Federal government	\$ 582,992	2,454	\$ 500,823	1,021
Other government	1,658	151	1,770	207
Corporate	14,634	50,226	16,248	50,162
Private institutions	106,109	4,625	93,884	3,209
Total	\$ 705,393	57,456	\$ 612,725	54,599

As of August 31, 2021 and 2020, Emory had unexpended grant awards of \$834.5 million and \$739.2 million, respectively, for which revenue will be recognized when conditions have been met or performance obligations have been satisfied.

(6) Net Patient Services Revenue and Receivables

Emory Healthcare has agreements with government and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Emory Healthcare believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in Emory Healthcare's hospitals receiving inpatient, outpatient, or emergency services. Emory Healthcare measures the performance obligation from admission, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when goods are provided to Emory Healthcare's patients and customers in a retail setting (e.g., pharmaceuticals), and Emory Healthcare does not believe it is required to provide additional goods or services related to that sale.

Emory Healthcare determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with Emory Healthcare policy, and implicit price concessions provided to patients. Emory Healthcare determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience.

Emory Healthcare provides care to patients regardless of their ability to pay. Emory Healthcare has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (e.g., co-pays and deductibles).

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Emory Healthcare expects to collect based on its collection history with those patients considering business and economic conditions, trends in healthcare coverage, and other collection indicators. Periodically, management assesses the adequacy of the allowance for implicit price concessions based upon historical write-off experience by payor category and adjusts the allowance as appropriate.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

Patient service revenue, net of contractual adjustments, implicit price concessions, and other discounts recognized from major payor sources for the years ended August 31 is as follows (in thousands):

	2021	2020
Medicare	\$ 1,474,617	\$ 1,213,659
Medicaid	178,384	180,758
Managed care and other third-party payors	3,092,695	2,728,112
Patients	58,089	68,508
Net patient service revenue	\$ 4,803,785	\$ 4,191,037

The composition of net patient service revenue based on the Emory Healthcare lines of business for the years ended August 31 is as follows (in thousands):

	2021	2020
Services lines:		
Hospital – inpatient	\$ 2,141,460	\$ 1,876,358
Hospital – outpatient	1,585,008	1,407,373
Physician services	1,077,317	907,306
Net patient service revenue	\$ 4,803,785	\$ 4,191,037

Emory Healthcare provides care to patients who meet certain criteria under its financial assistance policy without charge or at amounts less than their established rates and such amounts are not included in net patient service revenue.

Data is maintained to identify and monitor the level of charity care provided, including the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies.

The cost of charity care provided totaled \$124.6 million and \$130.3 million for the years ended August 31, 2021 and 2020, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

(7) Other Revenue

The major components of other sources of operating revenue for the years ended August 31 are as follows (in thousands):

	2021	2020
Retail pharmaceutical sales	\$ 198,358	\$ 140,598
CARES Act provider relief fund	219,139	–
Other	196,416	238,840
Other revenue	\$ 613,913	\$ 379,438

(8) Liquidity and Availability

Emory regularly monitors liquidity required to meet its operating needs and other contractual commitments, while also maximizing the investment of its available funds.

For purposes of analyzing resources available to meet general expenditures over a 12-month period, the University considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures.

In addition to financial assets available to meet general expenditures over the next 12 months, the University operates with a balanced budget and anticipates collecting sufficient revenue to cover general expenditures not covered by donor-restricted resources.

As of August 31, 2021 and 2020, the following financial assets could readily be made available within one year of the statements of financial position date to meet cash needs for general expenditures (in thousands):

	2021	2020
TOTAL ASSETS	\$ 20,458,905	\$ 17,172,361
Less:		
Property and equipment, net	(4,015,749)	(3,629,700)
Interest in perpetual trusts held by others	(1,848,427)	(1,670,377)
Donor-restricted and board-designated endowment funds	(7,974,988)	(5,889,384)
Other investments	(3,589,504)	(2,884,965)
Prepaid expenses, deferred charges, and other assets	(446,291)	(446,925)
Operating lease right-of-use assets	(182,372)	(212,499)
Contributions receivable, net	(180,994)	(160,429)
Loans receivable, net	(18,441)	(20,783)
Add:		
Endowment payout in following year	215,002	203,790
Contributions receivable due within one year for operations	76,980	122,430
Financial assets available to meet cash needs for general expenditures within one year	\$ 2,494,121	\$ 2,583,519

The University has \$2,494.1 million of financial assets as of August 31, 2021 to meet cash needs for general expenditures, consisting of cash of \$1,265.4 million, accounts receivable of \$871.1 million, contributions receivable, less than one year of \$77.0 million, payout on with and without donor-restricted endowment funds of \$215.0 million, and other operating investments of \$65.6 million.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

(9) Investments

The following table summarizes investments as of August 31 (in thousands):

	2021	2020
Short-term investments and cash equivalents ^(a)	\$ 717,537	\$ 384,127
Public equity ^(b)	4,689,741	3,663,833
Absolute return/fixed income ^{(c)(g)}	1,693,687	1,852,781
Private equity/venture capital ^(d)	3,649,517	2,196,033
Real assets ^(e)	822,990	650,838
Derivative instruments ^(f)	42,034	2,890
Total investments at fair value	11,615,506	8,750,502
Joint ventures (equity method)	14,598	27,586
Total investments	\$ 11,630,104	\$ 8,778,088

a) Includes short-term U.S. and non-U.S. Treasury securities with maturities of less than one year, as well as funds that invest in these types of investments.

b) Includes domestic and international stocks, as well as interests in funds that invest in both long only and long/short equity-based strategies; certain investments in funds may be subject to restrictions that limit the University's ability to withdraw capital until (i) certain "lock-up period" has expired or (ii) until certain underlying investments designated as "illiquid" or "side pockets" are sold. In addition, fund investments in this category may be subject to restrictions limiting the amount the University is able to withdraw as of a given redemption date. Also includes \$115.0 million and \$0.0 million in investment subscriptions paid in advance as well as \$220.0 million and \$0.0 million in investment proceeds receivable as of August 31, 2021 and 2020, respectively.

c) Includes directly-held actively traded global fixed-income securities (such as government bonds and corporate bonds) or commingled funds holding such securities of \$851.4 million and \$889.3 million and investments in multistrategy or credit funds, as well as opportunistic absolute return funds intended to enhance diversification and reduce correlation to public equity of \$842.3 million and \$963.5 million as of August 31, 2021 and 2020, respectively; certain fund investments included in this category may hold marketable securities and be subject to redemption terms governed by the respective fund agreement or may contain illiquid investments and, therefore, offer no liquidity over the fund life. Such funds holding illiquid investments are expected to yield liquidating distributions over the next seven years.

d) Includes illiquid investments in private and public companies, both domestically and internationally; the majority of these

investments are held through funds and also include buyout, venture capital, private debt, high yield, and subordinated debt strategies. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 12 years.

e) Includes investments in oil and gas, commodities, timber, and real estate, the majority of which are held through commingled funds; the nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 11 years.

f) Includes investments in equity options, swaps, and forwards value at fair value of each underlying investments

g) Amounts presented net of \$0.0 million and \$7.2 million of net pending trade payables related to unsettled forward purchases and sales of such securities as of August 31, 2021 and 2020, respectively.

As of August 31, 2021, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Absolute return	\$ 593,597	30-360 days or not eligible	31-306 days
Private equity/venture capital	728,742	not eligible	not eligible
Public equity	118,000	30-360 days	10-180 days
Real assets	353,876	not eligible	not eligible
	\$ 1,794,215		

Unfunded commitments are generally expected to be called by funds within five years of fund inception.

(10) Endowment Net Assets

The University's endowed assets (the Endowment) consist of 2,250 individual funds established for a variety of purposes, including with donor restriction endowment funds and without donor restrictions funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

funds are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The University follows the State of Georgia’s Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as donor-restricted historical value net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is classified as restricted appreciation until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the University considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University, and the investment policies of the University.

The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, funds held in trust for others, and miscellaneous investments. As of August 31, 2021, 68.6% of the investments described in note 9 are classified as endowed net assets. Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2021			2020		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds						
Appreciation	\$ –	4,469,428	4,469,428	\$ –	3,050,330	3,050,330
Historical value	–	1,148,348	1,148,348	–	1,105,996	1,105,996
Total donor restricted	–	5,617,776	5,617,776	–	4,156,326	4,156,326
Funds functioning as endowments or board-designated	2,357,212	–	2,357,212	1,733,058	–	1,733,058
Total endowment net assets	\$ 2,357,212	5,617,776	7,974,988	\$ 1,733,058	4,156,326	5,889,384

The following table represents endowment net asset composition by purpose as of August 31 (in thousands):

	2021			2020		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Student financial aid	\$ 235,097	1,147,799	1,382,896	\$ 168,002	852,068	1,020,070
Academic, research, and program support	1,258,129	4,148,567	5,406,696	933,303	3,062,131	3,995,434
Capital projects, real estate, and infrastructure	863,986	321,410	1,185,396	631,753	242,127	873,880
Total endowment net assets	\$ 2,357,212	5,617,776	7,974,988	\$ 1,733,058	4,156,326	5,889,384

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

		Without Donor Restrictions	With Donor Restrictions	Total
Balance as of August 31, 2019	\$	1,602,867	3,796,655	5,399,522
Investment return:				
Investment income		5,896	13,974	19,870
Net realized and unrealized gains on investments		196,339	488,317	684,656
Total investment return		202,235	502,291	704,526
Cash contributions		4,527	38,636	43,163
Additions of funds for endowments		–	4,792	4,792
Transfers of institutional funds for endowments without donor restrictions		3,719	–	3,719
Withdrawal of board-designated funds for strategic initiatives		(9,080)	–	(9,080)
Appropriations for expenditure		(64,604)	(168,834)	(233,438)
Appropriations for capital purposes		(6,606)	(17,214)	(23,820)
Balance as of August 31, 2020	\$	1,733,058	4,156,326	5,889,384
Investment return:				
Investment income		4,214	10,062	14,276
Net realized and unrealized gains on investments		660,156	1,597,142	2,257,298
Total investment return		664,370	1,607,204	2,271,574
Cash contributions		7,425	41,693	49,118
Additions of funds for endowments		–	535	535
Transfers of institutional funds for endowments without donor restrictions		32,608	–	32,608
Withdrawal of board-designated funds for strategic initiatives		(8,534)	–	(8,534)
Appropriations for expenditure		(65,091)	(170,612)	(235,703)
Appropriations for capital purposes		(6,624)	(17,370)	(23,994)
Balance as of August 31, 2021	\$	2,357,212	5,617,776	7,974,988

(b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. No significant deficiencies of this nature are reported in net assets with donor restrictions.

(c) Return Objectives and Risk Parameters

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment and seek to maintain the purchasing power of the endowment assets. Under this policy, as approved by the Board of Trustees, the endowment assets are invested within risk tolerances of the University to provide an expected total return in excess of spending and inflation over the long term.

(d) Strategies Employed for Achieving Objectives

To satisfy its long-term return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across public equity, absolute return/fixed income, private equity/venture capital, real assets, and derivative instruments to achieve its long-term return objectives within a prudent risk framework. The Endowment's long-term target asset allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

(e) Relationship between Investment Objectives and Spending Policy

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs. The distribution of endowment investment return in 2021 and 2020 was based on 4.8% of the average fair value of the endowment over the previous 12 months ended on August 31. The University considers the expected return on its endowment,

including the effect of inflation in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

(11) Fair Values of Assets and Liabilities

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2021 (in thousands):

	Investments Measured at NAV ⁽²⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ —	160,664	556,873	—	717,537
Public equity	4,215,093	469,059	5,586	3	4,689,741
Absolute return/fixed income	842,309	192,496	658,882	—	1,693,687
Private equity/venture capital	3,639,503	—	—	10,014	3,649,517
Real assets	820,907	8	1,625	450	822,990
Derivative instruments	—	—	42,034	—	42,034
Total investments at fair value	9,517,812	822,227	1,265,000	10,467	11,615,506
Interests in perpetual funds held by others ⁽¹⁾	—	—	—	1,848,427	1,848,427
Total assets at fair value	9,517,812	822,227	1,265,000	1,858,894	13,463,933
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	—	—	(211,164)	—	(211,164)
Funds held in trust for others ⁽³⁾	(1,239,045)	—	—	—	(1,239,045)
Total liabilities at fair value	\$ (1,239,045)	—	(211,164)	—	(1,450,209)

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2020 (in thousands):

	Investments Measured at NAV ⁽²⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ -	229,026	155,101	-	384,127
Public equity	3,398,975	259,516	5,340	3	3,663,834
Absolute return/fixed income	963,452	151,780	737,548	-	1,852,780
Private equity/venture capital	2,174,383	-	-	21,651	2,196,034
Real assets	648,682	31	1,674	450	650,837
Derivative instruments	-	-	2,890	-	2,890
Total investments at fair value	7,185,492	640,353	902,553	22,104	8,750,502
Interests in perpetual funds held by others ⁽¹⁾	-	-	-	1,670,377	1,670,377
Total assets at fair value	7,185,492	640,353	902,553	1,692,481	10,420,879
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	-	-	(270,976)	-	(270,976)
Funds held in trust for others ⁽³⁾	(911,138)	-	-	-	(911,138)
Total liabilities at fair value	\$ (911,138)	-	(270,976)	-	(1,182,114)

⁽¹⁾ Primarily invested in The Coca-Cola Company.

⁽²⁾ Certain investments that are measured at fair value using the net asset value (NAV) per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated statements of financial position.

⁽³⁾ Emory uses net asset value of units held as an estimate for fair value.

The following tables present a summary of the University's activity for investment categorized in Level 3 for the years ended August 31, 2021 and 2020 (in thousands):

	2021			2020		
	Purchases	Sales	Transfer out ⁽¹⁾	Purchases	Sales	Transfer out
Private equity/venture capital	\$ 9,411	(749)	(46,148)	\$ 59	(38)	-
Real assets	-	(47)	-	-	(472)	-
Total Investment	9,411	(796)	(46,148)	59	(510)	-
Interests in perpetual funds held by others	105,000	-	(177,699)	35,000	-	(84,777)
Total assets	\$ 114,411	(796)	(223,847)	\$ 35,059	(510)	(84,777)

⁽¹⁾ Private equity/venture capital transfer out is due to directly held shares of a private company exchanged for shares of a public company as a result of an IPO. Interests in perpetual funds held by others transfer out is due to funds released from operations.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

(12) Derivative Instruments and Hedging Activities

(a) Investments

Investment strategies employed by Emory and investment managers retained by Emory may incorporate futures, options, swaps, and other derivative instruments to adjust elements of investment exposures to various securities, markets, and

currencies without taking a position in the underlying assets. These instruments expose Emory to risk of an unexpected movement in the fair value of the underlying security, a counterparty failing to meet its obligations, and, in certain circumstances, not being able to unwind a position at current fair value due to market illiquidity. Emory has established procedures to monitor and manage these risks.

Emory's investment-related derivative exposures, categorized by primary underlying risk, as of and for the years ended August 31 are as follows (in thousands):

2021	Notional Amount ⁽¹⁾	Asset Fair Value	Liability Fair Value	Total Earnings ⁽²⁾
Foreign exchange contracts	\$ 175,251	87,626	(87,625)	5,712
Equity contracts ⁽³⁾	282,228	45,356	(3,323)	76,332
Total⁽⁴⁾	\$ 457,479	132,982	(90,948)	82,044

2020	Notional Amount ⁽¹⁾	Asset Fair Value	Liability Fair Value	Total Earnings ⁽²⁾
Interest-rate contracts	\$ –	–	–	2,974
Foreign exchange contracts	27	14	(14)	1,690
Equity contracts ⁽³⁾	133,704	14,288	(11,398)	(19,418)
Credit contracts	–	–	–	(74)
Total⁽⁴⁾	\$ 133,731	14,302	(11,412)	(14,828)

⁽¹⁾ The notional amount is representative of the absolute value of the open contracts as of August 31, 2021 and 2020, except as otherwise discussed below in (3).

⁽²⁾ Gains on derivative instruments incurred during the fiscal year are included in the consolidated statements of activities in investment return in excess of spending distribution for current operations in nonoperating activities.

⁽³⁾ The notional value for options is presented on a net delta-adjusted basis.

⁽⁴⁾ Derivatives are held primarily with six counterparties. No cash collateral is pledged or held as of August 31, 2021 and 2020.

(b) Debt

Historically, as a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. Since the inception of the interest rate swap agreements, the debt portfolio has changed to incorporate fixed rate debt not associated with derivatives. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by any potential basis risk with variable rate debt. Certain of the University's derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivative instruments in net

liability positions. At August 31, 2021, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2021, Emory had eight interest rate swap agreements expiring on various dates ranging from September 1, 2035 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.2% to 3.6% in exchange for variable rate payments from the counterparties based on a percentage of the three-month LIBOR.

Net settlement transactions related to the agreements described above resulted in interest expense totaling \$10.9 million and \$12.3 million, interest expenses related to nonintegrated agreements are reflected as nonoperating loss of \$10.2 million and \$2.6 million during 2021 and 2020, respectively. The fair value of each exchange agreement is estimated based on pricing

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

models that utilize significant observable inputs, such as relevant current interest rates, that reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

The aggregate fair value of all derivative instruments with credit risk-related contingent features that are in a liability position was \$211.2 million and \$271.0 million, collateralized by \$31.3 million and \$85.9 million of cash on August 31, 2021 and 2020, respectively. Collateral postings are reported in prepaid expenses, deferred charges, and other assets in the accompanying consolidated statements of financial position.

The following table summarizes the debt-related derivative instruments as of and for the years ended August 31 (in thousands):

Interest Rate Swaps		2021			2020		
Inception	Maturity	Notional Amount ⁽¹⁾	Liability Fair Value	Unrealized Gain	Liability Fair Value	Unrealized Loss	
August 4, 2005	September 1, 2035	\$ 125,000	(34,362)	10,016	\$ (44,378)	(5,951)	
August 25, 2005	September 1, 2035	40,000	(11,557)	3,473	(15,030)	(2,066)	
December 1, 2007	September 1, 2035	75,000	(24,632)	6,595	(31,227)	(3,726)	
May 1, 2008	September 1, 2038	75,000	(29,366)	7,731	(37,097)	(3,587)	
December 1, 2008	December 1, 2042	100,000	(40,150)	11,957	(52,107)	(7,376)	
December 1, 2009	September 1, 2035	75,000	(24,957)	6,628	(31,585)	(3,097)	
June 23, 2015	September 1, 2035	125,000	(34,583)	9,939	(44,522)	(5,281)	
June 23, 2015	September 1, 2035	40,000	(11,557)	3,473	(15,030)	(1,780)	
Total		\$ 655,000	(211,164)	59,812	\$ (270,976)	(32,864)	

⁽¹⁾ The notional amount is the predetermined dollar amount on which the exchanged interest payments are based.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and, therefore, potentially impact the value of the instruments. Emory management, with consultation from third-party financial advisers, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed. The swaps are exchanged with five counterparties.

(13) Property and Equipment, Net

Property and equipment, net as of August 31 is summarized as follows (in thousands):

	2021	2020
Land and improvements	\$ 242,799	\$ 241,771
Buildings and improvements	4,097,752	3,963,022
Equipment	2,968,148	2,824,581
Finance lease ROU assets (note 14)	22,190	20,820
Library and museum assets	507,039	483,366
Construction in progress	684,704	300,607
	8,522,632	7,834,167
Less: accumulated depreciation	(4,499,275)	(4,200,109)
Less: accumulated amortization of finance leases	(7,608)	(4,358)
Total property, plant, and equipment, net	\$ 4,015,749	\$ 3,629,700

The University has identified asset retirement obligations predominantly from commitments to remove asbestos and lead paint in the University's facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.0% and discount rate of 4.7%. The liability for asset retirement obligations at August 31, 2021 and 2020 is \$85.8 million and \$82.6 million, respectively.

(14) Leases

The University has operating and finance leases for office buildings, research and development facilities, hospital and educational buildings, and certain equipment. Leases have remaining lease terms of 1 year to 25 years, some of which include purchase options or options to extend the leases.

Operating leases are included in operating lease right-of-use assets and operating lease liabilities, finance leases are included in property, plant, and equipment, net, and finance lease liabilities

in the consolidated statements of financial position. Operating lease right-of-use (ROU) assets include any lease payments made and include lease incentives. Renewal options are excluded from the calculation of lease liabilities unless it is reasonably assured that the renewal option will be exercised. Costs associated with operating lease ROU assets are recognized on a straight-line basis within operating expenses over the term of the lease.

Finance lease ROU assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest-method over the lease term. Variable lease costs, such as common area maintenance, property taxes, and insurance are expensed as incurred.

Emory has lease agreements with lease and nonlease components. The University elected a practical expedient, primarily for its copier leases, whereby nonlease components are not separated from the lease component. This results in all of the lease and nonlease components being combined, and accounted for, as a single lease component and included in the measurement of the ROU assets and lease liabilities.

The components of lease expense for the year ended August 31, are as follows (in thousands):

	2021	2020
Finance lease cost	\$ 4,569	\$ 7,881
Amortization of ROU assets	3,250	4,358
Interest on lease liabilities	1,319	3,523
Operating lease cost	38,689	41,977
Short-term lease cost	15,194	15,963
Total lease expense	\$ 58,452	\$ 65,821

Aggregate future payments under noncancelable operating and finance leases as of August 31, 2021 are as follows (in thousands):

	Operating Leases	Finance Leases
2022	\$ 39,908	1,679
2023	33,216	1,429
2024	29,554	1,119
2025	23,280	1,070
2026	17,088	1,044
Thereafter	62,596	20,060
Total lease payments	205,642	26,401
Less: amounts representing interest	(19,382)	(8,777)
Total obligation	\$ 186,260	17,624

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The University has entered into a lease for space to serve as an expanded point of entry for imaging and surgical cases for Emory Healthcare, referred to as the Musculoskeletal Outpatient Center (MSK Center) at its Executive Park property. The University obtained the right of use of the asset with the corresponding lease effective September 13, 2021 aggregating \$71.1 million.

Supplemental cash flow information related to leases for the year ended August 31 is as follows (in thousands):

	2021	2020
Other information		
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	\$ 38,499	\$ 41,811
Operating cash flows from finance leases	3,250	3,523
Financing cash flows from finance leases	1,591	4,087
Right-of-use assets obtained in exchange for new lease obligations		
Operating leases	16,054	15,253
Finance leases	1,369	311
Weighted-average remaining lease term -- finance lease	22 years	24 years
Weighted-average remaining lease term -- operating lease	8 years	8 years
Weighted-average discount rate -- finance lease	3.72%	3.82%
Weighted-average discount rate -- operating lease	2.06%	2.00%

(15) Bonds and Notes Payable

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs, consisted of the following as of August 31 (dollars in thousands):

	Average Interest Rate	Final Maturity	Outstanding Principal	
			2021	2020
Tax-exempt, fixed-rate revenue bonds:				
2020 Series B	4.63%	September 1, 2041	\$ 486,470	\$ 486,470
2019 Series A	4.96	September 1, 2039	209,665	218,115
2019 Series B	5.00	September 1, 2048	39,725	39,725
2016 Series A	4.62	October 1, 2046	130,030	130,030
2016 Series B	4.20	October 1, 2043	195,750	201,280
2013 Series A	5.00	October 1, 2043	178,460	180,605
Total tax-exempt, fixed-rate revenue bonds			1,240,100	1,256,225
Tax-exempt, variable-rate revenue bonds:				
2013 Series B ⁽¹⁾	0.48	October 1, 2039	135,100	135,100
Total tax-exempt, variable-rate revenue bonds			135,100	135,100
Taxable, fixed-rate revenue bonds:				
2020 Series A	2.41	September 1, 2050	943,750	943,750
1994 Series C	8.00	October 1, 2024	2,945	3,545
1991 Series	8.85	April 1, 2022	41	85
Total taxable, fixed-rate revenue bonds			946,736	947,380
Commercial Paper:				
2008 Program 1 - Taxable	2.13	April 1, 2047	-	-
Total Commercial Paper			-	-
Unamortized bond premiums			212,772	233,401
Bond issuance costs			(8,571)	(9,191)
Total bonds and notes payable			\$ 2,526,137	\$ 2,562,915

⁽¹⁾ 2013 Series B bonds are floating rate notes and the interest rate is based on a spread to The Securities Industry and Financial Markets Association Index (SIFMA).

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The University incurred interest expense of \$75.0 million and \$72.2 million in 2021 and 2020, respectively, net of capitalized interest of \$2.8 million and \$1.5 million in 2021 and 2020, respectively. During 2021, the average interest rate on the University’s tax-exempt variable demand bonds was 0.48%. Related indices for this period were 0.06% for tax-exempt debt (SIFMA).

As of August 31, 2021, the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

	2021
PAYABLE IN FISCAL YEAR:	
2022	\$ 11,536
2023	11,345
2024	11,450
2025	19,305
2026	300,690
Thereafter	1,967,610
	2,321,936
Unamortized net premium	212,772
Unamortized net bond issuance costs	(8,571)
	\$ 2,526,137

During 2020, the University refunded its 1994 Series B bonds, 1995 Series B bonds, 1999 Series B bonds, 2011 Series A bonds, and a portion of the 2005 Series B bonds and 2008 taxable Commercial Paper program totaling \$332.6 million with proceeds from the University’s issuance of 2020 Series A bonds. Additionally, the University funded \$600.0 million for general corporate purposes with proceeds from the University’s issuance of the 2020 Series A bonds. The University also refunded its 2005 Series C bonds, 2013 Series C bonds, 2010 tax-exempt Commercial Paper program, and a portion of the 2005 Series B bonds and 2008 taxable Commercial Paper program totaling \$603.2 million with proceeds from the 2020 Series B bonds. The

University recognized a net accounting gain of \$4.4 million in conjunction with issuance of the 2020 Series A and 2020 Series B bonds, which is included in nonoperating activities, net in the accompanying 2020 consolidated statement of activities.

During 2020, the outstanding 2010 tax-exempt commercial paper of \$164.4 million was refunded as part of the 2020 Series B bonds issuance and the program expired.

The 2008 taxable Commercial Paper program of \$350.0 million had an outstanding balance of \$0.0 million and \$0.0 million, as of August 31, 2021 and 2020, respectively, under this program.

The University has a standby credit facility to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. Currently, it has one diversified facility totaling \$175.0 million that is committed for this sole purpose and cannot be used for operating needs of the University. There were no draws against this line of credit in 2021 or 2020.

Emory Healthcare entered into an affiliation agreement with one of its payors effective June 11, 2018, which was renewed in June 2020. This affiliation agreement includes, among other provisions, a \$100.0 million line of credit to Emory University, which can be utilized for any purpose that advances the charitable mission of Emory Healthcare. The affiliation agreement was renewed but the affiliated line of credit was terminated effective February 8, 2021. The University entered into a syndicated line of credit of \$750.0 million on April 16, 2021 that expires April 2026. There is also no outstanding balance as of August 31, 2021.

The University has a letter of credit with a commercial bank totaling \$1.1 million. There were no outstanding balances as of August 31, 2021 or 2020. The letter of credit agreement expires March 2022.

The terms of the University’s long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

(16) Net Assets

The following is a summary of net assets as of August 31 (in thousands):

	2021			2020		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Emory undesignated funds	\$ 1,742,921	–	1,742,921	\$ 1,457,398	–	1,457,398
Endowment funds	2,357,212	5,617,776	7,974,988	1,733,058	4,156,326	5,889,384
Investment in plant	1,535,380	–	1,535,380	1,269,046	–	1,269,046
Interest in perpetual funds held by others	–	1,848,427	1,848,427	–	1,670,377	1,670,377
Contributions receivable, net	–	180,994	180,994	–	160,429	160,429
Annuity and other split-interest agreements	–	12,081	12,081	–	8,810	8,810
Capital projects and other donor purposes	–	390,992	390,992	–	162,433	162,433
	\$ 5,635,513	8,050,270	13,685,783	\$ 4,459,502	6,158,375	10,617,877

(17) Retirement and Deferred Compensation Plans

The University has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Emory Healthcare sponsors a retirement plan, covering most full-time employees, under which annuities are purchased with contributions made by Emory Healthcare. Benefits to eligible employees were based on a formula defined in the plan. Benefits are paid as a monthly annuity at age 65 or an eligible employee can elect a reduced benefit as early as age 55. The benefits are vested only to the extent of the annuities purchased. Benefits were frozen as of 12/31/2011. Emory Healthcare also has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. Emory Healthcare contributes an amount equal to 2% of each eligible employee's compensation to the plan as well as a supplemental contribution of up to 5% based on a 1 to 1 match of employee contributions of up to 4% for eligible employees with less than 10 years of service and 5% if 10 or more years of service. Employer contributions cliff vest after three years of service.

TEC sponsors a defined-contribution plan under the Code, Section 403(b), The Emory Clinic, Inc. Retirement Savings Plan covering eligible employees. TEC contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match

of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Retirement expense totaled \$150.5 million and \$154.9 million during 2021 and 2020, respectively, and is included in fringe benefits expense in the accompanying consolidated statements of activities.

The University sponsors the Code Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the time of termination of employment from the University. As of August 31, 2021 and 2020, respectively, the University held assets of \$215.7 million and \$170.5 million under the Retirement Plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which the majority are classified as Level 1 in the fair value hierarchy. Associated liabilities for the obligations of \$215.7 million and \$170.5 million as of August 31, 2021 and 2020, respectively, are included in accrued liabilities for benefit obligations and professional liabilities and considered Level 2 in the fair value hierarchy.

(18) Pension Plans – Emory Healthcare

Emory Healthcare sponsors a defined-benefit pension plan (the Plan). The Plan was curtailed effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

date nor will new entrants into the Plan be permitted after the effective date.

The Plan’s investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the Plan’s investment policy. Asset allocation strategies and investment management structure are designed to meet the Plan’s investment objectives.

The Plan’s expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan’s target asset allocation.

The Joint Operating Company (JOC) assumed certain defined-benefit pension liabilities covering certain employees of the entities contributed to the JOC by Saint Joseph’s Health System SJHS (the SJHS Pension Plan). The plan was curtailed, effective

December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal year 2015, subject to certain terms and conditions.

The SJHS Pension Plan’s expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan’s target asset allocation.

In connection with the acquisition of DRHS, Emory Healthcare assumed sponsorship of DRHS’ trustee noncontributory, defined-benefit pension plan on September 1, 2018. Prior to the acquisition, the DRHS Pension Plan had been permanently frozen effective December 31, 2008 as a result of DRHS’ Board of Directors approving such action.

Given the curtailment of the plans, the accumulated benefit obligations at August 31, 2021 and 2020 are the same as the projected benefit obligations.

The changes in the projected benefit obligations as of and for the years ended August 31 are as follows (in thousands):

	2021		2020		
	Emory Healthcare	SJHS	Emory Healthcare	SJHS	DRHS
Projected benefit obligation, beginning of year	\$ 430,110	180,725	\$ 341,188	176,513	64,408
Interest cost	9,724	4,803	11,106	5,335	628
Actuarial (gain) loss	2,454	(2,175)	23,551	5,338	(3,228)
Plan combinations	–	–	61,547	–	(61,547)
Benefits paid	(9,447)	(6,769)	(7,282)	(6,461)	(261)
Projected benefit obligation, end of year	\$ 432,841	176,584	\$ 430,110	180,725	–

On December 31, 2019, the DRHS pension plan was merged into the Emory Healthcare Plan. Liabilities and assets were re-measured as of the date of the merger. The result was a liability

transfer of \$61.5 million, an asset transfer of \$60.0 million, and a transfer of unrecognized net loss of \$6.0 million for the plan combination.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2021			2020		
	Emory Healthcare	SJHS		Emory Healthcare	SJHS	DRHS
Fair Value of plan assets, beginning of year	\$ 319,729	144,088		\$ 228,046	127,001	62,160
Actual return on plan assets	51,255	18,727		36,490	17,134	(1,924)
Employer contributions	7,864	7,385		2,500	6,414	–
Plan combinations	–	–		59,975	–	(59,975)
Benefits paid	(9,447)	(6,769)		(7,282)	(6,461)	(261)
Fair value of plan assets, end of year	\$ 369,401	163,431		\$ 319,729	144,088	–
Funded status - accrued pension cost recognized in the consolidated statements of financial position	\$ (63,440)	(13,153)		\$ (110,381)	(36,637)	–

The components of net periodic pension cost for the years ended August 31 are as follows (in thousands):

	2021			2020		
	Emory Healthcare	SJHS		Emory Healthcare	SJHS	DRHS
Interest cost	\$ 9,724	4,803		\$ 11,106	5,335	628
Expected return on assets	(15,451)	(9,379)		(12,065)	(8,567)	(621)
Amortization of prior service cost	–	(438)		–	(438)	–
Amortization of net loss	3,731	2,487		2,832	2,654	91
Net periodic pension cost	\$ (1,996)	(2,527)		\$ 1,873	(1,016)	98

Net periodic pension costs are recognized as employees render the services necessary to earn the pension and postretirement benefits. Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position as of August 31 are as follows:

	2021			2020		
	Emory Healthcare	SJHS		Emory Healthcare	SJHS	DRHS
Discount rate	2.73%	2.68%		2.78%	2.71%	—%
Expected long-term rate of return on plan assets	5.20	6.50		4.65	6.75	–

Weighted average assumptions used to determine net periodic pension cost for the years ended August 31 are as follows:

	2021			2020		
	Emory Healthcare	SJHS		Emory Healthcare	SJHS	DRHS
Discount rate	2.78%	2.71%		3.11%	3.08%	3.14%
Expected long-term rate of return on plan assets	5.20	6.50		4.65	6.75	3.50

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The following tables summarize the plan assets, which are recorded at fair value as of August 31 as follows (in thousands):

	2021							
	Emory		Total	Fair Value Hierarchy			Total Fair Value	Target ⁽¹⁾ Allocation
	Healthcare	SJHS		Level 1	Level 2	NAV		
INVESTMENTS:								
Short-term investments and cash equivalents	\$ 1,075	5,780	6,855	4,422	–	2,433	6,855	—%
Public equity	150,441	44,406	194,847	17,928	133,118	43,801	194,847	60
Absolute Return	31,539	–	31,539	12,825	–	18,714	31,539	4
Private equity/ venture capital	5,106	–	5,106	–	–	5,106	5,106	2
Fixed income	181,240	100,534	281,774	9,199	269,675	2,900	281,774	30
Managed funds	–	12,711	12,711	–	–	12,711	12,711	4
Total investments	\$ 369,401	163,431	532,832	44,374	402,793	85,665	532,832	100%

	2020							
	Emory		Total	Fair Value Hierarchy			Total Fair Value	Target ⁽¹⁾ Allocation
	Healthcare	SJHS		Level 1	Level 2	NAV		
INVESTMENTS:								
Short-term investments and cash equivalents	\$ 528	6,392	6,920	(378)	1,362	5,936	6,920	—%
Public equity	209,979	72,528	282,507	28,583	209,979	43,945	282,507	60
Fixed income	109,222	49,294	158,516	–	158,516	–	158,516	30
Managed funds	–	15,874	15,874	–	–	15,874	15,874	10
Total investments	\$ 319,729	144,088	463,817	28,205	369,857	65,755	463,817	100%

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

Cash Flows

Emory Healthcare expects to contribute \$0.0 million to the Emory Healthcare Pension Plan, and \$3.9 million to the SJHS Pension Plan during fiscal year 2022.

Expected Future Benefit Payments

Emory Healthcare annual future benefit payments, excluding lump-sum settlements, are expected to range from \$12.0 million to \$17.6 million for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump-sum settlements, are expected to range from \$7.3 million to \$8.5 million for the next five years.

Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

(19) Postretirement Healthcare and Life Insurance Benefits

The University sponsors a postretirement life insurance and healthcare benefits plan. Participants hired after 2002 pay the full retiree-specific premium equivalent and are therefore assumed to pay the full cost of their coverage. The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed-income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	2021			2020	
	Emory University	Emory Healthcare	Total	Total	
APBO, beginning of year	\$ 136,735	72,844	209,579	\$ 200,735	
Service cost	1,936	501	2,437	2,610	
Interest cost	3,076	1,575	4,651	5,633	
Actuarial losses (gains)	4,045	1,204	5,249	6,262	
Benefits paid	(4,239)	(2,584)	(6,823)	(5,661)	
APBO, end of year	\$ 141,553	73,540	215,093	\$ 209,579	

Discount rate to determine APBO as of August 31, 2021 and 2020 was 2.7% and 2.8%, respectively.

The changes in the fair value of plan assets, funded status of the plan, and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2021			2020	
	Emory University	Emory Healthcare	Total	Total	
Fair value of plan assets, beginning of year	\$ 80,685	17,098	97,783	\$ 90,530	
Actual return on plan assets	16,977	2,415	19,392	9,016	
Benefits paid from plan assets	–	–	–	(1,763)	
Fair value of plan assets, end of year	\$ 97,662	19,513	117,175	\$ 97,783	
Funded status – accrued postretirement benefit cost recognized in the consolidated statements of financial position	\$ (43,891)	(54,027)	(97,918)	\$ (111,796)	

The components of net periodic postretirement benefit cost for the years ended August 31 are as follows (in thousands):

	2021			2020	
	Emory University	Emory Healthcare	Total	Total	
Service cost of benefits earned	\$ 1,936	501	2,437	\$ 2,610	
Interest cost on APBO	3,076	1,575	4,651	5,633	
Expected return on plan assets	(5,285)	(1,120)	(6,405)	(6,250)	
Recognized net actuarial loss	3,579	3,367	6,946	7,382	
Net periodic postretirement benefit cost	\$ 3,306	4,323	7,629	\$ 9,375	

Discount rate and expected return on plan assets used to determine net periodic postretirement benefit cost for the years ended August 31, 2021 and 2020 was 2.8% and 3.1%, respectively, and 6.6% and 7.0%, respectively.

The amounts accumulated in net assets without donor restrictions follow as of August 31 (in thousands):

	2021			2020	
	Emory University	Emory Healthcare	Total	Total	
Net unrecognized actuarial loss	\$ 56,550	26,045	82,595	\$ 97,309	
Prior service cost	(56)	–	(56)	(86)	
Total	\$ 56,494	26,045	82,539	\$ 97,223	

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

In fiscal year 2022, net unrecognized actuarial losses of \$2.7 million for Emory University and \$2.9 million for Emory Healthcare are expected to be amortized from net assets without donor restrictions into net periodic postretirement benefit cost.

Plan Assets

The Investment Committee of Emory University's Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans.

The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations. The secondary objective is to meet or exceed the plans' actuarial assumed rate of return over time without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

The following table summarizes the VEBA Trust assets for the University and Emory Healthcare as of August 31 (in thousands):

2021							
	Total Fair Value	Fair Value Hierarchy		NAV	Target Allocation	Total Asset Allocation	
		Level 1	Level 2				
Fixed income	\$ 19,215	9,784	9,431	–	15%	16%	
Public equity	83,615	8,931	49,291	25,393	70	71	
Absolute return	12,308	6,694	–	5,614	10	11	
Private Equity/ Venture Capital	1,824	–	–	1,824	5	2	
Short-term investment and cash equivalent	213	213	–	–	–	–	
Total investments	\$ 117,175	25,622	58,722	32,831	100%	100%	

2020							
	Total Fair Value	Fair Value Hierarchy		NAV	Target Allocation	Total Asset Allocation	
		Level 1	Level 2				
Fixed income	\$ 20,924	13,998	6,926	–	25%	21%	
Public equity	76,861	17,750	44,352	14,759	75	79	
Short-term investment and cash equivalent	(2)	(2)	–	–	–	–	
Total investments	\$ 97,783	31,746	51,278	14,759	100%	100%	

Cash Flows

Emory University and Emory Healthcare expect to contribute \$4.6 million and \$2.7 million, respectively, to the postretirement benefit plan during fiscal year 2022.

Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$4.5 million to \$5.6 million for Emory University and from \$2.7 million to \$3.3 million for Emory Healthcare for the next five years.

(20) Functional Expenses

The consolidated statements of activities present expenses by natural classification. The University also summarizes expenses

by functional classification, in accordance with its mission. The University's primary program services are instruction, research, public service, and the delivery of healthcare and medical services. Expenses for academic support, institutional support, and independent operations/auxiliary enterprises are generally incurred in support of these primary program activities, with academic support being related to student financial aid. Capital and plant expenditures, costs for operation and maintenance of plant, interest on indebtedness, and depreciation and amortization are allocated using a variety of cost allocation techniques, such as square footage and time and effort.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

The consolidated statements of activities include the following functional expenses for the years ended August 31 (in thousands, net of the cost allocations and recharges referenced above):

2021

		Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$	305,359	265,913	90,250	155,355	58,372	2,628,942	97,475	3,601,666
Fringe benefits		80,373	74,468	25,061	28,524	16,650	539,118	35,404	799,598
Student financial aid		–	–	28,678	–	–	–	–	28,678
Other operating expenses		54,970	210,471	58,698	26,322	45,565	1,921,526	29,538	2,347,090
Interest on indebtedness		6,338	10,089	4,029	2,034	1,594	32,144	18,731	74,959
Depreciation and amortization		30,007	50,238	18,115	25,967	8,259	161,504	21,316	315,406
Total expenses	\$	477,047	611,179	224,831	238,202	130,440	5,283,234	202,464	7,167,397

* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$5.0 billion. Healthcare administrative costs are \$432.1 million, included therein.

2020

		Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$	310,588	250,500	90,830	161,045	55,504	2,398,787	99,878	3,367,132
Fringe benefits		74,597	62,373	22,334	20,294	14,054	499,813	20,758	714,223
Student financial aid		–	–	27,302	–	–	–	–	27,302
Other operating expenses		55,590	198,984	56,377	4,898	42,579	1,715,070	27,361	2,100,859
Interest on indebtedness		7,046	11,216	4,479	2,261	1,771	27,072	18,919	72,764
Depreciation and amortization		29,537	49,476	17,832	25,563	8,130	155,687	17,120	303,345
Total expenses	\$	477,358	572,549	219,154	214,061	122,038	4,796,429	184,036	6,585,625

* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$4.6 billion. Healthcare administrative costs are \$445.8 million, included therein.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the space study and debt financing records. Total amounts allocated in 2021 and 2020 were \$190.6 million and \$175.8 million, respectively. Fundraising costs were approximately \$41.3 million and \$40.0 million in 2021 and 2020, respectively.

(21) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare's wholly owned offshore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2021 and 2020, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$255.5 million (discounted 2.5%) and \$262.1 million (discounted at 2.5%), respectively.

Emory has purchased layered excess and umbrella insurance and reinsurance coverage beyond the amounts retained by CCIC, through various carriers, for a total of \$105.0 million per claim and in the aggregate.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims, and the wide range of potential outcomes complicate the estimation. The University's management believes adequate provision has been made for the related risk.

(22) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former U.S. President Jimmy Carter and Rosalynn Carter, which sponsors various domestic and international programs. The Board of Trustees of CCI comprises 16 to 28 members, including its founders, and others as elected half by the University, including the University's president, and half by the Carter Center class trustees. The University's Board of Trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws. Funds held in trust for others include \$1.165 billion and \$866.1 million, representing CCI's investment

in the University's long-term investment portfolio as of August 31, 2021 and 2020, respectively. CCI is permitted partial withdrawals of up to 10% per year (inclusive of regular spending payouts), with 30 days' written notice prior to a calendar quarter or fiscal year end. A full withdrawal request by CCI requires at least one year's written notice and is subject to a multi-year distribution schedule in line with the duration of the long-term investment portfolio, as agreed upon by both CCI and the University.

Emory University and Children's Healthcare of Atlanta, Inc. (Children's), a Georgia nonprofit corporation, established the Emory + Children's Pediatric Institute (the Institute) effective September 1, 2018 under a Master Affiliation Agreement (the affiliation agreement). Under the terms of the affiliation agreement, approximately 350 Emory University School of Medicine Department of Pediatrics faculty physicians and PhD researchers transferred to the Institute and became employees thereof. The affiliation agreement restructured previous arrangements between the parties for pediatric teaching, research, and related clinical services. The ownership of the Institute is 50% Emory University and 50% Children's, with equal representation on the governing board. The funding obligations of each party are specified by the affiliation agreement, and each party funds its mission-related expenses. The University reports research and teaching expenses provided by these 350 faculty members in salaries, fringe benefits, professional fees and purchased services, and other operating expenses in the consolidated statements of activities.

(23) Commitments and Contingencies

Emory University and Emory Healthcare are in the process of constructing, renovating, and equipping certain facilities for which the outstanding commitments at August 31, 2021 totaled \$217.7 million and \$493.6 million, respectively.

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures which may be disallowed by the granting agencies, cannot be determined at this time, although management expects they will not have a material effect on the University's consolidated financial statements.

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2021 AND 2020

such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel review.

In addition, the University is subject to many federal and state regulations, and as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of many of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the consolidated statements of financial position or operating results of the University. The University also has a comprehensive program of primary and excess insurance. Management of the University believes any current pending lawsuit subjecting the University to liability would not have a materially adverse effect on the University's consolidated statements of financial position.

Emory Healthcare and SJHS have a JOC under the name of Emory/Saint Joseph's, Inc. to further the respective missions of Emory Healthcare and CHE Trinity Health. Under the JOC Contribution Agreement, Emory Healthcare maintains a 51% controlling ownership interest in the JOC. SJHS has a noncontrolling membership interest in the JOC of 49%. Effective August 31, 2014, CHE Trinity Health has a put right, as defined in the JOC Contribution Agreement, that may be exercised at any time with written notice to Emory Healthcare. Upon the occurrence of such event, Emory Healthcare may be required to purchase from SJHS its noncontrolling interest in the JOC.

As part of the terms of the Definitive Agreement to acquire DRHS, Emory Healthcare committed \$239.0 million on capital projects to benefit DRHS and its affiliates over a 7-year period, beginning September 1, 2018. Such period may be extended under certain circumstances to a period of no more than 10 years. The outstanding commitment amount based on the terms of the Definitive Agreement totaled approximately \$120.0 million as of August 31, 2021.

(24) Subsequent Events

Emory has evaluated subsequent events after the consolidated statements of financial position date of August 31, 2021 through December 20, 2021, the date the consolidated financial statements were available to be issued and noted that there are no other items to disclose.



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

The Board of Trustees
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statement of financial position as of August 31, 2021, the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 20, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia
December 20, 2021

**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF
FEDERAL AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Research and Development Cluster:				
U.S. Department of Agriculture:				
Agriculture Research – Basic and Applied Research:				
Sustainable Agriculture Research and Education:				
Pass-through University of Georgia	20163864025382	10.215	\$ —	6,675
Total CFDA No. 10.215			—	6,675
Agriculture and Food Research Initiative (AFRI)	2019-67013-29371	10.310	—	90,285
Agriculture and Food Research Initiative (AFRI)	20196701729642	10.310	—	69,613
Agriculture and Food Research Initiative (AFRI)	20206703431728	10.310	—	46,186
Pass-through Kansas State University	20206701931157	10.310	—	27,300
Total CFDA No. 10.310			—	233,384
Crop Protection and Pest Management Competitive Grants Program:				
Pass-through North Carolina State University	20,187,000,828,884	10.329	—	9,805
Total CFDA No. 10.329			—	9,805
U.S. Department of Agriculture Total			—	249,864
U.S. Department of Defense:				
Basic and Applied Scientific Research				
Total CFDA No. 12.300	N00014-09-1-0912	12.300	—	(11,249)
			—	(11,249)
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA1-15-C-0075	12.351	398,467	580,897
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA11810029	12.351	163,473	324,338
Total CFDA No. 12.351			561,940	905,235
Military Medical Research and Development	W81XWH-15-1-0154	12.420	19,040	72,478
Military Medical Research and Development	W81XWH-15-1-0545	12.420	—	313
Military Medical Research and Development	W81XWH-16-1-0584	12.420	—	1,257
Military Medical Research and Development	W81XWH-17-1-0104	12.420	—	(66)
Military Medical Research and Development	W81XWH-17-1-0271	12.420	—	296,239
Military Medical Research and Development	W81XWH-17-1-0438	12.420	—	19,973
Military Medical Research and Development	W81XWH-17-1-0439	12.420	—	(962)
Military Medical Research and Development	W81XWH-17-1-0459	12.420	—	2,728
Military Medical Research and Development	W81XWH1810373	12.420	45,477	45,477
Military Medical Research and Development	W81XWH1810526	12.420	—	309,453
Military Medical Research and Development	W81XWH1810700	12.420	—	348,096
Military Medical Research and Development	W81XWH-18-KCRP-CA	12.420	—	52,667
Military Medical Research and Development	W81XWH1910068	12.420	—	648
Military Medical Research and Development	W81XWH-19-1-0069	12.420	—	317,457
Military Medical Research and Development	W81XWH1910498	12.420	128,310	400,407
Military Medical Research and Development	W81XWH1910567	12.420	—	43,899
Military Medical Research and Development	W81XWH1910776	12.420	—	378,558
Military Medical Research and Development	W81XWH1910840	12.420	—	174,801
Military Medical Research and Development	W81XWH2010052	12.420	—	49,712
Military Medical Research and Development	W81XWH2010446	12.420	—	133,646
Military Medical Research and Development	W81XWH2010525	12.420	—	192,341
Military Medical Research and Development	W81XWH2010526	12.420	—	116,709
Military Medical Research and Development	W81XWH-17-1-0634	12.420	106,765	251,190
Military Medical Research and Development	W81XWH-17-C-0229	12.420	—	151,744
Pass-through Georgia Institute of Technology	W81XWH-18-1-0669	12.420	—	94,853
Pass-through University of Arizona	W81XWH-17-1-0443	12.420	—	378,377
Pass-through Wayne State University	W81XWH-19-1-0794	12.420	—	77,308
Total CFDA No. 12.420			299,592	3,909,303
Basic Scientific Research	W911NF-17-1-0382	12.431	—	1,369
Pass-through Arizona State University	W911NF1910231	12.431	—	125,244
Pass-through Mclean Hospital	W911NF-17-2-0086	12.431	—	99,523
Total CFDA No. 12.431			—	226,136
Basic, Applied, and Advanced Research in Science and Engineering:				
Pass-through University of Washington	W911NF1910291	12.630	—	24,527
Total CFDA No. 12.630			—	24,527
Uniformed Services University Medical Research Projects:				
Pass-through Duke University	HT9404-13-0032	12.750	—	(4,933)
Pass-through Henry M Jackson Foundation	HU0001-14-2-0052	12.750	—	5,893
Pass-through Henry M Jackson Foundation	HU00012020018	12.750	—	1,228,348
Pass-through Henry M Jackson Foundation	HU00012120029	12.750	5,453	259,669
Total CFDA No. 12.750			5,453	1,488,977
Air Force Defense Research Sciences Program	FA9550-17-1-0006	12.800	—	14,246
Air Force Defense Research Sciences Program	FA9550-18-1-0189	12.800	—	85,775
Air Force Defense Research Sciences Program	FA9550-18-1-0420	12.800	1,380,283	1,593,427
Air Force Defense Research Sciences Program	FA9550-20-1-0372	12.800	—	159,809
Air Force Defense Research Sciences Program	FA9550-20-1-0411	12.800	—	82,740
Pass-through State University of New York Buffalo	FA8650-18-2-5402	12.800	—	52,779
Pass-through Yale University	FA9550-17-0198	12.800	—	(767)
Total CFDA No. 12.800			1,380,283	1,988,009
Language Grant Program	H98230-20-1-0232	12.900	—	64,902
Total CFDA No. 12.900			—	64,902
Research and Technology Development:				
Pass-through Duke University	W911NF1920111	12.910	—	11,423
Pass-through Georgia Institute of Technology	HR001117C0124	12.910	—	44,160
Pass-through Georgia Institute of Technology	HR0011-19-2-0008	12.910	—	383,759
Pass-through Johns Hopkins University	2019-190516000005	12.910	—	117,780
Pass-through Vanderbilt University Medical Center	066469933	12.910	—	112,524
Total CFDA No. 12.910			—	669,646
Contract	HR0011940590	12.RD	85,742	106,808
Contract	W911NF-16-C-0008	12.RD	—	45
Contract	W81XWH	12.RD	—	257,961

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Contract	W81XWH-16-0108	12.RD	\$ —	89,482
Contract	W81XWH1810505	12.RD	—	280,665
Contract	W81XWH1910281	12.RD	—	177,188
Contract	W81XWH1910353	12.RD	—	217,729
Contract	W81XWH1910420/P00001	12.RD	—	347,089
Pass-through Geneva Foundation	W81XWH-17-C-0029	12.RD	—	193,629
Pass-through North Carolina State University	W911NF	12.RD	—	168,971
Pass-through University of Dayton	FA8651-20-F-1024	12.RD	—	76,104
Pass-through University of Michigan	DTNH2215D00017/693JJ918F000234	12.RD	—	19,296
Pass-through University of Michigan	W911QX17D0006	12.RD	—	11,709
Pass-through University of Pittsburgh	W81XWH-16-D-0024 – W81XWH18F0426	12.RD	—	(1,517)
Total CFDA No. 12.RD			85,742	1,945,159
U.S. Department of Defense Total			2,333,010	11,210,645
U.S. Department of Justice:				
National Institute of Justice Research, Evaluation, and Development Project Grants:				
Pass-through George Mason University	2019-R2-CX-0005	16.560	—	7,160
Total CFDA No. 16.560			—	7,160
Rural Domestic Violence, Dating Violence, Sexual Assault, and Stalking Assistance Program:				
Pass-through Childrens Healthcare of Atlanta	2017-WR-AX-0005	16.589	—	1,722
Total CFDA No. 16.589			—	1,722
U.S. Department of Justice Total			—	8,882
U.S. Department of State:				
Academic Exchange Programs – Humphrey Fellowship Program:				
Pass-through Institute of International Education	SECAGD19CA0047	19.010	—	7,134
Pass-through Institute of International Education	SECAGD20CA0002	19.010	—	124,448
Total CFDA No. 19.010			—	131,582
U.S. Department of State Total			—	131,582
U.S. Department of Transportation:				
National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants	DTNH2217D00068	20.614	—	(15)
Total CFDA No. 20.614			—	(15)
Contract	DTNH2217F00160	20.RD	40,450	649,980
Total CFDA No. 20.RD			40,450	649,980
U.S. Department of Transportation Total			40,450	649,965
National Aeronautics and Space Administration:				
Science	80NSSC19K0191	43.001	144,850	252,732
Science	80NSSC20K0309	43.001	—	1,701
Science	80NSSC21K0507	43.001	—	16,397
Science	NNX16AQ28G 000004	43.001	158	9,981
Pass-through California Institute of Technology	1588347	43.001	—	158,983
Pass-through Center for the Advancement of Science in Space, Inc.	NNH11CD70A	43.001	—	3,062
Pass-through University of Georgia	80NSSC20K0360	43.001	—	78,843
Total CFDA No. 43.001			145,008	521,699
Aeronautics				
Pass-through California Institute of Technology	NMO710860	43.002	—	31,398
Total CFDA No. 43.002			—	31,398
Exploration	80NSSC188K1116	43.003	—	456,951
Exploration	80NSSC21K0251	43.003	—	109,297
Total CFDA No. 43.003			—	566,248
National Aeronautics and Space Administration Total			145,008	1,119,345
National Endowment for the Humanities:				
Promotion of the Humanities Research	RQ-260871-18	45.161	—	56,360
Promotion of the Humanities Research	RZ – 230579-15	45.161	—	7,556
Total CFDA No. 45.161			—	63,916
National Leadership Grants:				
Pass-through Institute of Museum and Library Services	LG-94-17-0269-17	45.312	—	11,838
Total CFDA No. 45.312			—	11,838
National Endowment for the Humanities Total			—	75,754
National Science Foundation:				
Engineering Grants	1706891	47.041	—	119
Engineering Grants	1741691	47.041	220,154	490,937
Engineering Grants	1762211	47.041	—	109,915
Engineering Grants	1804198	47.041	—	86,753
Engineering Grants	1807568	47.041	—	108,185
Engineering Grants	1818476	47.041	—	3,309
Engineering Grants	1822606	47.041	18,828	81,232
Engineering Grants	184186	47.041	—	76,983
Engineering Grants	1926387	47.041	—	69,253
Engineering Grants	2002815	47.041	—	3,805
Engineering Grants	2005786	47.041	—	69,392
Engineering Grants	2032273	47.041	—	157,455
Engineering Grants	2044657	47.041	—	52,832
Engineering Grants	1749677	47.041	—	9,312
Pass-through Georgia Institute of Technology	EEC-1648035	47.041	—	933
Pass-through Georgia Institute of Technology			—	933
Pass-through Indiana University	1928481	47.041	—	154,521
Total CFDA No. 47.041			238,982	1,474,936
Mathematical and Physical Sciences	1463882	47.049	—	(1,302)
Mathematical and Physical Sciences	1555048	47.049	—	31,452
Mathematical and Physical Sciences	1557960	47.049	—	14,872
Mathematical and Physical Sciences	1565912	47.049	—	(232)

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mathematical and Physical Sciences	1606418	47.049	\$ —	(1,449)
Mathematical and Physical Sciences	1611102	47.049	—	(265)
Mathematical and Physical Sciences	1654485	47.049	—	106,561
Mathematical and Physical Sciences	1700982	47.049	2,722,113	4,076,792
Mathematical and Physical Sciences	1709182	47.049	—	1,419
Mathematical and Physical Sciences	1726536	47.049	—	693
Mathematical and Physical Sciences	1751636	47.049	—	59,097
Mathematical and Physical Sciences	1764385	47.049	—	59,261
Mathematical and Physical Sciences	1801951	47.049	—	80,542
Mathematical and Physical Sciences	1807865	47.049	—	24,248
Mathematical and Physical Sciences	1808288	47.049	—	141,868
Mathematical and Physical Sciences	1808509	47.049	—	(1,316)
Mathematical and Physical Sciences	1808771	47.049	—	79,750
Mathematical and Physical Sciences	1809566	47.049	—	24,565
Mathematical and Physical Sciences	1819042	47.049	—	45,036
Mathematical and Physical Sciences	1822262	47.049	—	(2,109)
Mathematical and Physical Sciences	1900532	47.049	—	113,122
Mathematical and Physical Sciences	1900555	47.049	—	107,216
Mathematical and Physical Sciences	1904885	47.049	—	189,745
Mathematical and Physical Sciences	1905782	47.049	—	159,760
Mathematical and Physical Sciences	1905809	47.049	—	30,762
Mathematical and Physical Sciences	1905947	47.049	—	151,592
Mathematical and Physical Sciences	1945200	47.049	—	4,313
Mathematical and Physical Sciences	1951682	47.049	—	18,121
Mathematical and Physical Sciences	1956154	47.049	—	96,290
Mathematical and Physical Sciences	2003157	47.049	—	37,143
Mathematical and Physical Sciences	2003692	47.049	—	125,637
Mathematical and Physical Sciences	2003962	47.049	—	211,455
Mathematical and Physical Sciences	2003987	47.049	—	98,843
Mathematical and Physical Sciences	2004080	47.049	—	273,672
Mathematical and Physical Sciences	2004126	47.049	—	98,538
Mathematical and Physical Sciences	2004846	47.049	—	167,821
Mathematical and Physical Sciences	2010524	47.049	—	161,592
Mathematical and Physical Sciences	2012686	47.049	—	16,682
Mathematical and Physical Sciences	2014173	47.049	—	102,189
Mathematical and Physical Sciences	2015540	47.049	—	24,941
Mathematical and Physical Sciences	2038019	47.049	—	26,978
Mathematical and Physical Sciences	2038118	47.049	—	20,655
Mathematical and Physical Sciences	2051019	47.049	—	126,376
Mathematical and Physical Sciences	2055579	47.049	—	139
Mathematical and Physical Sciences	2103515	47.049	—	103,228
Mathematical and Physical Sciences	2108621	47.049	—	29,226
Mathematical and Physical Sciences	2113350	47.049	—	20,879
Mathematical and Physical Sciences	CHE 1205646	47.049	—	80
Mathematical and Physical Sciences	CHE 1352040	47.049	—	(3,822)
Pass-through Georgia Institute of Technology	1806833	47.049	—	85,933
Total CFDA No. 47.049			2,722,113	7,338,589
Geosciences:				
Pass-through Natl Center For Atmospheric Research	1553579	47.050	—	41,856
Total CFDA No. 47.050			—	41,856
Computer and Information Science and Engineering	1553579	47.070	—	33,063
Computer and Information Science and Engineering	1636693	47.070	3,001	21,956
Computer and Information Science and Engineering	1722906	47.070	—	25,242
Computer and Information Science and Engineering	1755958	47.070	—	53,827
Computer and Information Science and Engineering	1822378	47.070	—	78,559
Computer and Information Science and Engineering	1835364	47.070	20,211	59,833
Computer and Information Science and Engineering	1838200	47.070	—	395,055
Computer and Information Science and Engineering	1907711	47.070	—	127,546
Computer and Information Science and Engineering	1952192	47.070	—	45,162
Computer and Information Science and Engineering	2003720	47.070	—	132,123
Computer and Information Science and Engineering	2011666	47.070	—	8,050
Computer and Information Science and Engineering	2027783	47.070	—	74,270
Computer and Information Science and Engineering	2103592	47.070	—	72,059
Computer and Information Science and Engineering	2103745	47.070	—	81,773
Computer and Information Science and Engineering	2106446	47.070	2,050	65,583
Computer and Information Science and Engineering	2110926	47.070	1,963	32,839
Pass-through Georgia Institute of Technology	1915504	47.070	—	73,974
Pass-through University of Virginia	2041952	47.070	—	19,524
Pass-through Virginia Tech	1547580	47.070	—	39,367
Total CFDA No. 47.070			27,225	1,439,805
Biological Sciences	1624104	47.074	—	69,130
Biological Sciences	1656247	47.074	4,261	48,842
Biological Sciences	1750553	47.074	—	178,494
Biological Sciences	1754431	47.074	—	141,139
Biological Sciences	1754595	47.074	—	160,263
Biological Sciences	1755002	47.074	—	100,883
Biological Sciences	1755418	47.074	—	54,002
Biological Sciences	1844803	47.074	7,524	23,858
Biological Sciences	1919953	47.074	—	85,147
Biological Sciences	1922720	47.074	—	186,086
Biological Sciences	1927411	47.074	—	20,506
Biological Sciences	1931697	47.074	—	319,412
Biological Sciences	1943415	47.074	—	124,042
Biological Sciences	2032084	47.074	—	83,396
Biological Sciences	2032610	47.074	—	88,120
Biological Sciences	2050009	47.074	—	145,965
Biological Sciences	2106137	47.074	—	19,222
Biological Sciences	DBI 1346549	47.074	—	3,000
Biological Sciences	IOS 1354998	47.074	—	87
Biological Sciences	MCB 1350829	47.074	—	(589)
Pass-through Case Western Reserve University	DBI-2015317	47.074	—	123,038
Pass-through University of California Riverside	S-001187	47.074	—	101,064

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Washington Seattle	1748843	47.074	\$ —	157,297
Total CFDA No. 47.074			11,785	2,232,404
Social, Behavioral, and Economic Sciences	1528091	47.075	—	(1,764)
Social, Behavioral, and Economic Sciences	1533260	47.075	116,654	229,773
Social, Behavioral, and Economic Sciences	1632477	47.075	—	12,834
Social, Behavioral, and Economic Sciences	1748293	47.075	—	104,824
Social, Behavioral, and Economic Sciences	1756853	47.075	—	51,594
Social, Behavioral, and Economic Sciences	1822677	47.075	—	197,041
Social, Behavioral, and Economic Sciences	1830816	47.075	—	2,438
Social, Behavioral, and Economic Sciences	1851501	47.075	—	36,926
Social, Behavioral, and Economic Sciences	1853185	47.075	—	271
Social, Behavioral, and Economic Sciences	1920081	47.075	—	3,229
Social, Behavioral, and Economic Sciences	1926075	47.075	—	36,142
Social, Behavioral, and Economic Sciences	1945046	47.075	—	85,900
Social, Behavioral, and Economic Sciences	1946767	47.075	—	221,640
Social, Behavioral, and Economic Sciences	1946768	47.075	—	195,383
Social, Behavioral, and Economic Sciences	1947845	47.075	—	11,627
Social, Behavioral, and Economic Sciences	1952882	47.075	—	69,086
Social, Behavioral, and Economic Sciences	2017425	47.075	—	69,085
Social, Behavioral, and Economic Sciences	2020234	47.075	—	23,541
Social, Behavioral, and Economic Sciences	2029678	47.075	—	10,629
Social, Behavioral, and Economic Sciences	2051553	47.075	—	22,349
Pass-through Natl Bureau of Economic Research	1919372	47.075	—	55,458
Total CFDA No. 47.075			116,654	1,438,006
Education and Human Resources	1821533	47.076	—	156,647
Education and Human Resources	1937971	47.076	—	1,522,830
Education and Human Resources	2010333	47.076	—	70,516
Pass-through Harvard University	1631563	47.076	—	3,394
Total CFDA No. 47.076			—	1,753,387
Polar Programs	1949637	47.078	—	714
Polar Programs	2025795	47.078	—	37,130
Total CFDA No. 47.078			—	37,844
International Science and Engineering (OISE)	1827201	47.079	—	9,699
Total CFDA No. 47.079			—	9,699
National Science Foundation Total			3,116,759	15,766,526
U.S. Department of Veterans Affairs:				
Contract:				
Pass-through Fdtn for Atlanta Veterans Educ and Res	MRC122-M20024	64.RD	—	30,843
Total CFDA No. 64.RD			—	30,843
U.S. Department of Veterans Affairs Total				
U.S. Department of Veterans Affairs Total				
U.S. Environmental Protection Agency:				
Science to Achieve Results (STAR) Research Program	83586901	66.509	47,155	59,510
Science to Achieve Results (STAR) Research Program	83615301 Mod. 2	66.509	—	15,490
Science to Achieve Results (STAR) Research Program	DP1DA042103	66.509	—	20,918
Pass-through Carleton University	4962-RFA17-2/18-4	66.509	—	155
Total CFDA No. 66.509			47,155	96,073
Solid Waste Management Assistance Grants	02D01621	66.808	—	40,906
Total CFDA No. 66.808			—	40,906
Environmental Education Grants	01D14720	66.951	6,000	43,631
Total CFDA No. 66.951			6,000	43,631
U.S. Environmental Protection Agency Total				
U.S. Environmental Protection Agency Total				
U.S. Department of Energy:				
Office of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	—	161,347
Office of Science Financial Assistance Program	DE-FG02-01ER15153-0016	81.049	—	56
Office of Science Financial Assistance Program	DE-FG02-07ER15906	81.049	—	214,328
Office of Science Financial Assistance Program	DE-SC0008798	81.049	—	402,419
Office of Science Financial Assistance Program	DE-SC0016004 MOD 0002	81.049	—	77,591
Office of Science Financial Assistance Program	DE-SC0018976	81.049	—	139,414
Office of Science Financial Assistance Program	DE-SC0019362	81.049	—	53,091
Office of Science Financial Assistance Program	DE-SC0019374	81.049	1,089,842	1,455,145
Office of Science Financial Assistance Program	DE-SC0020101	81.049	—	125,794
Office of Science Financial Assistance Program	DE-SC0020996	81.049	—	114,118
Office of Science Financial Assistance Program	DE-SC0021290	81.049	—	52,632
Pass-through University of North Carolina Chapel Hill	DE-SC0021173	81.049	—	102,777
Total CFDA No. 81.049			1,089,842	2,898,712
U.S. Department of Energy Total				
U.S. Department of Energy Total				
U.S. Department of Education:				
Education Research, Development, and Dissemination	R305A160240-18	84.305	51,505	67,799
Total CFDA No. 84.305			51,505	67,799
Research in Special Education:				
Pass-through Florida State University	R324A180193	84.324	156,074	187,774
Total CFDA No. 84.324			156,074	187,774
Contract	P022A190032	84.RD	—	10,606
Total CFDA No. 84.RD			—	10,606
U.S. Department of Education Total				
U.S. Department of Education Total				
U.S. Department of Health and Human Services:				
Global AIDS	NU14GH001237	93.067	824,714	1,031,195
Total CFDA No. 93.067			824,714	1,031,195

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Chronic Diseases: Research, Control, and Prevention				
Pass-through American College of Rheumatology	6 NU58DP006138-02-02	93.068	\$ —	7,426
Pass-through Lupus Foundation of America	NU58DP006139	93.068	—	1,185
Total CFDA No. 93.068			—	8,611
Birth Defects and Developmental Disabilities – Prevention and Surveillance				
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000057	93.073	—	433,793
Pass-through University of Iowa	NU50DD000098	93.073	—	249,391
Total CFDA No. 93.073	U01DD001223	93.073	—	9,379
Total CFDA No. 93.073			—	692,563
Family Smoking Prevention and Tobacco Control Act Regulatory Research				
Pass-through University of Michigan	U54CA229974	93.077	—	15,765
Total CFDA No. 93.077			—	15,765
Blood Disorder Program: Prevention, Surveillance, and Research				
Pass-through Georgia State University	NU58DD0000021	93.080	—	987
Pass-through Georgia State University	NU58DD000003	93.080	135	20,060
Pass-through Hemophilia of Georgia	NU27DD000020	93.080	—	26,348
Pass-through Hemophilia of Georgia	NU27DD001155	93.080	—	7,959
Total CFDA No. 93.080			135	55,354
Prevention of Disease, Disability, and Death by Infectious Diseases				
Pass-through Johns Hopkins University	U54CK000601	93.084	—	7,586
Pass-through Johns Hopkins University	18U01CK000554	93.084	70,006	254,514
Pass-through State University of New York Albany	U01CK000554	93.084	—	57,189
Pass-through University of Illinois at Chicago	NU38PS004650	93.084	—	260,282
Pass-through University of Maryland, Baltimore	U01CK000557	93.084	—	114,652
Pass-through University of Utah	U01CK000555	93.084	18,291	146,719
Pass-through Yale University	U01CK000556	93.084	—	295,923
Pass-through Yale University	U01CK000572	93.084	—	89,361
Total CFDA No. 93.084			88,297	1,226,226
Food and Drug Administration Research				
Food and Drug Administration Research	5R01FD003527-02 REVISED	93.103	—	55
Food and Drug Administration Research	R01FD004814	93.103	7,948	195,910
Food and Drug Administration Research	R01FD005746	93.103	250,087	474,059
Food and Drug Administration Research	U01FD006884	93.103	—	83,269
Pass-through Duke University	R01FD003539	93.103	—	9,061
Pass-through Health And Environmental Sciences Inst	U01FD006676	93.103	—	59,330
Total CFDA No. 93.103			258,035	821,684
Maternal and Child Health Federal Consolidated Programs				
Maternal and Child Health Federal Consolidated Programs	5T76MC28446-04	93.110	15,542	15,542
Pass-through Organization of Teratology Information Specialists	T76MC28446	93.110	50,903	351,210
Total CFDA No. 93.110	UG4MC27861	93.110	—	61,443
Total CFDA No. 93.110			66,445	428,195
Environmental Health				
Environmental Health	5R01ES025145-05	93.113	119,764	128,213
Environmental Health	D43ES030927	93.113	71,849	102,751
Environmental Health	F30ES029018	93.113	—	18,597
Environmental Health	F31ES030980	93.113	—	14,770
Environmental Health	F31ES031845	93.113	—	15,071
Environmental Health	F32ES031827	93.113	—	64,706
Environmental Health	K00ES033033	93.113	—	81,400
Environmental Health	P30ES019776	93.113	159,831	1,670,015
Environmental Health	P50ES026071	93.113	—	(157)
Environmental Health	R00ES026648	93.113	—	282,430
Environmental Health	R01ES023485	93.113	—	140,470
Environmental Health	R01ES025775	93.113	5,000	434,496
Environmental Health	R01ES026082	93.113	337,653	467,349
Environmental Health	R01ES027859	93.113	—	214,347
Environmental Health	R01ES027892	93.113	169,058	546,019
Environmental Health	R01ES028346	93.113	162,127	296,770
Environmental Health	R01ES029165	93.113	400,133	518,570
Environmental Health	R01ES029212	93.113	386,558	584,238
Environmental Health	R01ES031980	93.113	—	2,006
Environmental Health	R01ES032009	93.113	—	2,254
Environmental Health	R01ES032140	93.113	—	186,063
Environmental Health	R21ES028903	93.113	39,412	105,451
Environmental Health	R21ES031824	93.113	—	216,129
Environmental Health	R21ES032117	93.113	—	6,729
Environmental Health	R21ES032344	93.113	—	25,382
Environmental Health	R21ES032606	93.113	—	44,107
Environmental Health	R24ES028507	93.113	283,506	337,086
Environmental Health	R24ES028528	93.113	21,770	386,077
Environmental Health	R24ES029490	93.113	—	421,086
Environmental Health	T32ES012870	93.113	—	482,350
Pass-through Colorado State University	R01ES029995	93.113	—	18,228
Pass-through Georgia State University	R21ES029252	93.113	—	5,272
Pass-through Johns Hopkins University	R01ES030414	93.113	—	50,907
Pass-through Mount Sinai School of Medicine	R21ES029328	93.113	—	90,746
Pass-through University of Alabama Birmingham	U54ES030246	93.113	—	12,743
Pass-through University of California Los Angeles	R21ES030175	93.113	—	156
Pass-through University Of Louisville	R01ES032189	93.113	—	284,454
Pass-through University of Nevada	R01ES029528	93.113	—	20,791
Pass-through University of Southern California	R00ES027870	93.113	—	43,686
Pass-through University of Southern California	R01ES029944	93.113	—	53,881
Pass-through University of Southern California	R01ES032247	93.113	—	13,161
Pass-through University of Southern California	R21ES029681	93.113	—	15,023
Total CFDA No. 93.113			2,156,661	8,403,823
Preventive Medicine and Public Health Residency Training Program, Integrative Medicine Program, and National Center for Integrative Primary Healthcare				
National Center for Integrative Primary Healthcare	D33HP31663	93.117	—	373,483
Total CFDA No. 93.117			—	373,483
Oral Diseases and Disorders Research				
Oral Diseases and Disorders Research	R00DE025060	93.121	—	92,675
Oral Diseases and Disorders Research	R00DE026810	93.121	—	123,830
Oral Diseases and Disorders Research	R01DE025837	93.121	27,432	319,936

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Oral Diseases and Disorders Research	R01DE026333	93.121	\$ —	845,717
Oral Diseases and Disorders Research	R01DE026941	93.121	110,941	444,362
Oral Diseases and Disorders Research	R01DE028342	93.121	56,748	839,181
Oral Diseases and Disorders Research	R01DE028351	93.121	—	25,671
Oral Diseases and Disorders Research	R01DE028905	93.121	—	436,513
Oral Diseases and Disorders Research	R03DE027103	93.121	—	88,936
Oral Diseases and Disorders Research	R03DE028387	93.121	—	14,669
Oral Diseases and Disorders Research	R03DE030118	93.121	—	4,545
Oral Diseases and Disorders Research	R21DE029698	93.121	—	188,232
Pass-through Georgia Institute of Technology	R56DE029703	93.121	—	96,276
Pass-through Massachusetts General Hospital	R01DE027983	93.121	—	122,636
Pass-through Medical University of South Carolina	R21DE029592	93.121	—	99,825
Pass-through University of Iowa	1 R01 DE027362-01A1	93.121	—	89,193
Pass-through University of North Carolina Chapel Hill	R01DE028146	93.121	—	57,151
Total CFDA No. 93.121			195,121	3,889,348
Nurse Anesthetist Traineeships	A2231815	93.124	—	8,583
Total CFDA No. 93.124			—	8,583
COVID-19 – Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006377	93.135	—	55,498
Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006377	93.135	428,915	2,549,418
Pass-through Morehouse School of Medicine	U48DP006411	93.135	—	39,065
Total CFDA No. 93.135			428,915	2,643,981
Injury Prevention and Control Research and State and Community Based Programs	R01CE003104	93.136	—	330,368
Injury Prevention and Control Research and State and Community Based Programs	R49CE003072	93.136	14,201	534,314
Injury Prevention and Control Research and State and Community Based Programs	U01CE002939	93.136	70,112	442,796
Total CFDA No. 93.136			84,313	1,307,478
NIEHS Hazardous Waste Worker Health and Safety Training: Pass-through Nova Southeastern University	5U45ES019350	93.142	—	37,174
Total CFDA No. 93.142			—	37,174
NIEHS Superfund Hazardous Substances_Basic Research and Education: Pass-through Michigan State University	P42ES004911	93.143	—	25,425
Total CFDA No. 93.143			—	25,425
AIDS Education and Training Centers	5H4AHA00067-09-00	93.145	—	(259)
Total CFDA No. 93.145			—	(259)
Health Program for Toxic Substances and Disease Registry: Pass-through American Academy of Pediatrics	NU61TS000296	93.161	—	252,624
Total CFDA No. 93.161			—	252,624
Human Genome Research: Pass-through University of Chicago	RM1HG008935	93.172	—	375,696
Total CFDA No. 93.172			—	375,696
Research Related to Deafness and Communication Disorders	R01DC008343	93.173	—	408,719
Research Related to Deafness and Communication Disorders	R01DC014496	93.173	—	271,118
Research Related to Deafness and Communication Disorders	R21DC017272	93.173	—	174,354
Pass-through University of Memphis	R01DC015108	93.173	10,344	34,893
Total CFDA No. 93.173			10,344	889,084
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects Pass-through Yale University	U01IP001117	93.185	171,041	423,801
	U01IPO11110	93.185	—	78,610
Total CFDA No. 93.185			171,041	502,411
Telehealth Programs Pass-through University of Arizona	H2ARH39957	93.211	—	235,033
Pass-through University of Arizona	G22RH30360	93.211	—	63,626
	GA5RH37465	93.211	—	63,634
Total CFDA No. 93.211			—	362,293
Research and Training in Complementary and Alternative Medicine	K01AT010488	93.213	—	130,477
Research and Training in Complementary and Alternative Medicine	K23AT009713	93.213	—	121,819
Research and Training in Complementary and Alternative Medicine	K24AT009893	93.213	—	156,818
Research and Training in Complementary and Alternative Medicine	R01AT011267	93.213	—	136,314
Research and Training in Complementary and Alternative Medicine	R21AT010774	93.213	156,432	239,899
Research and Training in Complementary and Alternative Medicine	R21AT011105	93.213	—	182,792
Research and Training in Complementary and Alternative Medicine	R61AT010457	93.213	21,092	348,048
Pass-through Veterans Medical Research Foundation	U01AT010332	93.213	—	33,991
Total CFDA No. 93.213			177,524	1,350,158
National Research Service Awards_Health Services Research Training	F32HS028558	93.225	—	5,772
Total CFDA No. 93.225			—	5,772
Research on Healthcare Costs, Quality and Outcomes	1R01HS026081	93.226	142,715	361,969
Research on Healthcare Costs, Quality and Outcomes	5R18HS024499-03	93.226	277	1,878
Research on Healthcare Costs, Quality and Outcomes	K08HS025240	93.226	—	154,761
Research on Healthcare Costs, Quality and Outcomes	R01HS026232	93.226	82,834	371,886
Research on Healthcare Costs, Quality and Outcomes	R03HS027689	93.226	—	73,781
Research on Healthcare Costs, Quality and Outcomes	R13HS027064	93.226	34,664	34,664
Research on Healthcare Costs, Quality and Outcomes	R18HS026877	93.226	110,344	353,232
Pass-through Clemson University	R01HS025981	93.226	—	121,186
Pass-through Northwestern University	R01HS024712	93.226	—	20,289
Pass-through University of Iowa	R0HS026724	93.226	—	21,330
Pass-through University of Kentucky	R01HS025148	93.226	—	30,714
Total CFDA No. 93.226			370,834	1,545,690
National Center on Sleep Disorders Research	F31HL151126	93.233	—	34,832
National Center on Sleep Disorders Research	K01HL138211	93.233	—	160,879
Total CFDA No. 93.233			—	195,711

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	5R01MH102690-04	93.242	\$	(3,495)
Mental Health Research Grants	F30MH117878	93.242	—	52,271
Mental Health Research Grants	R25MH101079	93.242	—	74,887
Mental Health Research Grants	1R21MH118092-01REVISED	93.242	—	69,227
Mental Health Research Grants	1R56MH116994-01	93.242	—	1,441
Mental Health Research Grants	5F30MH108276-03	93.242	—	5,771
Mental Health Research Grants	5R01MH073719-09 REVISED	93.242	—	(154)
Mental Health Research Grants	5R01MH100318-05	93.242	—	50,072
Mental Health Research Grants	5R01MH104534-05	93.242	—	47,978
Mental Health Research Grants	5R01MH104632-05	93.242	—	47,561
Mental Health Research Grants	5R01MH107305-05	93.242	—	49,259
Mental Health Research Grants	5R56MH111459-02	93.242	—	9,948
Mental Health Research Grants	5U01MH081988	93.242	—	131,082
Mental Health Research Grants	F30MH117873	93.242	—	49,115
Mental Health Research Grants	F31MH114624	93.242	—	42,770
Mental Health Research Grants	F31MH116622	93.242	—	15,196
Mental Health Research Grants	F31MH119745	93.242	—	43,740
Mental Health Research Grants	F32 MH115692	93.242	—	61,897
Mental Health Research Grants	F32MH119750	93.242	—	68,305
Mental Health Research Grants	F32MH124273	93.242	—	64,935
Mental Health Research Grants	K01MH108741	93.242	—	143,094
Mental Health Research Grants	K01MH121653	93.242	—	127,046
Mental Health Research Grants	K23MH114037-02	93.242	—	206,225
Mental Health Research Grants	K23MH114771	93.242	—	124,196
Mental Health Research Grants	K23MH123816	93.242	—	153,914
Mental Health Research Grants	P50MH100023	93.242	413,297	2,188,105
Mental Health Research Grants	P50MH100029	93.242	333,194	1,794,181
Mental Health Research Grants	R01MH069852	93.242	—	340,373
Mental Health Research Grants	R01MH072908	93.242	—	303,096
Mental Health Research Grants	R01MH082833	93.242	40,562	345,062
Mental Health Research Grants	R01MH105561	93.242	101,843	272,740
Mental Health Research Grants	R01MH107033	93.242	—	108,761
Mental Health Research Grants	R01MH108605	93.242	—	71,063
Mental Health Research Grants	R01MH108826	93.242	71,938	390,554
Mental Health Research Grants	R01MH109026	93.242	—	150,239
Mental Health Research Grants	R01MH109637	93.242	—	1,488
Mental Health Research Grants	R01MH110701	93.242	4,164	471,258
Mental Health Research Grants	R01MH111416	93.242	—	363,882
Mental Health Research Grants	R01MH112076	93.242	—	151,301
Mental Health Research Grants	R01MH112788	93.242	—	594,968
Mental Health Research Grants	R01MH114692	93.242	505,651	1,243,683
Mental Health Research Grants	R01MH115174	93.242	11,990	426,136
Mental Health Research Grants	R01MH115831	93.242	—	339,410
Mental Health Research Grants	R01MH116695	93.242	—	614,155
Mental Health Research Grants	R01MH117009	93.242	2,248	665,209
Mental Health Research Grants	R01MH117103	93.242	—	469,413
Mental Health Research Grants	R01MH117122	93.242	27,992	448,149
Mental Health Research Grants	R01MH117315	93.242	—	772,045
Mental Health Research Grants	R01MH118285	93.242	55,317	356,208
Mental Health Research Grants	R01MH118534	93.242	5,059	302,674
Mental Health Research Grants	R01MH118771	93.242	—	556,617
Mental Health Research Grants	R01MH118982	93.242	230,493	505,855
Mental Health Research Grants	R01MH119251	93.242	—	78,117
Mental Health Research Grants	R01MH120133	93.242	—	344
Mental Health Research Grants	R01MH120262	93.242	—	587,931
Mental Health Research Grants	R01MH120299	93.242	93,259	308,044
Mental Health Research Grants	R01MH121363	93.242	79,908	465,029
Mental Health Research Grants	R01MH121962	93.242	—	540,122
Mental Health Research Grants	R01MH122341	93.242	—	461,232
Mental Health Research Grants	R01MH125457	93.242	47,848	626,659
Mental Health Research Grants	R01MH125956	93.242	—	21,182
Mental Health Research Grants	R01MH126195	93.242	—	208,818
Mental Health Research Grants	R21MH114151	93.242	—	(2,040)
Mental Health Research Grants	R21MH117338	93.242	—	50,933
Mental Health Research Grants	R21MH117512	93.242	—	87,423
Mental Health Research Grants	R21MH120414	93.242	—	50,808
Mental Health Research Grants	R21MH121164	93.242	52,223	211,556
Mental Health Research Grants	R21MH121891	93.242	—	177,643
Mental Health Research Grants	R21MH123711	93.242	—	185,886
Mental Health Research Grants	R21MH127404	93.242	—	2,782
Mental Health Research Grants	R25MH101079	93.242	—	176,390
Mental Health Research Grants	R34MH116805	93.242	102,784	262,558
Mental Health Research Grants	R34MH119007	93.242	26,955	110,740
Mental Health Research Grants	R34MH124638	93.242	—	220,133
Mental Health Research Grants	R34MH128048	93.242	—	3,198
Mental Health Research Grants	R36MH127827	93.242	—	8,802
Mental Health Research Grants	R56MH119903	93.242	—	258,758
Mental Health Research Grants	R61MH121625	93.242	—	434,934
Mental Health Research Grants	RF1MH119622	93.242	—	186,059
Mental Health Research Grants	U01MH116441	93.242	634,110	965,030
Pass-through Boston University	R01MH110453	93.242	—	46,967
Pass-through Brown University	R01MH117960	93.242	—	41,260
Pass-through Butler Hospital	R01MH101107	93.242	—	159,647
Pass-through Child Mind Institute	R24MH114806	93.242	—	39,000
Pass-through Childrens Hospital Of Los Angeles	R01MH120133	93.242	—	7,984
Pass-through Creighton University	R01MH116003	93.242	—	63,421
Pass-through Duke University	R01MH108348	93.242	—	51,559
Pass-through Duke University	R01MH111671	93.242	—	45,386
Pass-through Florida State University	R01MH104423	93.242	—	3,000
Pass-through Georgia Institute of Technology	R01MH119189	93.242	—	2,776
Pass-through Georgia Institute of Technology	R21MH122825	93.242	—	36,010
Pass-through Georgia State University	R01MH110212	93.242	—	128,499
Pass-through Hartford Hospital	R01MH119815	93.242	—	29,166
Pass-through Johns Hopkins University	R01MH110358	93.242	—	247,857
Pass-through Massachusetts General Hospital	R34MH122362	93.242	—	12,540
Pass-through Mclean Hospital	R01MH117292	93.242	—	245,445

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Research Foundation for Mental Hygiene	R01MH123660	93.242	\$ —	14,173
Pass-through Rhode Island Hospital	R01MH125796	93.242	—	128,178
Pass-through Stanford University	R01MH123486	93.242	—	26,438
Pass-through State University of New York	R01MH104964	93.242	—	77,926
Pass-through University of Alabama Birmingham	R01MH104114	93.242	—	133,520
Pass-through University of California Los Angeles	R01MH100027	93.242	—	152,209
Pass-through University of California Los Angeles	R01MH118514	93.242	—	228,187
Pass-through University of California Los Angeles	R01MH118973	93.242	—	22,688
Pass-through University of California San Diego	R01MH124590	93.242	—	20,584
Pass-through University of California San Francisco	R01MH123396	93.242	—	121,751
Pass-through University of Cape Town	U01MH115484	93.242	—	357,482
Pass-through University of Georgia	R01MH116039	93.242	—	60,811
Pass-through University of Georgia	R01MH120092	93.242	—	5,116
Pass-through University of Illinois at Chicago	R01MH116721	93.242	—	139,225
Pass-through University of Illinois at Chicago	RO1MH114847	93.242	—	31,995
Pass-through University of Louisiana at Lafayette	R01MH125395	93.242	—	23,730
Pass-through University of Maryland, Baltimore	R01MH121102	93.242	—	201,017
Pass-through University of North Carolina Chapel Hill	U01MH110925	93.242	—	79,547
Pass-through University of Pittsburgh	R01MH115922	93.242	—	19,958
Pass-through University of Pittsburgh	R01MH116943	93.242	—	8,316
Pass-through University of Pittsburgh	R01MH118270	93.242	—	14,969
Pass-through University of Pittsburgh	R01MH121619	93.242	—	19,958
Pass-through University of Pittsburgh	R21MH119543	93.242	—	19,960
Pass-through University of Pittsburgh	R21MH121120	93.242	—	63,298
Pass-through University of Pittsburgh	U01MH111658	93.242	—	63,069
Pass-through University of Rochester	R01MH045573	93.242	—	67,917
Pass-through University of Washington	R01MH121424	93.242	—	54,835
Pass-through Vanderbilt University Medical Center	R61MH123029	93.242	—	104,118
Pass-through Wayne State University	R01MH111682	93.242	—	185,119
Pass-through Wayne State University	R33MH111935	93.242	—	109,920
Pass-through Yale University	U01MH124639	93.242	—	15,275
Total CFDA No. 93.242			2,840,835	26,303,783
Substance Abuse and Mental Health Services Projects of Regional and National Significance	H79SM081774	93.243	184,212	1,236,070
Total CFDA No. 93.243			184,212	1,236,070
Advanced Nursing Education Grant Program	T14HP33112	93.247	266,083	419,032
Advanced Nursing Education Grant Program	T9642058	93.247	—	24,310
Total CFDA No. 93.247			266,083	443,342
Occupational Safety and Health Program	5R01OH010745-03	93.262	55,395	508,859
Total CFDA No. 93.262			55,395	508,859
COVID-19 – Alcohol Research Programs	U01AA029345	93.273	17,586	249,275
Alcohol Research Programs	1R21AA027345-01	93.273	—	(754)
Alcohol Research Programs	R01AA022601	93.273	—	49,066
Alcohol Research Programs	F31AA029000	93.273	—	28,272
Alcohol Research Programs	K08AA024512	93.273	—	138,243
Alcohol Research Programs	R01AA025854	93.273	—	368,262
Alcohol Research Programs	R01AA025857	93.273	—	150,757
Alcohol Research Programs	R01AA026086	93.273	—	438,667
Alcohol Research Programs	R01AA027020	93.273	—	357,721
Alcohol Research Programs	R01AA027396	93.273	—	301,375
Alcohol Research Programs	R01AA028527	93.273	—	30,193
Alcohol Research Programs	R03AA027335	93.273	—	53,633
Alcohol Research Programs	R03AA027662	93.273	—	29,706
Alcohol Research Programs	R21AA025723	93.273	—	8,315
Alcohol Research Programs	U01AA026108	93.273	117,659	372,204
Pass-through Fdtn for Atlanta Veterans Educ and Res	M20029	93.273	—	18,323
Pass-through University of California San Diego	R01AA026579	93.273	—	37,680
Pass-through University of California San Diego	R01AA027785	93.273	—	117,591
Pass-through University of California San Diego	U01AA014835	93.273	—	26,023
Pass-through University of Colorado	R24AA019661	93.273	—	1,816
Pass-through University of Georgia	R01AA026623	93.273	—	26,749
Pass-through Wayne State University	R01AA025905	93.273	—	25,156
Total CFDA No. 93.273			135,245	2,828,273
Drug Abuse and Addiction Research Programs	5K24A114444-05	93.279	—	6,682
Drug Abuse and Addiction Research Programs	R01DA052909	93.279	—	308,098
Drug Abuse and Addiction Research Programs	5R01DA038453-05	93.279	116,062	123,445
Drug Abuse and Addiction Research Programs	5R01DA038588-04	93.279	—	68,106
Drug Abuse and Addiction Research Programs	DP1DA042103	93.279	99,209	360,707
Drug Abuse and Addiction Research Programs	F31DA044726	93.279	—	15,467
Drug Abuse and Addiction Research Programs	F31DA051184	93.279	—	43,287
Drug Abuse and Addiction Research Programs	F31DA053005	93.279	—	7,487
Drug Abuse and Addiction Research Programs	K01DA051696	93.279	—	148,942
Drug Abuse and Addiction Research Programs	R01DA042712	93.279	—	205,245
Drug Abuse and Addiction Research Programs	R01DA042742	93.279	154,493	561,642
Drug Abuse and Addiction Research Programs	R01DA043263	93.279	—	312,990
Drug Abuse and Addiction Research Programs	R01DA044297	93.279	—	474,295
Drug Abuse and Addiction Research Programs	R01DA045612	93.279	312,720	1,095,275
Drug Abuse and Addiction Research Programs	R01DA046197	93.279	148,504	684,107
Drug Abuse and Addiction Research Programs	R01DA046619	93.279	119,018	480,917
Drug Abuse and Addiction Research Programs	R01DA049257	93.279	21,668	243,531
Drug Abuse and Addiction Research Programs	R21DA046738	93.279	—	53,908
Drug Abuse and Addiction Research Programs	R34DA050340	93.279	—	231,873
Drug Abuse and Addiction Research Programs	T32DA050552	93.279	—	123,980
Drug Abuse and Addiction Research Programs	UG3DA048502	93.279	28,915	307,113
Drug Abuse and Addiction Research Programs	UG3DA050234	93.279	24,034	50,828
Drug Abuse and Addiction Research Programs	UH3DA050234	93.279	68,344	448,444
Pass-through Boston Medical Center	R01DA037768	93.279	—	37,110
Pass-through Case Western Reserve University	R01DA042712	93.279	—	33,166
Pass-through Case Western Reserve University	R01DA043263	93.279	—	43,494
Pass-through Johns Hopkins University	R61DA047022	93.279	—	160,558
Pass-through Magee-Womens Research Institute and Foundation	R25DA043880	93.279	—	21,533
Pass-through Mclean Hospital	UG1DA015831	93.279	—	3,399

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Miriam Hospital	R01DA044504	93.279	\$ —	84,496
Pass-through Miriam Hospital	R25DA037190	93.279	—	3,769
Pass-through Northwestern University	P30DA027828	93.279	—	9,315
Pass-through Northwestern University	R01DA042711	93.279	—	4,609
Pass-through Ohio State University	R21DA045236	93.279	—	20,095
Pass-through Oregon Health and Science University	R01DA046229	93.279	—	13,236
Pass-through Pennsylvania State University	R01DA047396	93.279	—	31,510
Pass-through University of California San Francisco	R61DA047024	93.279	—	51,778
Pass-through University of Kentucky	UG3DA044798	93.279	—	(1,385)
Pass-through University of Kentucky	UH3DA044798	93.279	—	172,239
Pass-through University of Miami	UG1DA013720	93.279	—	81,655
Pass-through University of North Carolina	R01DA051578	93.279	—	11,759
Pass-through Yale University	UG1DA015831	93.279	—	236,715
Total CFDA No. 93.279			1,092,967	7,375,420
Centers for Disease Control and Prevention. Investigations and Technical Assistance	U01DP006488	93.283	7,481	790,232
Pass-through Fdtn for Atlanta Veterans Educ and Res	40500-036-20192856	93.283	3,037	813,838
Pass-through Fdtn for Atlanta Veterans Educ and Res	NU50CK000485	93.283	—	1,546,675
Pass-through Georgia Dept of Public Health	40500-036-15110270	93.283	—	393,733
Pass-through Georgia State University	200-2017-93187	93.283	—	3,910
Total CFDA No. 93.283			10,518	3,548,388
COVID-19 – Discovery and Applied Research for Technological Innovations to Improve Human Health	U54EB027690	93.286	15,758,101	27,219,398
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB027147	93.286	3,515	393,188
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB027774	93.286	15,497	152,730
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB028350	93.286	17,848	146,951
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB029320	93.286	92,337	638,095
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB029857	93.286	90,120	148,591
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB025646	93.286	16,400	48,003
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB026591	93.286	—	248,045
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB028519	93.286	21,344	128,165
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB029622	93.286	—	71,729
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB031545	93.286	—	631
Discovery and Applied Research for Technological Innovations to Improve Human Health	U01EB028145	93.286	589,941	776,798
Discovery and Applied Research for Technological Innovations to Improve Human Health	U54EB027690	93.286	871,974	1,335,143
Pass-through Beth Israel Deaconess Medical Center	R01EB030362	93.286	—	42,000
Pass-through Duke University	R01EB028324	93.286	—	35,541
Pass-through Georgia Institute of Technology	R01EB029331	93.286	—	23,881
Pass-through Georgia Institute of Technology	R01EB023808	93.286	—	98,092
Pass-through Georgia Institute of Technology	R01EB028916	93.286	—	33,880
Pass-through Georgia Institute of Technology	T32EB021962	93.286	—	56,313
Pass-through Georgia Institute of Technology	T32EB025816	93.286	—	95,632
Pass-through Univ of Massachusetts Medical School	U54HL143541	93.286	219,561	835,493
Pass-through University of Pittsburgh	R01EB028248	93.286	—	18,628
Pass-through University of South Florida	R01EB020601	93.286	—	9,806
Total CFDA No. 93.286			17,696,638	32,557,123
Minority Health and Health Disparities Research	5R01MD010290-05	93.307	—	126,277
Minority Health and Health Disparities Research	SU01MD010611	93.307	6,654	385,219
Minority Health and Health Disparities Research	F31MD014051	93.307	—	13,773
Minority Health and Health Disparities Research	K23MD015088	93.307	—	189,590
Minority Health and Health Disparities Research	R01MD009746	93.307	—	260,188
Minority Health and Health Disparities Research	R01MD010455	93.307	—	258,709
Minority Health and Health Disparities Research	R01MD011682	93.307	76,443	678,765
Minority Health and Health Disparities Research	R01MD013320	93.307	156,631	275,265
Minority Health and Health Disparities Research	R01MD015204	93.307	—	11,153
Minority Health and Health Disparities Research	R01MD016031	93.307	—	631,579
Minority Health and Health Disparities Research	R03MD013509	93.307	—	80,998
Minority Health and Health Disparities Research	R21MD011590	93.307	78,250	110,838
Minority Health and Health Disparities Research	5R01MD008966-05 REVISED	93.307	—	5,913
Pass-through Morehouse School of Medicine	U54MD007602	93.307	—	150,527
Pass-through New York University	U54MD000538	93.307	—	218,178
Pass-through Nova Southeastern University	R01MD010368	93.307	—	(77)
Pass-through University of Illinois at Chicago	R21MD015813	93.307	—	10,850
Pass-through University of Minnesota	R01MD013801	93.307	—	90,269
Pass-through University of Pennsylvania	R01MD013558	93.307	—	103,980
Pass-through University of Pennsylvania	U01MD011274	93.307	—	287,743
Pass-through University of Southern California	R01MD011698	93.307	—	168,627
Pass-through University of Utah	R21MD014281	93.307	—	16,456
Pass-through Yale University	U54MD010711	93.307	—	11,483
Total CFDA No. 93.307			317,978	4,086,303
COVID-19 – Trans-NIH Research Support	P30DK111024	93.310	258,570	1,395,184
Trans-NIH Research Support	U01CA235493	93.310	74,966	88,559
Trans-NIH Research Support	U01CA242109	93.310	6,357	6,357
Trans-NIH Research Support	R03TR003380	93.310	—	33,147
Trans-NIH Research Support	5R21GM122632-02	93.310	—	(195)
Trans-NIH Research Support	1DP2AI12242-01 REVISED	93.310	—	(344)
Trans-NIH Research Support	SU24DK112341	93.310	239,104	1,021,275
Trans-NIH Research Support	1U2CES026560-01 REVISED	93.310	73,839	170,363
Trans-NIH Research Support	U2CES030163	93.310	123,038	1,047,803
Trans-NIH Research Support	5K01OD023039-03	93.310	—	(941)
Trans-NIH Research Support	DP5OD019792-05	93.310	—	203,295
Trans-NIH Research Support	OT2OD030535	93.310	329,738	622,734
Trans-NIH Research Support	UH3OD023318	93.310	—	1,684,701
Pass-through Albert Einstein College of Medicine	UH3OD023320	93.310	—	18,334
Pass-through Children's Hospital of Philadelphia	U2CHL138346	93.310	—	113,748
Pass-through Duke University	U2COD023375	93.310	—	97,432
Pass-through Georgia Institute of Technology	UG3TR002855	93.310	—	554
Pass-through Research Foundation for Mental Hygiene	UH3OD023328	93.310	—	34,059
Pass-through State University of New York Buffalo	U01CA221244	93.310	—	(28)
Pass-through University of California San Francisco	R61HD105618	93.310	—	8,708
Pass-through University of Miami	1OT2OD26551-01	93.310	—	2,581,590
Pass-through University of Michigan	R01HD086676	93.310	—	(157)
Pass-through University of North Carolina	UH3OD023348	93.310	—	26,317
Pass-through Vanderbilt University Medical Center	UH3OD023282	93.310	—	32,975

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Pass-through Women & Infants Hospital of Rhode Island	UH3OD023347	93.310	\$ —	198,232
Total CFDA No. 93.310			1,105,612	9,383,702
Rare Disorders: Research, Surveillance, Health Promotion, and Education: Pass-through Research Foundation for Mental Hygiene	U01DD001189	93.315	—	1,756
Total CFDA No. 93.315			—	1,756
COVID-19 – Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	—	73,711
Total CFDA No. 93.318			—	73,711
National Center for Advancing Translational Sciences	5R21TR001751-02	93.350	—	229
National Center for Advancing Translational Sciences	KL2TR002381	93.350	262,664	1,079,771
National Center for Advancing Translational Sciences	TL1TR002382	93.350	121,700	973,764
National Center for Advancing Translational Sciences	UL1TR000454	93.350	—	(275)
National Center for Advancing Translational Sciences	UL1TR002378	93.350	4,062,549	9,075,485
Pass-through University of Pittsburgh	UL1TR001857	93.350	17,628	36,500
Total CFDA No. 93.350			4,464,541	11,165,474
Research Infrastructure Programs	1S10OD025105-01	93.351	—	2,000,000
Research Infrastructure Programs	5R24OD020174-04	93.351	48,267	269,189
Research Infrastructure Programs	K01OD031900	93.351	—	29,609
Research Infrastructure Programs	P51OD011132	93.351	130,870	11,147,953
Research Infrastructure Programs	R24OD020349	93.351	56,554	406,607
Research Infrastructure Programs	R24OD030035	93.351	—	12,228
Research Infrastructure Programs	R25GM129213	93.351	—	191,231
Research Infrastructure Programs	S10OD028673	93.351	—	739,877
Research Infrastructure Programs	U42OD011023	93.351	—	2,070,623
Pass-through Oregon Health and Science University	R24OD021324	93.351	—	15,378
Pass-through University of Georgia	R01OD028223	93.351	—	41,638
Total CFDA No. 93.351			235,691	16,924,333
Construction Support	C06OD030081	93.352	—	185,284
Total CFDA No. 93.352			—	185,284
21st Century Cures Act – Beau Biden Cancer Moonshot: Pass-through Dana Farber Cancer Institute	U01CA243688	93.353	—	85,982
Pass-through Dana Farber Cancer Institute	U24CA233243	93.353	—	91,221
Pass-through University of Alabama Birmingham	U01CA246567	93.353	—	161,124
Pass-through University of Michigan	U01CA254822	93.353	—	3,282
Total CFDA No. 93.353			—	341,609
COVID-19 – Nurse Education, Practice and Retention Grants Nurse Education, Practice and Retention Grants	T1PHP39097	93.359	—	65,469
	UK1HP31697	93.359	—	600,881
Total CFDA No. 93.359			—	666,350
Nursing Research	F31NR018369	93.361	—	79
Nursing Research	K01NR016971	93.361	—	27,587
Nursing Research	K01NR017664	93.361	—	79,426
Nursing Research	K24NR018866	93.361	—	103,533
Nursing Research	K99NR017897	93.361	—	(11)
Nursing Research	P30NR018090	93.361	—	753,003
Nursing Research	R00NR017897	93.361	—	138,837
Nursing Research	R01NR014973	93.361	—	25,941
Nursing Research	R01NR015783	93.361	27,292	27,292
Nursing Research	R01NR017018	93.361	240,853	913,356
Nursing Research	R01NR017939	93.361	211,993	405,456
Nursing Research	R01NR018666	93.361	40,902	443,569
Nursing Research	R01NR019083	93.361	—	28,973
Nursing Research	R01NR020154	93.361	—	5,460
Nursing Research	R21NR018015	93.361	—	151,281
Nursing Research	R21NR019872	93.361	—	52,548
Nursing Research	R56NR019482	93.361	78,440	387,976
Nursing Research	T32NR012715	93.361	—	389,539
Pass-through Columbia University	R01NR013520	93.361	—	55,745
Pass-through Northwestern University	R01NR015444	93.361	—	25,289
Total CFDA No. 93.361			599,480	4,014,879
National and State Tobacco Control Program	R01HL155711	93.387	—	67,567
Total CFDA No. 93.387			—	67,567
Cancer Cause and Prevention Research	F99CA245789	93.393	—	132
Cancer Cause and Prevention Research	F99CA253576	93.393	—	31,550
Cancer Cause and Prevention Research	R00CA204601	93.393	—	202,149
Cancer Cause and Prevention Research	R01CA095318	93.393	—	139,623
Cancer Cause and Prevention Research	R01CA178999	93.393	—	309,279
Cancer Cause and Prevention Research	R01CA203719	93.393	—	409,986
Cancer Cause and Prevention Research	R01CA207260	93.393	309,631	496,453
Cancer Cause and Prevention Research	R01CA207467	93.393	159,160	241,813
Cancer Cause and Prevention Research	R01CA211574	93.393	263,325	438,613
Cancer Cause and Prevention Research	R01CA218155	93.393	50,527	401,530
Cancer Cause and Prevention Research	R01CA218399	93.393	23,491	331,618
Cancer Cause and Prevention Research	R01CA230268	93.393	—	221,002
Cancer Cause and Prevention Research	R01CA234538	93.393	26,643	481,090
Cancer Cause and Prevention Research	R01CA235721	93.393	41,287	504,380
Cancer Cause and Prevention Research	R01CA237318	93.393	367,380	847,298
Cancer Cause and Prevention Research	R01CA245063	93.393	164,423	467,795
Cancer Cause and Prevention Research	R01CA254403	93.393	—	524,903
Cancer Cause and Prevention Research	R01CA259192	93.393	—	107,784
Cancer Cause and Prevention Research	R03CA259665	93.393	—	15,180
Cancer Cause and Prevention Research	R21CA238356	93.393	17,221	167,395
Cancer Cause and Prevention Research	R37CA234119	93.393	398,732	544,071
Cancer Cause and Prevention Research	U01CA217875	93.393	2,769	891,656
Cancer Cause and Prevention Research	U01CA220401	93.393	—	(400)
Cancer Cause and Prevention Research	U01CA240581	93.393	27,432	629,088

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Cancer Cause and Prevention Research	R01CA236871	93.393	\$ —	427,606
Cancer Cause and Prevention Research	R21CA208161	93.393	—	23,741
Pass-through Duke University	R37CA233777	93.393	—	18,622
Pass-through George Washington University	R01CA215155	93.393	—	58,190
Pass-through Georgia State University	R01CA239120	93.393	—	8,282
Pass-through Georgia State University	R01CA248551	93.393	—	73,843
Pass-through Mayo Clinic	R01CA248288	93.393	—	28,148
Pass-through Mayo Clinic	U01CA195568	93.393	—	19,117
Pass-through Northwestern University	U01CA220401	93.393	—	48,898
Pass-through Stanford University	61795884-129906	93.393	—	17,717
Pass-through State University of New York Stony Brook	1UG3CA22502101	93.393	—	143,065
Pass-through University of Southern California	U19CA214253	93.393	—	786,207
Pass-through University Of Texas Md Anderson Cancer	R01CA188943	93.393	—	17,685
Pass-through University of Utah	R01CA200854	93.393	—	101,765
Pass-through University of Washington Saint Louis	R01CA235773	93.393	—	42,686
Pass-through Vanderbilt University Medical Center	R01CA225005	93.393	—	3,558
Pass-through Vanderbilt University Medical Center	R01CA230352	93.393	—	58,603
Pass-through Wayne State University	R01CA240607	93.393	—	110,612
Total CFDA No. 93.393			<u>1,852,021</u>	<u>10,392,333</u>
COVID-19 – Cancer Detection and Diagnosis Research	U54CA260563	93.394	—	1,312,486
Cancer Detection and Diagnosis Research	5U24CA194362-04 REVISED	93.394	17,915	108,801
Cancer Detection and Diagnosis Research	R01CA202846	93.394	—	214,959
Cancer Detection and Diagnosis Research	R01CA203388	93.394	55,740	322,033
Cancer Detection and Diagnosis Research	R01CA261251	93.394	—	28,348
Cancer Detection and Diagnosis Research	R21CA256280	93.394	—	70,337
Cancer Detection and Diagnosis Research	R21CA256375	93.394	—	49,031
Cancer Detection and Diagnosis Research	R21CA256605	93.394	—	24,200
Cancer Detection and Diagnosis Research	R21CA259935	93.394	—	87,690
Cancer Detection and Diagnosis Research	U01CA113913	93.394	103,624	1,011,023
Cancer Detection and Diagnosis Research	U01CA198913	93.394	—	76,677
Pass-through Children's Hospital of Philadelphia	R01CA248501	93.394	—	4,474
Pass-through Dartmouth College	PO1CA190193	93.394	—	15,037
Pass-through Georgia Institute of Technology	R21223853	93.394	—	11,868
Pass-through Georgia Institute of Technology	R37CA239039	93.394	—	3,692
Pass-through Georgia State University	U01CA242936	93.394	—	17,000
Pass-through Massachusetts General Hospital	R01CA237133	93.394	—	18,762
Pass-through Radboud University	R01CA181171	93.394	—	3,733
Pass-through Thomas Jefferson University	UG3CA247605	93.394	—	9,149
Pass-through Univ of Arkansas for Medical Services	U24CA215109	93.394	—	420,215
Pass-through University Of Colorado Denver	R01CA236857	93.394	—	88,026
Pass-through University of Michigan	U24CA086368	93.394	—	(2,146)
Total CFDA No. 93.394			<u>177,279</u>	<u>3,895,395</u>
Cancer Treatment Research	1R01CA223220-01A1	93.395	—	346,314
Cancer Treatment Research	5R01CA207768	93.395	—	353,716
Cancer Treatment Research	5R01CA214557-03	93.395	9,902	9,902
Cancer Treatment Research	R01CA136534	93.395	—	103,877
Cancer Treatment Research	R01CA194037	93.395	—	156,173
Cancer Treatment Research	R01CA202705	93.395	—	374,931
Cancer Treatment Research	R01CA202763	93.395	104,665	309,843
Cancer Treatment Research	R01CA203928	93.395	—	349,655
Cancer Treatment Research	R01CA208253	93.395	72,566	244,579
Cancer Treatment Research	R01CA208328	93.395	135,647	357,656
Cancer Treatment Research	R01CA215718	93.395	—	300,235
Cancer Treatment Research	R01CA226992	93.395	—	654,587
Cancer Treatment Research	R01CA228406	93.395	—	318,649
Cancer Treatment Research	R01CA228414	93.395	124,377	414,408
Cancer Treatment Research	R01CA238471	93.395	—	588,587
Cancer Treatment Research	R01CA245386	93.395	—	337,932
Cancer Treatment Research	R01CA255257	93.395	—	110,967
Cancer Treatment Research	R01CA257861	93.395	—	238,121
Cancer Treatment Research	R03CA246039	93.395	—	131,725
Cancer Treatment Research	R21CA223300	93.395	—	28,691
Cancer Treatment Research	R21CA255831	93.395	—	181,200
Cancer Treatment Research	R37CA255459	93.395	—	5,547
Cancer Treatment Research	R50CA233168	93.395	—	107,252
Cancer Treatment Research	UG1CA233259	93.395	517,933	603,608
Cancer Treatment Research	R00CA222493	93.395	—	218,746
Cancer Treatment Research	UG1CA233247	93.395	—	737,371
Pass-through Childrens Healthcare of Atlanta	U10CA180866	93.395	—	36,993
Pass-through Childrens Healthcare of Atlanta	U10CA180866	93.395	—	38,517
Pass-through City of Hope	R01CA194742	93.395	—	39,179
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820	93.395	—	50,194
Pass-through Fred Hutchinson Cancer Research Center	0000804235	93.395	—	4,884
Pass-through Georgia Institute of Technology	R01CA207619	93.395	—	67,928
Pass-through Georgia State University	R01CA180519	93.395	—	2,808
Pass-through Indiana University	R01CA235632	93.395	—	40,782
Pass-through Johns Hopkins University	UM1CA186691	93.395	—	20,171
Pass-through Massachusetts General Hospital	233380	93.395	—	(151)
Pass-through Medical University of South Carolina	P01CA203628	93.395	—	74,933
Pass-through Nrg Oncology Foundation, Inc.	U10CA180868	93.395	—	133,452
Pass-through Ohio State University	R01CA201382	93.395	—	107,397
Pass-through St. Jude Childrens Research Hospital	UM1CA081457	93.395	8,196	96,810
Pass-through Stanford University	U01CA199241	93.395	—	68,892
Pass-through University of California Los Angeles	UM1CA121947	93.395	—	3,040
Pass-through University of Florida	R01CA200697	93.395	—	94,225
Pass-through University of Minnesota	5P01CA111412-13	93.395	—	10,316
Pass-through University of North Carolina Chapel Hill	R01CA249190	93.395	—	184,865
Pass-through University of Pennsylvania	R21CA238108	93.395	—	19,029
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA193609	93.395	—	42,388
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA240447	93.395	—	286,027
Pass-through University of Utah	R01CA206522	93.395	—	32,069
Pass-through Vanderbilt University Medical Center	R21CA226562	93.395	—	31,615
Total CFDA No. 93.395			<u>973,286</u>	<u>9,070,795</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Biology Research	3R01CA201340-04S1	93.396	\$ —	136,005
Cancer Biology Research	5R01CA140515-09	93.396	1,670	1,670
Cancer Biology Research	5R21CA232244	93.396	69,040	229,881
Cancer Biology Research	P30CA138292	93.396	83,030	3,086,550
Cancer Biology Research	R00CA197804	93.396	—	147,125
Cancer Biology Research	R01CA175316	93.396	—	382,157
Cancer Biology Research	R01CA192844	93.396	55,463	225,197
Cancer Biology Research	R01CA208514	93.396	22,801	230,734
Cancer Biology Research	R01CA236369	93.396	—	249,447
Cancer Biology Research	R01CA247367	93.396	—	97,213
Cancer Biology Research	R01CA250422	93.396	—	322,588
Cancer Biology Research	R01CA251393	93.396	—	43,672
Cancer Biology Research	R35CA197603	93.396	—	565,130
Pass-through Georgia Institute of Technology	R21CA240214	93.396	—	12,414
Pass-through Georgia Institute of Technology	U01CA214354	93.396	—	27,782
Pass-through Georgia Institute of Technology	U01CA250040	93.396	—	304,260
Pass-through Georgia State University	R33CA235319	93.396	—	109,404
Pass-through Medical University of South Carolina	R01CA244361	93.396	—	9,218
Pass-through Medical University of South Carolina	R01CA248359	93.396	—	16,521
Pass-through Roswell Park Cancer Institute	R01CA121044	93.396	—	26,946
Pass-through Univ of Texas Health Sciences Ctr	R01CA239227	93.396	—	40,468
Pass-through University of Alabama Birmingham	U01CA223976	93.396	—	44,538
Pass-through University of Arizona	1U01CA198946-01	93.396	—	35,702
Pass-through University of Chicago	R01CA174786	93.396	—	8,842
Pass-through University of Rochester	R01CA250531	93.396	—	672
Pass-through Wake Forest University	R01CA228137	93.396	—	17,031
Total CFDA No. 93.396			232,004	6,371,167
Cancer Centers Support Grants	P50CA217691	93.397	108,380	1,723,627
Pass-through Yale University	U54CA209992	93.397	—	59,752
Total CFDA No. 93.397			108,380	1,783,379
Cancer Research Manpower	5F31CA221002-02	93.398	—	(270)
Cancer Research Manpower	F30CA206291	93.398	—	22,431
Cancer Research Manpower	F30CA216639	93.398	—	26,504
Cancer Research Manpower	F30CA236231	93.398	—	26,976
Cancer Research Manpower	F30CA243250	93.398	—	51,368
Cancer Research Manpower	F31CA225119	93.398	—	(1,004)
Cancer Research Manpower	F31CA225124	93.398	—	(983)
Cancer Research Manpower	F31CA236493	93.398	—	40,661
Cancer Research Manpower	F31CA239563	93.398	—	45,184
Cancer Research Manpower	F31CA243220	93.398	—	45,340
Cancer Research Manpower	F31CA243472	93.398	—	44,314
Cancer Research Manpower	F31CA243502	93.398	—	42,323
Cancer Research Manpower	F31CA246689	93.398	—	45,094
Cancer Research Manpower	F31CA246689	93.398	—	45,094
Cancer Research Manpower	F31CA247415	93.398	—	44,025
Cancer Research Manpower	F31CA247564	93.398	—	45,575
Cancer Research Manpower	F31CA254207	93.398	—	13,946
Cancer Research Manpower	F32CA257436	93.398	—	42,976
Cancer Research Manpower	K07CA211956	93.398	—	141,802
Cancer Research Manpower	K08CA194162	93.398	—	88
Cancer Research Manpower	K08CA248962	93.398	—	285,191
Cancer Research Manpower	K12CA237806	93.398	—	374,498
Cancer Research Manpower	K24CA201524	93.398	—	81
Total CFDA No. 93.398			—	1,336,120
Cancer Control:				
Pass-through Ecog-Acrin Medical Research Foundation	UG1CA189828	93.399	14,844	36,333
Pass-through Nrg Oncology Foundation, Inc.	UG1CA189867	93.399	—	160,222
Total CFDA No. 93.399			14,844	196,555
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health:				
Pass-through CDC Foundation	NU38OT000288-03-01,	93.421	—	60,328
Pass-through Natl Assoc of County & City Health Office	NU38OT000306	93.421	—	38,500
Total CFDA No. 93.421			—	98,828
Every Student Succeeds Act/Preschool Development Grants:				
Pass-through Georgia Department Of Early Care And Lea	90TP0070	93.434	—	1,822
Total CFDA No. 93.434			—	1,822
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke:				
Pass-through Wisconsin Department of Health and Family	NU58DP006607	93.435	—	3,197
Total CFDA No. 93.435			—	3,197
Affordable Care Act (ACA) Public Health Training Centers Program	UB6HP31680	93.516	285,176	1,054,351
Total CFDA No. 93.516			285,176	1,054,351
University Centers for Excellence in Developmental Disabilities Education, Research, and Service:				
Pass-through University of Georgia	90DDUC0083	93.632	—	13,334
Total CFDA No. 93.632			—	13,334
ACA – REINVESTMENT OF CIVIL MONEY PENALTIES TO BENEFIT NURSING HOME RESIDENTS:				
Pass-through Georgia Department of Community Health	2019-04-GA-1009	93.636	—	104,015
Total CFDA No. 93.636			—	104,015
Child Welfare Services, State Grants:				
Pass-through Georgia Department of Human Services	42700-040-0000088042	93.645	—	3,000
Total CFDA No. 93.645			—	3,000
Trans-NIH Recovery Act Research Support:				
Pass-through Wistar Institute	PO1AI082282	93.701	—	567
Total CFDA No. 93.701			—	567

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Health Careers Opportunity Program	1D18HP32120-01-00	93.822	\$ 21,248	692,183
Total CFDA No. 93.822			21,248	692,183
Ebola Support: Transmission and Prevention Control, Public Health Preparedness, Vaccine Development	1U54CK000453-01-06	93.823	—	5,961
Total CFDA No. 93.823			—	5,961
COVID-19 – National Ebola Training and Education Center	U3REP150549	93.825	639,733	2,462,002
COVID-19 – National Ebola Training and Education Center	NU38CK000481	93.825	—	61,851
National Ebola Training and Education Center	U3REP150549	93.825	4,770,402	6,048,882
National Ebola Training and Education Center	U3REP170552	93.825	1,710,820	1,741,543
Total CFDA No. 93.825			7,120,955	10,314,278
Planning Grant for Healthcare and Public Health Sector Cybersecurity Information Sharing: Pass-through University of Florida	R01NS112291	93.835	—	340,329
Total CFDA No. 93.835			—	340,329
Cardiovascular Diseases Research	5K08HL124292-05	93.837	—	15,555
Cardiovascular Diseases Research	5K22HL126922-03	93.837	—	70,594
Cardiovascular Diseases Research	5P01HL095070-09	93.837	—	81,395
Cardiovascular Diseases Research	5R01HL127726-04	93.837	—	2,313
Cardiovascular Diseases Research	5R01HL130471-04	93.837	—	230,977
Cardiovascular Diseases Research	F31HL143900	93.837	—	8,911
Cardiovascular Diseases Research	F31HL145974	93.837	—	51,179
Cardiovascular Diseases Research	F31HL149272	93.837	—	42,387
Cardiovascular Diseases Research	F31HL149285	93.837	—	42,770
Cardiovascular Diseases Research	F31HL154725	93.837	—	45,208
Cardiovascular Diseases Research	F31HL156426	93.837	—	2,153
Cardiovascular Diseases Research	F31HL156495	93.837	—	30,878
Cardiovascular Diseases Research	F32HL147547	93.837	—	51,291
Cardiovascular Diseases Research	F32HL151163	93.837	—	62,928
Cardiovascular Diseases Research	K01HL133466	93.837	—	38,685
Cardiovascular Diseases Research	K01HL149982	93.837	—	105,627
Cardiovascular Diseases Research	K01HL155235	93.837	—	70,283
Cardiovascular Diseases Research	K08HL136873	93.837	—	178,342
Cardiovascular Diseases Research	K23HL122361	93.837	—	125,036
Cardiovascular Diseases Research	K23HL127251	93.837	—	6,296
Cardiovascular Diseases Research	K23HL128795	93.837	—	96,374
Cardiovascular Diseases Research	K23HL143164	93.837	—	88,481
Cardiovascular Diseases Research	K23HL152903	93.837	—	140,476
Cardiovascular Diseases Research	K24HL148521	93.837	—	141,835
Cardiovascular Diseases Research	OT2HL 155038-02	93.837	—	327,606
Cardiovascular Diseases Research	OT2HL152762	93.837	73,372	282,986
Cardiovascular Diseases Research	R00HL127295	93.837	—	231,524
Cardiovascular Diseases Research	R01HL109413	93.837	—	607,623
Cardiovascular Diseases Research	R01HL119798	93.837	141,002	720,689
Cardiovascular Diseases Research	R01HL122392	93.837	131,642	456,056
Cardiovascular Diseases Research	R01HL125442	93.837	171,464	333,086
Cardiovascular Diseases Research	R01HL125761	93.837	218,575	450,108
Cardiovascular Diseases Research	R01HL127236	93.837	11,202	51,598
Cardiovascular Diseases Research	R01HL130915	93.837	—	62,357
Cardiovascular Diseases Research	R01HL133667	93.837	—	963,808
Cardiovascular Diseases Research	R01HL135145	93.837	38,018	434,855
Cardiovascular Diseases Research	R01HL135183	93.837	—	338,367
Cardiovascular Diseases Research	R01HL136205	93.837	873	338,955
Cardiovascular Diseases Research	R01HL136345	93.837	—	290,748
Cardiovascular Diseases Research	R01HL136915	93.837	—	465,292
Cardiovascular Diseases Research	R01HL137338	93.837	350,529	591,500
Cardiovascular Diseases Research	R01HL139757	93.837	—	413,997
Cardiovascular Diseases Research	R01HL140223	93.837	—	493,291
Cardiovascular Diseases Research	R01HL142762	93.837	—	391,470
Cardiovascular Diseases Research	R01HL143065	93.837	—	468,937
Cardiovascular Diseases Research	R01HL143348	93.837	46,736	660,354
Cardiovascular Diseases Research	R01HL143350	93.837	120,824	691,583
Cardiovascular Diseases Research	R01HL144741	93.837	211,342	468,051
Cardiovascular Diseases Research	R01HL145644	93.837	159,864	804,071
Cardiovascular Diseases Research	R01HL146147	93.837	237,388	680,120
Cardiovascular Diseases Research	R01HL147270	93.837	—	382,938
Cardiovascular Diseases Research	R01HL150005	93.837	—	281,510
Cardiovascular Diseases Research	R01HL150562	93.837	—	435,676
Cardiovascular Diseases Research	R01HL150887	93.837	35,470	449,370
Cardiovascular Diseases Research	R01HL158141	93.837	—	148,554
Cardiovascular Diseases Research	R01HL158571	93.837	—	117,545
Cardiovascular Diseases Research	R03HL146874	93.837	8,070	26,001
Cardiovascular Diseases Research	R03HL146879	93.837	13,527	49,581
Cardiovascular Diseases Research	R03HL155253	93.837	—	20,372
Cardiovascular Diseases Research	R03HL156476	93.837	—	53,177
Cardiovascular Diseases Research	R21HL145486	93.837	—	100,433
Cardiovascular Diseases Research	R61HL154116	93.837	—	569,514
Cardiovascular Diseases Research	T32HL007745	93.837	—	513,609
Cardiovascular Diseases Research	T32HL130025	93.837	—	483,275
Cardiovascular Diseases Research	U01HL128566	93.837	297,803	773,114
Cardiovascular Diseases Research	U54HL141981	93.837	117,579	1,413,909
Cardiovascular Diseases Research	UG1HL135682	93.837	222,926	298,943
Cardiovascular Diseases Research	U01HL146241	93.837	98,477	2,192,336
Pass-through Ann & Robert H. Lurie Children's Hospital of Chicago	UG3HL148318	93.837	—	2,649
Pass-through Beth Israel Deaconess Medical Center	R01HL086741	93.837	—	157,622
Pass-through Boston University	R01HL139867	93.837	—	117,594
Pass-through Boston University	U01HL146382	93.837	—	106,194
Pass-through Children's Hospital of Philadelphia	P01HL139420	93.837	—	39,340
Pass-through Duke University	R01HL130443	93.837	—	18,000
Pass-through Georgia Institute of Technology	R01HL135505	93.837	—	58,581
Pass-through Georgia Institute of Technology	R01HL140325	93.837	—	226,990
Pass-through Georgia Institute of Technology	R01HL144714	93.837	—	96,777
Pass-through Georgia State University	R01HL14205	93.837	—	40,622
Pass-through Henry M Jackson Foundation	R01HL130448	93.837	9,341	11,976

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Michigan Technological University	R15HL140596	93.837	\$ —	(507)
Pass-through New York University	R25HL105444	93.837	—	1,446
Pass-through Ohio State University	R01HL128857	93.837	—	27,477
Pass-through Ohio State University	R01HL148581	93.837	—	7,754
Pass-through University of California Los Angeles	R01HL118650	93.837	—	323
Pass-through University of California San Francisco	R25HL126146	93.837	—	1,372
Pass-through University of Minnesota	R01HL126837	93.837	—	5,333
Pass-through University of Minnesota	R01HL131579	93.837	—	3,991
Pass-through University of Minnesota	R01HL136679	93.837	—	6,458
Pass-through University of Minnesota	R01HL141288	93.837	—	22,484
Pass-through University of Rochester	416745	93.837	—	2,123
Pass-through University of Utah	R01HL150608	93.837	—	14,079
Pass-through University of Virginia	R01HL130918	93.837	—	135,241
Pass-through University of Virginia	R01HL137112	93.837	—	220,274
Pass-through Vanderbilt University	R01HL132338	93.837	—	24,533
Pass-through Wake Forest University	01HL135853	93.837	—	58,553
Total CFDA No. 93.837			2,716,024	23,466,142
Lung Diseases Research	SR01HL125042-04	93.838	—	65
Lung Diseases Research	F31HL139109	93.838	—	(2,288)
Lung Diseases Research	F31HL139134	93.838	—	(924)
Lung Diseases Research	F31HL143863	93.838	—	44,810
Lung Diseases Research	F31HL149323	93.838	—	45,193
Lung Diseases Research	F31HL156639	93.838	—	30,697
Lung Diseases Research	F32HL151133	93.838	—	59,199
Lung Diseases Research	K23HL151897	93.838	—	207,818
Lung Diseases Research	K99HL151965	93.838	—	126,705
Lung Diseases Research	R01HL113548	93.838	33,049	320,183
Lung Diseases Research	R01HL133053	93.838	—	177,523
Lung Diseases Research	R01HL136414	93.838	341,770	627,726
Lung Diseases Research	R01HL139876	93.838	355,873	623,100
Lung Diseases Research	R01HL142866	93.838	—	372,349
Lung Diseases Research	R01HL144478	93.838	—	285,022
Lung Diseases Research	R35HL150803	93.838	—	925,206
Lung Diseases Research	R56HL150658	93.838	—	227,602
Lung Diseases Research	R56HL152167	93.838	—	572,794
Lung Diseases Research	T32HL116271	93.838	—	399,342
Lung Diseases Research	UM1HL134590	93.838	3,133,362	5,036,720
Pass-through Medical College of Georgia	R01HL138410	93.838	—	120,470
Pass-through Morehouse School of Medicine	1OT2HL1568	93.838	—	89,515
Pass-through New York University	OT2HL161847-01	93.838	—	24,118
Pass-through University of Arizona	U01HL130045	93.838	—	50,702
Pass-through University of Arizona	UG3HL147016	93.838	—	48,822
Pass-through University of Georgia	R01HL136707	93.838	—	172,383
Total CFDA No. 93.838			3,864,054	10,584,852
COVID-19 – Blood Diseases and Resources Research	R01HL138656	93.839	—	83,468
Blood Diseases and Resources Research	5K23HL128942-03	93.839	—	(480)
Blood Diseases and Resources Research	SR01HL117061-06	93.839	—	(15)
Blood Diseases and Resources Research	SR01HL123984-04	93.839	—	19
Blood Diseases and Resources Research	SR01HL131414-03	93.839	—	40,668
Blood Diseases and Resources Research	5T32HL069769-15 REVISED	93.839	—	(12,664)
Blood Diseases and Resources Research	F31HL138934	93.839	—	25,320
Blood Diseases and Resources Research	F31HL149357	93.839	—	45,227
Blood Diseases and Resources Research	F31HL154656	93.839	—	45,412
Blood Diseases and Resources Research	F31HL154703	93.839	—	8,860
Blood Diseases and Resources Research	F31HL159223	93.839	—	6,459
Blood Diseases and Resources Research	K01HL131333	93.839	—	37,074
Blood Diseases and Resources Research	K01HL133518	93.839	—	14,966
Blood Diseases and Resources Research	K08HL141635	93.839	—	170,473
Blood Diseases and Resources Research	K23HL133457	93.839	16,473	155,980
Blood Diseases and Resources Research	K23HL136900	93.839	—	157,355
Blood Diseases and Resources Research	K23HL140142	93.839	15,586	180,447
Blood Diseases and Resources Research	K23HL146904	93.839	—	142,634
Blood Diseases and Resources Research	K25HL141636	93.839	—	138,509
Blood Diseases and Resources Research	K99HL150595	93.839	—	174,231
Blood Diseases and Resources Research	K99HL150626	93.839	—	189,392
Blood Diseases and Resources Research	P01HL086773	93.839	93,564	224,793
Blood Diseases and Resources Research	R01HL082808	93.839	97,367	423,328
Blood Diseases and Resources Research	R01HL129141	93.839	—	364,343
Blood Diseases and Resources Research	R01HL130995	93.839	—	91,966
Blood Diseases and Resources Research	R01HL135575	93.839	—	(34,154)
Blood Diseases and Resources Research	R01HL137128	93.839	1,157	41,158
Blood Diseases and Resources Research	R01HL138423	93.839	—	33,473
Blood Diseases and Resources Research	R01HL138656	93.839	95,030	541,558
Blood Diseases and Resources Research	R01HL138714	93.839	—	207,627
Blood Diseases and Resources Research	R01HL140589	93.839	461,416	796,229
Blood Diseases and Resources Research	R01HL141335	93.839	—	360,223
Blood Diseases and Resources Research	R01HL143794	93.839	55,450	549,378
Blood Diseases and Resources Research	R01HL146668	93.839	91,324	244,867
Blood Diseases and Resources Research	R01HL152074	93.839	—	580,215
Blood Diseases and Resources Research	R01HL152131	93.839	—	211,577
Blood Diseases and Resources Research	R01HL152322	93.839	—	337,939
Blood Diseases and Resources Research	R01HL154034	93.839	—	206,568
Blood Diseases and Resources Research	R01HL154824	93.839	—	403,291
Blood Diseases and Resources Research	R03HL154629	93.839	—	80,815
Blood Diseases and Resources Research	R21HL146299	93.839	53,345	115,421
Blood Diseases and Resources Research	R35HL145000	93.839	—	642,857
Blood Diseases and Resources Research	R56HL147760	93.839	—	206,962
Blood Diseases and Resources Research	T32HL069769	93.839	—	53,724
Blood Diseases and Resources Research	T32HL139443	93.839	—	232,457
Blood Diseases and Resources Research	U01HL139483	93.839	—	685,583
Blood Diseases and Resources Research	UG3HL148560	93.839	—	214,701
Blood Diseases and Resources Research	5R01HL121264-05 REVISED	93.839	572	572
Blood Diseases and Resources Research	R01HL155330	93.839	—	260,407
Pass-through Ann & Robert H. Lurie Children's Hospital of Chicago	R01HL136480	93.839	2,346	23,577

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Augusta University Research Institute Inc	R25HL106365	93.839	\$ —	3,001
Pass-through Augusta University Research Institute Inc	RHL106365	93.839	—	7,287
Pass-through Boston Children's Hospital	P01HL046925	93.839	—	386,768
Pass-through Medical College of Wisconsin	U01HL143477	93.839	—	4,491
Pass-through New England Research Institutes	U01HL072268	93.839	—	5,974
Pass-through Rice University	R01HL152314	93.839	—	197,267
Pass-through University of Alabama Birmingham	R01HL133896	93.839	900	15,641
Pass-through University of Florida	UG1HL069301	93.839	—	75,382
Pass-through University of Pittsburgh	UG3HL143192	93.839	—	28,509
Pass-through University of Virginia	P01HL132819	93.839	—	5,902
Pass-through University of Washington	R01HL141781	93.839	—	5,170
Total CFDA No. 93.839			984,530	10,379,182
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	1R61HL138657-01 REVISED	93.840	—	(1,032)
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	K23HL152368	93.840	—	125,212
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	R33HL138657	93.840	—	1,037,706
Pass-through All India Institute of Medical Sciences	U01HL138635	93.840	—	63,347
Pass-through Seattle Biomedical Research Institute	U01HL142103	93.840	—	8,231
Pass-through University of Washington	R01HL137808	93.840	—	86,471
Pass-through University Of Witwatersrand	UG3HL156388	93.840	—	246,124
Total CFDA No. 93.840			—	1,566,059
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR067786-04	93.846	—	867
Arthritis, Musculoskeletal and Skin Diseases Research	F31AR078047	93.846	—	42,770
Arthritis, Musculoskeletal and Skin Diseases Research	F32AR074249	93.846	—	46,483
Arthritis, Musculoskeletal and Skin Diseases Research	K23AR075888	93.846	—	142,888
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR047901	93.846	—	634
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR048266	93.846	1,803	5,566
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR048615	93.846	—	249,914
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR050501	93.846	—	2,593
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR061907	93.846	—	343,568
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR068157	93.846	—	164,843
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070091	93.846	—	606,700
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070736	93.846	—	348,283
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070898	93.846	26,621	530,088
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR071397	93.846	—	324,780
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR073874	93.846	168,578	761,321
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR076089	93.846	—	145,947
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR076153	93.846	—	47,935
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR076427	93.846	—	76,100
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR077926	93.846	—	339,185
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR071529	93.846	—	48,541
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR071536	93.846	1,813	38,551
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR072222	93.846	12,251	31,956
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR073593	93.846	—	68,198
Arthritis, Musculoskeletal and Skin Diseases Research	U01AR067997	93.846	—	270,730
Pass-through Cincinnati Childrens Hospital	R01AR070474	93.846	—	41,386
Pass-through Georgia Institute of Technology	R01AR071026	93.846	—	13,386
Pass-through Mayo Clinic Rochester	R01AR055563	93.846	—	62,471
Pass-through Mount Sinai School of Medicine	R01AR069315	93.846	—	32,503
Pass-through University of Alabama Birmingham	1R01AR072697-01	93.846	—	7,737
Pass-through University of Michigan	R01AR070470	93.846	—	33,784
Pass-through University of Michigan	U01AR073485	93.846	—	27,943
Pass-through University of Oregon	R01AR069297	93.846	—	31,284
Total CFDA No. 93.846			211,066	4,886,935
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK055679-16 REVI	93.847	—	112
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK059888-14REVIS	93.847	—	111
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK089763-04	93.847	—	111
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK092722-07	93.847	—	24,853
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK100582-04	93.847	—	(1,083)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK107900-04	93.847	—	136,311
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK117570	93.847	—	25,320
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK122745	93.847	—	45,258
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126435	93.847	—	43,504
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126501	93.847	—	42,999
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK120195	93.847	—	32,807
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK127848	93.847	—	58,127
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK109025	93.847	—	97,620
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK128384	93.847	—	55,742
Diabetes, Digestive, and Kidney Diseases Extramural Research	K08DK111998	93.847	—	124,059
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK113241	93.847	—	184,597
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK118189	93.847	6,843	141,228
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122115	93.847	—	171,012
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122199	93.847	—	184,033
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK123384	93.847	—	188,473
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK124647	93.847	—	178,452
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK111024	93.847	70,949	552,730
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK125013	93.847	—	214,173
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK044234	93.847	—	368,520
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK047987	93.847	—	492,731
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK054514	93.847	—	4,833
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK080684	93.847	155,844	440,113
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK087694	93.847	39,867	660,257
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK107719	93.847	—	134,298
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK108070	93.847	93,142	278,194
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK110409	93.847	—	249,750
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK111678	93.847	—	366,147
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK112946	93.847	—	494,037
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK114891	93.847	5,679	184,103
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115213	93.847	—	385,612
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115937	93.847	149,484	427,983
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK116799	93.847	—	503,126
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119229	93.847	—	283,051
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK122701	93.847	—	508,531
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK124821	93.847	—	171,097

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125187	93.847	\$ 232,063	704,444
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125246	93.847	—	109,057
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125701	93.847	—	92,072
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125936	93.847	1,445	239,862
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK127083	93.847	—	4,932
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK122111	93.847	—	130,129
Diabetes, Digestive, and Kidney Diseases Extramural Research	R18DK118467	93.847	—	266,268
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK119997	93.847	—	196,972
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK122229	93.847	60,946	185,098
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK123616	93.847	—	78,520
Diabetes, Digestive, and Kidney Diseases Extramural Research	R25DK101390	93.847	—	74,444
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK074731	93.847	—	274,031
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK098231	93.847	—	60,167
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK007656	93.847	—	196,165
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK108735	93.847	—	154,213
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK062470	93.847	499,356	1,232,015
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK106994	93.847	—	59,478
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK116099	93.847	38,048	378,242
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119793	93.847	—	357,246
Pass-through Augusta University Research Institute Inc	U24DK115255	93.847	—	48,072
Pass-through Beth Israel Deaconess Medical Center	U24DK115255	93.847	—	377,472
Pass-through Children's Hospital of Philadelphia	R01DK110749	93.847	—	59,274
Pass-through Cornell University	R01DK056626	93.847	—	115,897
Pass-through Cornell University	R01DK103046	93.847	—	154,617
Pass-through Fdtn for Atlanta Veterans Educ and Res	U01DK098246	93.847	—	4,499
Pass-through Georgia State University	R01DK099071	93.847	—	17,450
Pass-through Georgia State University	R01DK114700	93.847	—	12,185
Pass-through Johns Hopkins University	R01DK110375	93.847	—	588,484
Pass-through Mayo Clinic	RC2DK118619	93.847	—	698,983
Pass-through Mount Sinai School of Medicine	U01DK119200	93.847	—	26,887
Pass-through Natl Jewish Health	R01DK107735	93.847	—	(2,870)
Pass-through Research Institute at Nationwide Children's Hospital	U01DK100866	93.847	—	36,596
Pass-through Translational Genomics Research Inst	R01 DK107735	93.847	—	65,737
Pass-through University of Alabama Birmingham	R01DK115473	93.847	—	45,520
Pass-through University of Alabama Birmingham	U01DK106858	93.847	—	22,345
Pass-through University of Georgia	R01DK112874	93.847	—	11,142
Pass-through University of Kansas Medical Center	R01DK099611	93.847	—	11,332
Pass-through University of Kansas Medical Center	R01DK113111	93.847	—	191,974
Pass-through University of Kentucky	R01DK095662	93.847	—	14,389
Pass-through University of Michigan	R01DK089763	93.847	—	31,142
Pass-through University of South Florida	U01DK106993	93.847	—	50,594
Pass-through University of South Florida	UC4DK117009	93.847	—	1,154
Pass-through University of Texas Southwestern	U01KD58639	93.847	—	(1,760)
Pass-through Vanderbilt University Medical Center	R01DK120814	93.847	—	25,155
Pass-through Virginia Commonwealth University	U01DK061731	93.847	241	54,431
Pass-through Wright State University	R21DK119879	93.847	—	59,162
Pass-through Yale University	R01DK121326	93.847	—	28,743
Total CFDA No. 93.847			1,353,907	15,994,893
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS110312	93.853	—	42,985
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS120182	93.853	—	346,992
Extramural Research Programs in the Neurosciences and Neurological Disorders	R03HD104276	93.853	—	11,683
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS112740	93.853	—	112,021
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS112948	93.853	—	134,865
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS104801-01A1	93.853	—	19
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106346-01	93.853	—	12,850
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS123882-01	93.853	—	8,575
Extramural Research Programs in the Neurosciences and Neurological Disorders	1UG3NS113879	93.853	—	179,201
Extramural Research Programs in the Neurosciences and Neurological Disorders	3R01NS092122-03S1 REVISED	93.853	2,312	21,118
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101786-02	93.853	—	(121)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101806-02	93.853	—	3,881
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS110193-02	93.853	—	100
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079858-05REVISED	93.853	—	(1,342)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085568-05	93.853	—	15,341
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088528-05	93.853	—	1,558
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088748-05	93.853	—	(727)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS089719-04	93.853	—	(8,393)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090319-04	93.853	—	(5,975)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090677-04	93.853	14,464	291,733
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091585	93.853	—	179,730
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095279-04	93.853	—	200,227
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS102652-02	93.853	—	319
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R24NS092989-03	93.853	—	38
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS103363	93.853	—	20,894
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS106755	93.853	—	31,106
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS113530	93.853	—	46,914
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS113572	93.853	—	46,736
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS115479	93.853	—	47,065
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS117086	93.853	—	42,295
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS118867	93.853	—	42,828
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS124269	93.853	—	4,306
Extramural Research Programs in the Neurosciences and Neurological Disorders	K00NS108539	93.853	—	70,180
Extramural Research Programs in the Neurosciences and Neurological Disorders	K08NS099474	93.853	—	162,302
Extramural Research Programs in the Neurosciences and Neurological Disorders	K08NS105929	93.853	—	173,991
Extramural Research Programs in the Neurosciences and Neurological Disorders	K23NS097576	93.853	—	160,911
Extramural Research Programs in the Neurosciences and Neurological Disorders	K23NS105944	93.853	—	199,013
Extramural Research Programs in the Neurosciences and Neurological Disorders	NS091201	93.853	—	64,386
Extramural Research Programs in the Neurosciences and Neurological Disorders	P50NS098685	93.853	—	1,316,360
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS036232	93.853	—	489,299
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS037112	93.853	—	523,781
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS045962	93.853	131,999	687,897
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS047357	93.853	—	144,112
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS065992	93.853	—	420,184
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS078095	93.853	—	373,092
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS083654	93.853	—	235,503
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS084844	93.853	—	428,813

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS085387	93.853	\$ —	76,603
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS088748	93.853	123,852	497,084
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS089694	93.853	—	(7,594)
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS091201	93.853	—	299,487
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS092343	93.853	—	299,459
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS093016	93.853	—	151,584
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS093362	93.853	—	173,774
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS095181	93.853	—	285,455
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS095269	93.853	—	312,322
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS097549	93.853	376,542	672,732
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS097776	93.853	—	194,267
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS098441	93.853	—	461,877
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS099375	93.853	26,133	383,419
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS100908	93.853	—	386,328
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS100967	93.853	—	297,639
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS101701	93.853	—	383,151
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102306	93.853	242,691	456,305
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102850	93.853	—	342,260
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102871	93.853	—	348,645
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS105971	93.853	—	332,692
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS105982	93.853	—	289,300
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS107505	93.853	—	676,297
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS109237	93.853	255,014	568,313
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS109242	93.853	—	804,261
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS110110	93.853	74,375	564,193
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS110386	93.853	—	374,278
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111280	93.853	—	304,682
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111470	93.853	82,268	452,524
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111969	93.853	—	354,250
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS112308	93.853	—	356,120
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS112350	93.853	—	176,861
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS113746	93.853	221,554	715,766
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114130	93.853	15,146	570,818
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114221	93.853	—	382,754
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114253	93.853	130,795	485,627
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS118819	93.853	—	159,450
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS120676	93.853	—	27,814
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS123447	93.853	—	96,519
Extramural Research Programs in the Neurosciences and Neurological Disorders	R03NS114791	93.853	—	18,296
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS102913	93.853	—	129,594
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS106120	93.853	—	97,169
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS106209	93.853	—	18,575
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS106325	93.853	—	15,721
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS108758	93.853	—	67,906
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS108760	93.853	—	142,541
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS110416	93.853	—	184,851
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS111765	93.853	—	107,730
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS113019	93.853	—	216,664
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114603	93.853	—	158,410
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114795	93.853	—	195,812
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114839	93.853	—	252,178
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114882	93.853	—	213,143
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114908	93.853	—	177,234
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS115758	93.853	—	164,572
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116311	93.853	—	259,763
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116318	93.853	—	351,601
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116438	93.853	43,863	229,473
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116665	93.853	—	175,788
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116724	93.853	—	282,112
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS117113	93.853	—	184,815
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS121850	93.853	—	38,878
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS122011	93.853	—	90,752
Extramural Research Programs in the Neurosciences and Neurological Disorders	R33NS101167	93.853	57,186	99,681
Extramural Research Programs in the Neurosciences and Neurological Disorders	R33NS106120	93.853	—	72,439
Extramural Research Programs in the Neurosciences and Neurological Disorders	R35NS111602	93.853	—	663,255
Extramural Research Programs in the Neurosciences and Neurological Disorders	R35NS111619	93.853	—	637,787
Extramural Research Programs in the Neurosciences and Neurological Disorders	T32NS007480	93.853	—	143,347
Extramural Research Programs in the Neurosciences and Neurological Disorders	T32NS096050	93.853	—	365,235
Extramural Research Programs in the Neurosciences and Neurological Disorders	U24NS100673	93.853	62,984	159,244
Extramural Research Programs in the Neurosciences and Neurological Disorders	U24NS107234	93.853	—	292,073
Extramural Research Programs in the Neurosciences and Neurological Disorders	U54NS116025	93.853	884,810	1,181,159
Extramural Research Programs in the Neurosciences and Neurological Disorders	UG3NS100559	93.853	—	323,371
Pass-through Albert Einstein College of Medicine	K12NS080223	93.853	—	146,600
Pass-through Baylor College of Medicine	R21NS104953	93.853	—	213
Pass-through Brigham and Womens Hospital	R21NS119660	93.853	—	77,169
Pass-through Childrens Healthcare of Atlanta	R21NS103507	93.853	—	3,135
Pass-through Children's Hospital of Philadelphia	U01NS106845	93.853	2,604	20,701
Pass-through Children's Hospital of Philadelphia	U54NS115052	93.853	12,773	48,350
Pass-through Columbia University	R01NS110826	93.853	—	54,872
Pass-through Creighton University	R01NS118731	93.853	—	88,995
Pass-through Georgia Institute of Technology	R01NS109226	93.853	—	43,701
Pass-through Georgia Institute of Technology	R01NS115994	93.853	—	231,009
Pass-through Georgia Institute of Technology	R21NS117067	93.853	—	94,749
Pass-through Georgia State University	R21NS111355	93.853	—	46,495
Pass-through Johns Hopkins University	R01NS111283	93.853	—	4,393
Pass-through Mayo Clinic	P01NS084974	93.853	—	484,673
Pass-through Mayo Clinic	U54NS115198	93.853	—	15,566
Pass-through Medical University of South Carolina	R01NS110347	93.853	—	87,039
Pass-through Medical University of South Carolina	U24NS100655	93.853	—	45,471
Pass-through Morehouse School of Medicine	R01NS112422	93.853	—	136,353
Pass-through Morehouse School of Medicine	R21 NS116726	93.853	—	30,314
Pass-through Mount Sinai School of Medicine	UH3NS103550	93.853	—	118,762
Pass-through Pennsylvania State University	EMUNS113912	93.853	—	68,710
Pass-through Stanford University	U01NS038455	93.853	—	329,029
Pass-through Univ of Texas Health Sciences Ctr	R61NS113329-01	93.853	—	7,047
Pass-through University of Akron	R15NS109957	93.853	—	70,466

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Pass-through University of Cincinnati	U01NS086872	93.853	\$ —	19,760
Pass-through University of Georgia	R01NS099596	93.853	—	63,272
Pass-through University of Idaho	R01NS111283	93.853	—	15,908
Pass-through University of Miami	R01NS084288	93.853	—	72,279
Pass-through University of Pennsylvania	P01NS097206	93.853	—	46
Pass-through University of Pennsylvania	U01NS113198	93.853	—	140,713
Pass-through University of Pittsburgh	R21NS111063	93.853	—	8,797
Pass-through University Of South Carolina	R01NS117821	93.853	—	91,307
Pass-through University of Southern California	R01NS115845	93.853	—	35,446
Pass-through University of Utah	R01NS097819	93.853	—	37,596
Pass-through University of Wisconsin-Madison	R01NS099158	93.853	—	7,316
Pass-through University of Wisconsin-Madison	R01NS108756	93.853	—	245,450
Pass-through Weill Cornell Medical College	R01NS093002	93.853	—	48,334
Pass-through Weill Cornell Medical College	R01NS115963	93.853	—	51,291
Pass-through Wright State University	R01NS107398	93.853	—	66,843
Total CFDA No. 93.853			<u>2,761,365</u>	<u>31,855,301</u>
COVID-19 – Allergy, Immunology and Transplantation Research	P01AI125180	93.855	—	957,384
COVID-19 – Allergy, Immunology and Transplantation Research	R01AI123126	93.855	—	359,782
COVID-19 – Allergy, Immunology and Transplantation Research	R01AI127799	93.855	—	104,111
COVID-19 – Allergy, Immunology and Transplantation Research	R01AI141327	93.855	—	294,220
COVID-19 – Allergy, Immunology and Transplantation Research	R01AI143875	93.855	102,439	3,749,405
COVID-19 – Allergy, Immunology and Transplantation Research	R01AI148378	93.855	—	115,645
COVID-19 – Allergy, Immunology and Transplantation Research	R01AI161570	93.855	—	4,208
COVID-19 – Allergy, Immunology and Transplantation Research	U19AI057266	93.855	698,714	2,726,681
COVID-19 – Allergy, Immunology and Transplantation Research	U19AI090023	93.855	1,577,000	3,647,356
COVID-19 – Allergy, Immunology and Transplantation Research	U19AI110483	93.855	18,137	1,143,348
COVID-19 – Allergy, Immunology and Transplantation Research	UM1AI069418	93.855	—	453,684
COVID-19 – Allergy, Immunology and Transplantation Research	UM1AI148576	93.855	91,000	9,861,293
COVID-19 – Allergy, Immunology and Transplantation Research	UM1AI148684	93.855	1,450,649	1,951,347
COVID-19 – Allergy, Immunology and Transplantation Research	P51OD011132	93.855	—	363,233
COVID-19 – Allergy, Immunology and Transplantation Research	P51OD011132	93.855	2,101	828,339
Allergy, Immunology and Transplantation Research	1K23AI144036-01	93.855	—	156,857
Allergy, Immunology and Transplantation Research	1R03AI139871-01	93.855	25,263	33,689
Allergy, Immunology and Transplantation Research	1R21AI141094-01	93.855	—	86,362
Allergy, Immunology and Transplantation Research	1U01AI132904	93.855	—	45,361
Allergy, Immunology and Transplantation Research	2P30AI050409-19 REVISED	93.855	—	(1,066)
Allergy, Immunology and Transplantation Research	4R01AI070101-10 revised	93.855	—	368
Allergy, Immunology and Transplantation Research	5011649 / 8470038	93.855	—	112,258
Allergy, Immunology and Transplantation Research	5R01AI030048-24	93.855	—	(55)
Allergy, Immunology and Transplantation Research	5R01AI065429-15	93.855	—	(15,578)
Allergy, Immunology and Transplantation Research	5R01AI110334-03	93.855	—	(6,404)
Allergy, Immunology and Transplantation Research	5R01AI110334-05	93.855	—	(79)
Allergy, Immunology and Transplantation Research	5R01AI110680-05	93.855	—	182,303
Allergy, Immunology and Transplantation Research	5R01AI110701-05	93.855	—	(1,055)
Allergy, Immunology and Transplantation Research	5R01AI11557-04	93.855	—	22
Allergy, Immunology and Transplantation Research	5R01AI112723-04	93.855	—	(3,120)
Allergy, Immunology and Transplantation Research	5R01AI113021-05	93.855	—	143
Allergy, Immunology and Transplantation Research	5R01AI116379-05	93.855	—	(754)
Allergy, Immunology and Transplantation Research	5R01AI116933-04	93.855	—	75,232
Allergy, Immunology and Transplantation Research	5R01AI118853-04	93.855	—	(2,551)
Allergy, Immunology and Transplantation Research	5R21AI135711-02	93.855	—	67,227
Allergy, Immunology and Transplantation Research	5R33AI104278-05	93.855	—	1,007
Allergy, Immunology and Transplantation Research	5U01AI115651-05	93.855	234,758	508,404
Allergy, Immunology and Transplantation Research	SU19AI051731-17	93.855	1,243,832	2,169,339
Allergy, Immunology and Transplantation Research	SUM1AI069418-13	93.855	942,880	1,502,561
Allergy, Immunology and Transplantation Research	F30AI152342	93.855	—	47,770
Allergy, Immunology and Transplantation Research	F31AI136310	93.855	—	1,040
Allergy, Immunology and Transplantation Research	F31AI145750	93.855	—	42,770
Allergy, Immunology and Transplantation Research	F31AI147589	93.855	—	42,845
Allergy, Immunology and Transplantation Research	F31AI147611	93.855	—	46,660
Allergy, Immunology and Transplantation Research	F31AI150114	93.855	—	45,560
Allergy, Immunology and Transplantation Research	F31AI152459	93.855	—	42,879
Allergy, Immunology and Transplantation Research	F32AI145150	93.855	—	4,615
Allergy, Immunology and Transplantation Research	F32AI161857	93.855	—	22,725
Allergy, Immunology and Transplantation Research	K08AI132747	93.855	—	238,733
Allergy, Immunology and Transplantation Research	K08AI139348	93.855	—	198,924
Allergy, Immunology and Transplantation Research	K23AI124913	93.855	—	150,301
Allergy, Immunology and Transplantation Research	K23AI134182	93.855	—	177,546
Allergy, Immunology and Transplantation Research	K23AI143479	93.855	12,132	182,972
Allergy, Immunology and Transplantation Research	K23AI144040	93.855	—	125,674
Allergy, Immunology and Transplantation Research	K24AI114444	93.855	—	119,164
Allergy, Immunology and Transplantation Research	K99AI146271	93.855	—	378
Allergy, Immunology and Transplantation Research	K99AI153736	93.855	—	76,886
Allergy, Immunology and Transplantation Research	P01AI125180	93.855	471,592	1,555,697
Allergy, Immunology and Transplantation Research	P30AI050409	93.855	263,204	3,571,758
Allergy, Immunology and Transplantation Research	R00AI138860	93.855	—	152,919
Allergy, Immunology and Transplantation Research	R01AI020211	93.855	—	384,857
Allergy, Immunology and Transplantation Research	R01AI021150	93.855	91,901	261,938
Allergy, Immunology and Transplantation Research	R01AI030048	93.855	—	303,418
Allergy, Immunology and Transplantation Research	R01AI051231	93.855	475,473	1,058,434
Allergy, Immunology and Transplantation Research	R01AI053668	93.855	133,528	352,407
Allergy, Immunology and Transplantation Research	R01AI064060	93.855	134,513	413,101
Allergy, Immunology and Transplantation Research	R01AI073707	93.855	—	387,337
Allergy, Immunology and Transplantation Research	R01AI088025	93.855	3,308	381,279
Allergy, Immunology and Transplantation Research	R01AI1072435	93.855	—	464,528
Allergy, Immunology and Transplantation Research	R01AI107960	93.855	49,097	275,875
Allergy, Immunology and Transplantation Research	R01AI113021	93.855	—	329,910
Allergy, Immunology and Transplantation Research	R01AI114902	93.855	110,680	312,706
Allergy, Immunology and Transplantation Research	R01AI116933	93.855	—	227,003
Allergy, Immunology and Transplantation Research	R01AI120860	93.855	94,833	207,915
Allergy, Immunology and Transplantation Research	R01AI121252	93.855	—	192,084
Allergy, Immunology and Transplantation Research	R01AI121315	93.855	182,133	580,782
Allergy, Immunology and Transplantation Research	R01AI123126	93.855	—	212,741
Allergy, Immunology and Transplantation Research	R01AI123733	93.855	—	321,394
Allergy, Immunology and Transplantation Research	R01AI124680	93.855	564,568	867,101

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology and Transplantation Research	R01AI125064	93.855	\$ —	188,292
Allergy, Immunology and Transplantation Research	R01AI125202	93.855	—	286,228
Allergy, Immunology and Transplantation Research	R01AI125268	93.855	—	226,267
Allergy, Immunology and Transplantation Research	R01AI126322	93.855	—	175,104
Allergy, Immunology and Transplantation Research	R01AI127799	93.855	189,133	352,593
Allergy, Immunology and Transplantation Research	R01AI128799	93.855	—	324,523
Allergy, Immunology and Transplantation Research	R01AI128837	93.855	54,847	1,084,948
Allergy, Immunology and Transplantation Research	R01AI129862	93.855	304,011	562,398
Allergy, Immunology and Transplantation Research	R01AI130163	93.855	266,370	691,216
Allergy, Immunology and Transplantation Research	R01AI132766	93.855	40,018	445,424
Allergy, Immunology and Transplantation Research	R01AI132833	93.855	—	376,962
Allergy, Immunology and Transplantation Research	R01AI133706	93.855	58,626	805,122
Allergy, Immunology and Transplantation Research	R01AI134244	93.855	—	908,465
Allergy, Immunology and Transplantation Research	R01AI135806	93.855	20,281	404,748
Allergy, Immunology and Transplantation Research	R01AI136533	93.855	117,763	530,145
Allergy, Immunology and Transplantation Research	R01AI136581	93.855	—	427,236
Allergy, Immunology and Transplantation Research	R01AI137127	93.855	—	188,391
Allergy, Immunology and Transplantation Research	R01AI137679	93.855	55,220	58,792
Allergy, Immunology and Transplantation Research	R01AI138646	93.855	321,326	423,048
Allergy, Immunology and Transplantation Research	R01AI138783	93.855	342,124	579,821
Allergy, Immunology and Transplantation Research	R01AI139406	93.855	282,357	555,539
Allergy, Immunology and Transplantation Research	R01AI141327	93.855	77,110	453,263
Allergy, Immunology and Transplantation Research	R01AI141883	93.855	—	211,765
Allergy, Immunology and Transplantation Research	R01AI143414	93.855	—	762,109
Allergy, Immunology and Transplantation Research	R01AI143875	93.855	397,871	594,278
Allergy, Immunology and Transplantation Research	R01AI144067	93.855	—	430,142
Allergy, Immunology and Transplantation Research	R01AI145231	93.855	—	938,299
Allergy, Immunology and Transplantation Research	R01AI145640	93.855	25,036	869,249
Allergy, Immunology and Transplantation Research	R01AI146017	93.855	204,791	663,464
Allergy, Immunology and Transplantation Research	R01AI146260	93.855	—	146,657
Allergy, Immunology and Transplantation Research	R01AI147609	93.855	97,887	386,258
Allergy, Immunology and Transplantation Research	R01AI148377	93.855	—	976,815
Allergy, Immunology and Transplantation Research	R01AI148382	93.855	608,841	1,075,572
Allergy, Immunology and Transplantation Research	R01AI148471	93.855	66,388	362,927
Allergy, Immunology and Transplantation Research	R01AI148661	93.855	88,349	598,222
Allergy, Immunology and Transplantation Research	R01AI149297	93.855	121,568	493,638
Allergy, Immunology and Transplantation Research	R01AI149486	93.855	—	332,572
Allergy, Immunology and Transplantation Research	R01AI149527	93.855	—	72,471
Allergy, Immunology and Transplantation Research	R01AI149724	93.855	—	344,506
Allergy, Immunology and Transplantation Research	R01AI150453	93.855	11,310	568,196
Allergy, Immunology and Transplantation Research	R01AI150774	93.855	170,000	311,844
Allergy, Immunology and Transplantation Research	R01AI152516	93.855	—	294,579
Allergy, Immunology and Transplantation Research	R01AI153071	93.855	—	278,800
Allergy, Immunology and Transplantation Research	R01AI153102	93.855	—	393,209
Allergy, Immunology and Transplantation Research	R01AI153152	93.855	—	124,871
Allergy, Immunology and Transplantation Research	R01AI154894	93.855	—	183,788
Allergy, Immunology and Transplantation Research	R01AI155007	93.855	—	768
Allergy, Immunology and Transplantation Research	R01AI156052	93.855	—	41,352
Allergy, Immunology and Transplantation Research	R01AI162267	93.855	—	279,827
Allergy, Immunology and Transplantation Research	R01AI162633	93.855	—	15,397
Allergy, Immunology and Transplantation Research	R01AI47839	93.855	74,311	533,003
Allergy, Immunology and Transplantation Research	R13AI150088	93.855	—	8,500
Allergy, Immunology and Transplantation Research	R21AI142489	93.855	—	104,124
Allergy, Immunology and Transplantation Research	R21AI142507	93.855	—	170,447
Allergy, Immunology and Transplantation Research	R21AI145541	93.855	—	42,475
Allergy, Immunology and Transplantation Research	R21AI145650	93.855	—	157,706
Allergy, Immunology and Transplantation Research	R21AI146443	93.855	80,398	178,398
Allergy, Immunology and Transplantation Research	R21AI146503	93.855	—	219,173
Allergy, Immunology and Transplantation Research	R21AI148847	93.855	—	91,595
Allergy, Immunology and Transplantation Research	R21AI149252	93.855	—	244,785
Allergy, Immunology and Transplantation Research	R21AI150292	93.855	—	322,215
Allergy, Immunology and Transplantation Research	R21AI152031	93.855	—	7,174
Allergy, Immunology and Transplantation Research	R21AI154232	93.855	—	180,567
Allergy, Immunology and Transplantation Research	R21AI154352	93.855	—	306,269
Allergy, Immunology and Transplantation Research	R21AI155142	93.855	—	94,633
Allergy, Immunology and Transplantation Research	R21AI155221	93.855	—	26,176
Allergy, Immunology and Transplantation Research	R21AI156161	93.855	—	39,975
Allergy, Immunology and Transplantation Research	R21AI157730	93.855	—	85,440
Allergy, Immunology and Transplantation Research	R21AI157911	93.855	—	36,181
Allergy, Immunology and Transplantation Research	R21AI159765	93.855	—	71,110
Allergy, Immunology and Transplantation Research	R21AI163427	93.855	—	18,146
Allergy, Immunology and Transplantation Research	R21AI164733	93.855	—	1,311
Allergy, Immunology and Transplantation Research	R21AI38079	93.855	—	43,643
Allergy, Immunology and Transplantation Research	R24AI162317	93.855	—	223,675
Allergy, Immunology and Transplantation Research	R37AI021150	93.855	12,155	24,820
Allergy, Immunology and Transplantation Research	R37AI066998	93.855	—	342,950
Allergy, Immunology and Transplantation Research	R37AI076119	93.855	102,144	535,254
Allergy, Immunology and Transplantation Research	R37AI11278	93.855	—	1,133,009
Allergy, Immunology and Transplantation Research	R37AI141258	93.855	—	645,457
Allergy, Immunology and Transplantation Research	R37AI157862	93.855	—	2,905
Allergy, Immunology and Transplantation Research	R38AI140299	93.855	—	316,390
Allergy, Immunology and Transplantation Research	R56AI132833	93.855	—	35,791
Allergy, Immunology and Transplantation Research	R56AI145231	93.855	—	(3,987)
Allergy, Immunology and Transplantation Research	R56AI150401	93.855	44,020	569,842
Allergy, Immunology and Transplantation Research	R56AI154895	93.855	—	297,209
Allergy, Immunology and Transplantation Research	T32 AI138952	93.855	—	193,651
Allergy, Immunology and Transplantation Research	T32AI070081	93.855	—	184,861
Allergy, Immunology and Transplantation Research	T32AI074492	93.855	—	332,067
Allergy, Immunology and Transplantation Research	T32AI106699	93.855	—	245,332
Allergy, Immunology and Transplantation Research	U01AI131295	93.855	—	344,300
Allergy, Immunology and Transplantation Research	U01AI131566	93.855	224,304	338,416
Allergy, Immunology and Transplantation Research	U01AI138909	93.855	—	615,032
Allergy, Immunology and Transplantation Research	U01AI141993	93.855	101,562	796,961
Allergy, Immunology and Transplantation Research	U01AI148069	93.855	988,312	1,657,455
Allergy, Immunology and Transplantation Research	U01AI150747	93.855	544,620	898,822
Allergy, Immunology and Transplantation Research	U19AI057266	93.855	1,314,143	2,832,290

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Allergy, Immunology and Transplantation Research	U19AI090023	93.855	\$ 1,407,778	1,724,656
Allergy, Immunology and Transplantation Research	U19AI110483	93.855	4,407,040	6,003,447
Allergy, Immunology and Transplantation Research	U19AI11121	93.855	841,218	2,442,743
Allergy, Immunology and Transplantation Research	U19AI117891	93.855	29,709	300,516
Allergy, Immunology and Transplantation Research	U19AI158080	93.855	—	719,885
Allergy, Immunology and Transplantation Research	U19AI159819	93.855	—	142,822
Allergy, Immunology and Transplantation Research	U24AI120134	93.855	75,300	411,646
Allergy, Immunology and Transplantation Research	UH3AI122320	93.855	139,033	977,503
Allergy, Immunology and Transplantation Research	UM1AI069418	93.855	249,831	2,011,737
Allergy, Immunology and Transplantation Research	UM1AI124436	93.855	1,134,737	5,962,298
Allergy, Immunology and Transplantation Research	UM1AI148576	93.855	—	901,980
Allergy, Immunology and Transplantation Research	UM1AI148684	93.855	2,127,788	3,400,060
Allergy, Immunology and Transplantation Research	UM1AI164562	93.855	—	138
Allergy, Immunology and Transplantation Research	5R01AI047498-13	93.855	—	2,722
Allergy, Immunology and Transplantation Research	5R33AI121684-04	93.855	66,563	163,375
Allergy, Immunology and Transplantation Research	R01AI064462	93.855	—	173,113
Allergy, Immunology and Transplantation Research	R01AI148378	93.855	—	710,238
Allergy, Immunology and Transplantation Research	R21AI138563	93.855	14,097	22,328
Allergy, Immunology and Transplantation Research	P30AI124414	93.855	—	63,640
Pass-through Albert Einstein College of Medicine	R01HL149921	93.855	—	23,677
Pass-through Albert Einstein College of Medicine	R01I114304	93.855	—	238,500
Pass-through Benaroya Research Institute at Virginia	UM1AI109565	93.855	—	283,040
Pass-through Beth Israel Deaconess Medical Center	R01AI143457	93.855	—	101,648
Pass-through Beth Israel Deaconess Medical Center	UM1AI124377	93.855	—	151,444
Pass-through Boston Children's Hospital	U01AI125051	93.855	9,810	15,802
Pass-through Brigham and Womens Hospital	R01AI138801	93.855	—	88,215
Pass-through Case Western Reserve University	1R37AI141258-01	93.855	—	546,263
Pass-through Case Western Reserve University	A1072219-11	93.855	—	100,827
Pass-through Cincinnati Childrens Hospital	R01AI148276	93.855	—	45,914
Pass-through Cincinnati Childrens Hospital	U01AI144673	93.855	—	741,907
Pass-through Dana Farber Cancer Institute	R21AI129017	93.855	—	(10,240)
Pass-through Dana Farber Cancer Institute	R33AI129017	93.855	—	196,810
Pass-through Drexel University	U19AI128910	93.855	—	489,382
Pass-through Duke University	P01AI131276	93.855	—	171,529
Pass-through Duke University	P01AI131276	93.855	—	349,960
Pass-through Duke University	U19AI131471	93.855	—	4,465
Pass-through Duke University	UM1AI104681	93.855	—	122,371
Pass-through Family Health International	PO15004277	93.855	84,542	95,383
Pass-through Fred Hutchinson Cancer Research Center	UM1AI068614	93.855	—	3,544,128
Pass-through Fred Hutchinson Cancer Research Center	UM1AI068635	93.855	—	21,969
Pass-through Fred Hutchinson Cancer Research Center	UM1AI068635	93.855	—	15,724
Pass-through Georgia Institute of Technology	R56AI153116	93.855	—	18,551
Pass-through Georgia Institute of Technology	U01AI124270	93.855	—	54,588
Pass-through Georgia Institute of Technology	UH2AI153028	93.855	—	24,818
Pass-through Georgia State University	R01AI071002	93.855	—	137,901
Pass-through Georgia State University	R01AI141222	93.855	—	507,575
Pass-through Georgia State University	R01AI153400	93.855	—	191,911
Pass-through Georgia Tech Foundation	SP00013950-01/AMND 1	93.855	—	50,821
Pass-through Harvard University	R01AI155007	93.855	—	17,336
Pass-through Harvard University	P01AI056299	93.855	—	167,937
Pass-through Harvard University	P30AI060354	93.855	—	26,781
Pass-through Henry M Jackson Foundation	U19AI144180	93.855	—	59,390
Pass-through Johns Hopkins University	R21AI139784	93.855	—	9,386
Pass-through Johns Hopkins University	U01AI069918	93.855	—	150,125
Pass-through Johns Hopkins University	UH3AI133669	93.855	—	171,699
Pass-through Johns Hopkins University	UM1 AI068632	93.855	—	15,537
Pass-through Johns Hopkins University	UM1AI068632	93.855	—	26,839
Pass-through Johns Hopkins University	UM2AI130836	93.855	159,602	211,382
Pass-through La Jolla Institute for Allergy	R01AI125068	93.855	—	279,298
Pass-through La Jolla Institute for Allergy	U19AI142742	93.855	—	53,532
Pass-through Massachusetts General Hospital	R01AI124718	93.855	—	1,386
Pass-through Mayo Clinic Rochester	R01AI121054	93.855	—	326,990
Pass-through Medical University of South Carolina	U01AI125159	93.855	—	229,155
Pass-through Mount Sinai School of Medicine	0255-8689-4609	93.855	—	(340)
Pass-through Mount Sinai School of Medicine	P01AI097092	93.855	—	381,653
Pass-through Mount Sinai School of Medicine	U01A163594	93.855	—	97,665
Pass-through Mount Sinai School of Medicine	U19AI118610	93.855	—	184,830
Pass-through Mount Sinai School of Medicine	U19AI135972	93.855	—	166,218
Pass-through Ohio State University	R01AI127863	93.855	—	99,867
Pass-through Regents of the University of California	R01AI125842	93.855	—	106,278
Pass-through Regents of the University of California	UM1AI068636	93.855	—	20,687
Pass-through Research Institute at Nationwide Children's Hospital	R01AI096882	93.855	—	182,578
Pass-through Research Institute at Nationwide Children's Hospital	R01AI126890	93.855	—	262,146
Pass-through Scripps Research Institute	R01AI145629	93.855	—	390,129
Pass-through Scripps Research Institute	U19AI142790	93.855	—	168,555
Pass-through Scripps Research Institute	UM1 AI144462	93.855	—	1,622,961
Pass-through Scripps Research Institute	UM1AI144462	93.855	—	638,023
Pass-through Seattle Children's Research Institute	R01AI134419	93.855	—	42,858
Pass-through South Dakota State University	R01AI14188	93.855	—	8,039
Pass-through St Jude Childrens Research Hospital	R56AI114442	93.855	—	30,962
Pass-through St Jude Childrens Research Hospital	U01AI144616	93.855	—	263,421
Pass-through Temple University	R01AI143653	93.855	—	24,066
Pass-through Texas Biomedical Research Institute	R01AI111943	93.855	—	53,085
Pass-through Texas Biomedical Research Institute	R01AI123047	93.855	—	277,148
Pass-through Tufts University	R01AI137424	93.855	—	75,506
Pass-through University of Alabama	U19AI142737	93.855	—	58,116
Pass-through University of Alabama Birmingham	R01AI153365	93.855	—	21,037
Pass-through University of Alabama Birmingham	U19AI142759	93.855	—	301,876
Pass-through University of Alabama Birmingham	U54AI150225	93.855	210	4,024
Pass-through University Of California Berkeley	R01AI148127	93.855	—	35,879
Pass-through University Of California Berkeley	U01AI151788	93.855	—	37,892
Pass-through University of California Los Angeles	UM1AI068636	93.855	—	187,525
Pass-through University of California Los Angeles	UM1AI068636	93.855	—	14,394
Pass-through University of California San Francisco	R01AI143464	93.855	—	38,064
Pass-through University of California San Francisco	R01AI151075	93.855	—	276,289
Pass-through University of California San Francisco	R01AI152161	93.855	—	86,170

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of California San Francisco	U01118594	93.855	\$ —	111,315
Pass-through University of Georgia	R01AI125738	93.855	—	41,208
Pass-through University of Houston	R01AI125362	93.855	—	108,749
Pass-through University of Illinois	R01AI147487	93.855	—	4,580
Pass-through University of Kentucky	R01AI141889	93.855	—	136,468
Pass-through University of Louisiana at Lafayette	R01AI111907	93.855	—	(519)
Pass-through University of Louisiana at Lafayette	U19AI142636	93.855	—	30,037
Pass-through University of Maryland, Baltimore	P01AI124912	93.855	—	144,340
Pass-through University of Mississippi	R21AI144571	93.855	—	54,177
Pass-through University of Nebraska	R01AI129745	93.855	—	57,953
Pass-through University of Nevada	R01AI122266	93.855	—	28,215
Pass-through University of North Carolina	UM1AI126619	93.855	—	1,249,500
Pass-through University of North Carolina Chapel Hill	R01AI136990	93.855	—	178,102
Pass-through University of North Carolina Chapel Hill	R01AI153007	93.855	—	9,514
Pass-through University of North Carolina Chapel Hill	U01AI114378	93.855	—	11,574
Pass-through University of North Carolina Chapel Hill	UAI100625C	93.855	—	11,263
Pass-through University of Pennsylvania	PO1AI131338	93.855	—	674,332
Pass-through University of Pennsylvania	R01AI139188	93.855	—	104,797
Pass-through University of Pennsylvania	U19AI131130	93.855	—	146,163
Pass-through University of Texas Southwestern	R01AI141101	93.855	—	107,036
Pass-through University of Utah	R01AI147641	93.855	—	78,680
Pass-through University of Virginia	R01AI154242	93.855	—	21,760
Pass-through University of Washington	R01AI137679	93.855	—	131,412
Pass-through University of Washington	R01AI142647	93.855	—	357,589
Pass-through University of Wisconsin-Madison	R01AI148707	93.855	—	115,897
Pass-through University of Wisconsin-Madison	U01AI102456	93.855	—	31,754
Pass-through Vanderbilt University	U19AI095227	93.855	—	93,600
Pass-through Washington State University	U01AI151799	93.855	—	114,306
Pass-through Washington University	R56AI147623	93.855	—	181,903
Pass-through Wayne State University	R21AI140033	93.855	—	78,422
Pass-through Weill Cornell Medical College	P01AI131276	93.855	—	672,778
Pass-through Yale University	R01AI112970	93.855	—	14,991
Total CFDA No. 93.855			27,128,189	130,665,781
Microbiology and Infectious Diseases Research	R01GM099142	93.856	—	232,225
Pass-through Baylor College of Medicine	HHSN272013000151	93.856	—	114,934
Pass-through University of Florida	RF1AG052476	93.856	—	122,446
Total CFDA No. 93.856			—	469,605
Biomedical Research and Research Training	IDSEP190055	93.859	44,469	98,443
Biomedical Research and Research Training	1F32GM128407-01REVISED	93.859	—	1,882
Biomedical Research and Research Training	ZR01GM100151-05	93.859	—	577
Biomedical Research and Research Training	5R01GM084070-09	93.859	—	(1,949)
Biomedical Research and Research Training	5R01GM117946-04	93.859	867	56,162
Biomedical Research and Research Training	5R35GM122549	93.859	—	407,085
Biomedical Research and Research Training	F31GM130112	93.859	—	41,129
Biomedical Research and Research Training	F31GM131609	93.859	—	44,440
Biomedical Research and Research Training	F31GM134849	93.859	—	45,652
Biomedical Research and Research Training	F31GM143891	93.859	—	4,306
Biomedical Research and Research Training	F32GM133091	93.859	—	11,398
Biomedical Research and Research Training	K12GM000680	93.859	165,534	1,194,132
Biomedical Research and Research Training	K23GM137182	93.859	—	145,480
Biomedical Research and Research Training	R00GM129460	93.859	—	138,849
Biomedical Research and Research Training	R01AI150453	93.859	50,000	168,482
Biomedical Research and Research Training	R01GM035463	93.859	—	187,761
Biomedical Research and Research Training	R01GM051173	93.859	—	124,816
Biomedical Research and Research Training	R01GM053640	93.859	—	335,991
Biomedical Research and Research Training	R01GM083889	93.859	—	503,962
Biomedical Research and Research Training	R01GM084070	93.859	—	472,058
Biomedical Research and Research Training	R01GM093278	93.859	45	184,913
Biomedical Research and Research Training	R01GM099142	93.859	—	2,349
Biomedical Research and Research Training	R01GM104323	93.859	—	254,676
Biomedical Research and Research Training	R01GM113243	93.859	—	77,477
Biomedical Research and Research Training	R01GM116065	93.859	1,417	185,278
Biomedical Research and Research Training	R01GM116991	93.859	—	147,499
Biomedical Research and Research Training	R01GM118012	93.859	137,138	297,566
Biomedical Research and Research Training	R01GM120271	93.859	—	43,876
Biomedical Research and Research Training	R01GM121967	93.859	—	351,121
Biomedical Research and Research Training	R01GM122083	93.859	176,730	246,137
Biomedical Research and Research Training	R01GM123136-	93.859	72,703	241,412
Biomedical Research and Research Training	R01GM124061	93.859	—	(17,693)
Biomedical Research and Research Training	R01GM124280	93.859	73,618	416,333
Biomedical Research and Research Training	R01GM124472	93.859	—	232,356
Biomedical Research and Research Training	R01GM129495	93.859	—	264,464
Biomedical Research and Research Training	R01GM131099	93.859	26,409	336,157
Biomedical Research and Research Training	R01GM132598	93.859	—	428,713
Biomedical Research and Research Training	R01GM136893	93.859	—	228,527
Biomedical Research and Research Training	R01GM137011	93.859	—	216,081
Biomedical Research and Research Training	R01GM138544	93.859	—	306,786
Biomedical Research and Research Training	R01GM140632	93.859	—	16,176
Biomedical Research and Research Training	R01GM140657	93.859	—	172,213
Biomedical Research and Research Training	R01GM142113	93.859	—	180,254
Biomedical Research and Research Training	R21GM127971	93.859	—	142,058
Biomedical Research and Research Training	R35GM119426	93.859	—	248,005
Biomedical Research and Research Training	R35GM122526	93.859	—	408,005
Biomedical Research and Research Training	R35GM122558	93.859	—	408,716
Biomedical Research and Research Training	R35GM122591	93.859	—	581,141
Biomedical Research and Research Training	R35GM133509	93.859	—	430,330
Biomedical Research and Research Training	R35GM136407	93.859	—	391,521
Biomedical Research and Research Training	R35GM138123	93.859	—	263,831
Biomedical Research and Research Training	R35GM138313	93.859	4,139	281,932
Biomedical Research and Research Training	R35GM142503	93.859	—	4,718
Biomedical Research and Research Training	R35GM143050	93.859	—	31,311
Biomedical Research and Research Training	T32GM008169	93.859	—	1,170,673
Biomedical Research and Research Training	T32GM008602	93.859	—	284,153
Biomedical Research and Research Training	R01AI150451	93.859	—	114,942
Biomedical Research and Research Training	K23GM128221	93.859	—	167,769

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Biomedical Research and Research Training	R01GM072808	93.859	\$ —	382,088
Biomedical Research and Research Training	R01GM109501	93.859	23,561	23,561
Biomedical Research and Research Training	R01GM130950	93.859	—	511,541
Biomedical Research and Research Training	R01GM141074	93.859	—	14,622
Biomedical Research and Research Training	R21GM134564	93.859	53,073	214,521
Biomedical Research and Research Training	R25GM125598	93.859	—	480,953
Biomedical Research and Research Training	R35GM119426	93.859	—	231,818
Biomedical Research and Research Training	R35GM133719	93.859	—	443,839
Biomedical Research and Research Training	R35GM139408	93.859	—	364,426
Biomedical Research and Research Training	T32GM008490	93.859	—	478,768
Biomedical Research and Research Training	T32GM095442	93.859	—	296,983
Biomedical Research and Research Training	T32GM135060	93.859	—	333,233
Biomedical Research and Research Training	R01GM134245	93.859	—	335,860
Pass-through George Mason University	R01GM140476	93.859	—	50,715
Pass-through Georgia Institute of Technology	R01AI148740	93.859	—	158,293
Pass-through Georgia Institute of Technology	R01GM118803	93.859	—	8,000
Pass-through Georgia Institute of Technology	T32GM008433	93.859	—	46,678
Pass-through Johns Hopkins University	R01GM127578	93.859	—	150,287
Pass-through North Carolina State University	R25GM130528	93.859	—	38,848
Pass-through Ohio State University	R01GM065183	93.859	—	36,423
Pass-through Ohio State University	R01GM30135	93.859	—	76,711
Pass-through Pennsylvania State University	R01GM121650	93.859	—	62,911
Pass-through Scripps Research Institute	U54GM103368	93.859	—	139,259
Pass-through Seattle Children's Research Institute	U54AI150472	93.859	—	460,797
Pass-through Univ of Texas Health Sciences Ctr	R01GM130147	93.859	—	153,270
Pass-through University of California San Diego	R01GM118609	93.859	—	48,597
Pass-through University of Maryland, Baltimore	R01GM130617	93.859	—	12,120
Pass-through University of Michigan	R01GM124061	93.859	—	154,961
Pass-through University of Washington	R01AI150467	93.859	—	23,017
Pass-through University of Wisconsin-Madison	R01GM127687	93.859	—	34,856
Total CFDA No. 93.859			629,703	19,083,383
Child Health and Human Development Extramural Research	1R03HD097737-01	93.865	—	61,826
Child Health and Human Development Extramural Research	1R21HD089160-02	93.865	—	84
Child Health and Human Development Extramural Research	1R21HD095138-01	93.865	3,716	117,136
Child Health and Human Development Extramural Research	5K01HD079584-05	93.865	—	(1,581)
Child Health and Human Development Extramural Research	5K25HD086276-03	93.865	—	15,502
Child Health and Human Development Extramural Research	5R01HD075784-05	93.865	—	(4,333)
Child Health and Human Development Extramural Research	5R01HD085877-03 REVISED	93.865	—	21,303
Child Health and Human Development Extramural Research	5R03HD087606-02	93.865	—	21,242
Child Health and Human Development Extramural Research	5R21HD080107-02 REVISED	93.865	—	512
Child Health and Human Development Extramural Research	5R21HD093027-02	93.865	—	12,931
Child Health and Human Development Extramural Research	F31HD096815	93.865	—	61,237
Child Health and Human Development Extramural Research	F31HD097918	93.865	—	27,839
Child Health and Human Development Extramural Research	F31HD098816	93.865	—	46,913
Child Health and Human Development Extramural Research	F31HD100145	93.865	—	43,324
Child Health and Human Development Extramural Research	F31HD100265	93.865	—	48,138
Child Health and Human Development Extramural Research	F32HD096816	93.865	—	36,627
Child Health and Human Development Extramural Research	F32HD097920	93.865	—	63,833
Child Health and Human Development Extramural Research	F32HD100176	93.865	—	57,477
Child Health and Human Development Extramural Research	K01HD100588	93.865	—	126,290
Child Health and Human Development Extramural Research	K12HD072245	93.865	—	427,767
Child Health and Human Development Extramural Research	K12HD085850	93.865	—	521,150
Child Health and Human Development Extramural Research	K99HD097290	93.865	—	64,756
Child Health and Human Development Extramural Research	K99HD104991	93.865	—	43,360
Child Health and Human Development Extramural Research	P50HD104458	93.865	684,584	1,244,064
Child Health and Human Development Extramural Research	R00HD092625	93.865	—	261,979
Child Health and Human Development Extramural Research	R00HD093858	93.865	—	199,180
Child Health and Human Development Extramural Research	R00HD096322	93.865	—	77,272
Child Health and Human Development Extramural Research	R00HD097290	93.865	—	44,913
Child Health and Human Development Extramural Research	R01HD046922	93.865	—	589,122
Child Health and Human Development Extramural Research	R01HD082373	93.865	—	168,186
Child Health and Human Development Extramural Research	R01HD090642	93.865	91,505	253,485
Child Health and Human Development Extramural Research	R01HD090925	93.865	—	734,282
Child Health and Human Development Extramural Research	R01HD092033	93.865	—	316,933
Child Health and Human Development Extramural Research	R01HD092580	93.865	135,309	317,647
Child Health and Human Development Extramural Research	R01HD092595	93.865	385,234	578,621
Child Health and Human Development Extramural Research	R01HD093602	93.865	—	238,562
Child Health and Human Development Extramural Research	R01HD094716	93.865	—	323,665
Child Health and Human Development Extramural Research	R01HD095741	93.865	94,514	765,646
Child Health and Human Development Extramural Research	R01HD097175	93.865	211,119	584,947
Child Health and Human Development Extramural Research	R01HD099224	93.865	—	239,233
Child Health and Human Development Extramural Research	R01HD099480	93.865	226,228	522,215
Child Health and Human Development Extramural Research	R01HD101600	93.865	—	68,175
Child Health and Human Development Extramural Research	R01HD102534	93.865	24,564	133,146
Child Health and Human Development Extramural Research	R03HD102513	93.865	—	75,640
Child Health and Human Development Extramural Research	R21HD100820	93.865	49,730	120,017
Child Health and Human Development Extramural Research	R21HD103030	93.865	—	196,171
Child Health and Human Development Extramural Research	R25HD079102	93.865	—	21,511
Child Health and Human Development Extramural Research	T32HD071845	93.865	—	271,913
Child Health and Human Development Extramural Research	UG1HD027851	93.865	—	149,596
Child Health and Human Development Extramural Research	R01HD095975	93.865	—	329,081
Child Health and Human Development Extramural Research	R21HD097491	93.865	17,124	67,569
Child Health and Human Development Extramural Research	U54NS091859	93.865	—	71,609
Pass-through Baylor College of Medicine	P50H104463	93.865	—	430,271
Pass-through Bradley Hospital	7127549	93.865	—	24,644
Pass-through Case Western Reserve University	R01HD092351	93.865	—	74,459
Pass-through Children's Hospital of Philadelphia	R01HD101528	93.865	—	5,149
Pass-through Cincinnati Childrens Hospital	PL1HD101059	93.865	—	18,334
Pass-through Harvard School of Public Health	R01HD093761	93.865	—	28,996
Pass-through Harvard University	P01HD103133	93.865	—	9,365
Pass-through Harvard University	R01HD102342	93.865	—	26,438
Pass-through Mclean Hospital	R21HD097524	93.865	—	38,501
Pass-through Michigan State University	R01HD096033	93.865	—	15,258
Pass-through Morehouse School of Medicine	R01HD097843	93.865	—	50,828
Pass-through Mount Sinai School of Medicine	R01HD099231	93.865	—	271,937

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Northwestern University	5K12HD073945-08	93.865	\$ —	36,026
Pass-through Northwestern University	R01HD099344	93.865	—	21,430
Pass-through Ohio State University	R01HD091274	93.865	—	78,608
Pass-through Phoenix Children's Hospital	R01HD088528	93.865	—	89,058
Pass-through Research Institute at Nationwide Children's Hospital	R01HD091347	93.865	—	33,710
Pass-through Rutgers The State University	R21HD104558	93.865	—	116,821
Pass-through Seattle Children's Research Institute	R01HD086978	93.865	29,502	95,418
Pass-through Tulane University	U01HD052104	93.865	—	741
Pass-through Univ of Massachusetts Medical School	U54HD082013	93.865	—	(2,516)
Pass-through University of California Davis	01HD074346	93.865	—	(412)
Pass-through University Of Connecticut	R01HD106617	93.865	—	2,548
Pass-through University of Georgia	R01HD094879	93.865	—	11,144
Pass-through University of Miami	R01HD101352	93.865	—	325,619
Pass-through University of North Carolina Chapel Hill	R01HD094009	93.865	—	64,546
Pass-through University of North Carolina Chapel Hill	U19HD089881	93.865	—	1,609,331
Pass-through University of North Carolina Chapel Hill	U24HD089880	93.865	—	639,624
Pass-through University of Pennsylvania	U24HD089880	93.865	—	54,482
Pass-through University of Pittsburgh	R01HD102313	93.865	—	81,987
Pass-through University of Washington	R01HD089831	93.865	—	82,267
Pass-through University of Washington	R21HD102825	93.865	—	44,668
Pass-through Wayne State University	R01HD099178	93.865	—	87,489
Pass-through Weill Cornell Medical College	R21HD099000	93.865	—	9,637
Pass-through Women & Infants Hospital of Rhode Island	R01HD084515	93.865	—	227,718
Total CFDA No. 93.865			1,953,129	15,481,837
Aging Research	P30AG064200	93.866	377,416	1,208,825
Aging Research	R01AG070704	93.866	—	49,704
Aging Research	R21AG065977	93.866	—	145,322
Aging Research	1R21AG058866-01	93.866	—	84,820
Aging Research	1RF1AG051538-01A1	93.866	—	6,197
Aging Research	1RF1AG057247-01	93.866	—	171
Aging Research	1RF1AG057471-01	93.866	65,322	65,322
Aging Research	1RF1AG057965-01A1 REVISED	93.866	59,303	324,375
Aging Research	1RF1AG060285-01A1 REVISED	93.866	65,768	846,845
Aging Research	3U01AG052460-03S1	93.866	—	566,335
Aging Research	5R01AG042127-06 REVISED	93.866	—	25
Aging Research	5R21AG055995-02 REVISED	93.866	—	67,003
Aging Research	5R21AG058445-02	93.866	—	23,382
Aging Research	F31AG067623	93.866	—	13,324
Aging Research	F31AG069502	93.866	—	43,106
Aging Research	F31AG072907	93.866	—	13,946
Aging Research	F32AG064862	93.866	—	57,475
Aging Research	K08AG068604	93.866	—	167,382
Aging Research	K23AG065452	93.866	—	155,221
Aging Research	K23AG065505	93.866	—	205,185
Aging Research	K23AG066931	93.866	—	75,010
Aging Research	K24AG062786	93.866	—	164,214
Aging Research	P30AG066511	93.866	—	2,722,483
Aging Research	P50AG025688	93.866	27,433	295,686
Aging Research	R01AG047408	93.866	—	16,675
Aging Research	R01AG049752	93.866	—	90,196
Aging Research	R01AG054046	93.866	81,268	317,104
Aging Research	R01AG054079	93.866	245	88,864
Aging Research	R01AG054991	93.866	74,214	214,423
Aging Research	R01AG055634	93.866	—	443,706
Aging Research	R01AG056533	93.866	32,346	526,206
Aging Research	R01AG057714	93.866	43,685	528,348
Aging Research	R01AG058704	93.866	248,210	417,036
Aging Research	R01AG061175	93.866	—	765,121
Aging Research	R01AG061179	93.866	5,113	365,349
Aging Research	R01AG061971	93.866	249,711	727,174
Aging Research	R01AG062577	93.866	12,130	406,886
Aging Research	R01AG062581	93.866	—	397,337
Aging Research	R01AG062691	93.866	—	727,903
Aging Research	R01AG064464	93.866	—	256,849
Aging Research	R01AG065177	93.866	—	486,380
Aging Research	R01AG065611	93.866	102,744	599,028
Aging Research	R01AG066203	93.866	91,424	567,930
Aging Research	R01AG067736	93.866	—	244,664
Aging Research	R01AG068247	93.866	—	324,332
Aging Research	R01AG070937	93.866	—	2,193,843
Aging Research	R01AG071174	93.866	—	39,213
Aging Research	R03AG066559	93.866	—	99,125
Aging Research	R03AG067207	93.866	—	33,439
Aging Research	R13AG047064	93.866	—	42,709
Aging Research	R21AG054903	93.866	—	(17,905)
Aging Research	R21AG062386	93.866	—	91,049
Aging Research	R21AG064405	93.866	—	125,566
Aging Research	R21AG065815	93.866	38,313	124,197
Aging Research	R21AG072142	93.866	—	19,876
Aging Research	R34AG058835	93.866	177,173	238,703
Aging Research	R56AG019206	93.866	—	101
Aging Research	R56AG059714	93.866	169,741	493,329
Aging Research	R56AG062633	93.866	—	356,083
Aging Research	R56AG070861	93.866	—	5,278
Aging Research	R56AG072473	93.866	—	100,867
Aging Research	RF1AG051514	93.866	—	9,868
Aging Research	RF1AG051633	93.866	38,377	38,377
Aging Research	RF1AG057470	93.866	26,146	26,146
Aging Research	RF1AG069114	93.866	—	62,521
Aging Research	RF1AG069253	93.866	—	99,895
Aging Research	RF1AG071170	93.866	—	207,394
Aging Research	RF1AG071587	93.866	—	68,849
Aging Research	U01AG046161	93.866	—	(5,138)
Aging Research	U01AG061357	93.866	277,148	2,406,916
Aging Research	U54AG062334	93.866	189,004	1,350,399

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Aging Research	U54AG065187	93.866	\$ 4,710,976	6,235,614
Pass-through Baylor College of Medicine	R01AG057339	93.866	—	67,077
Pass-through Baylor College of Medicine	R01AG53960	93.866	—	252,151
Pass-through Beth Israel Deaconess Medical Center	1RF2AG062181-01	93.866	—	449,475
Pass-through Boston University	5U34AG051418	93.866	—	1,780
Pass-through Brown University	U54AG063546	93.866	—	46,044
Pass-through Columbia University	R01AG062624	93.866	—	19,914
Pass-through Columbia University	U01AG061356	93.866	—	52,401
Pass-through Duke University	R01AG057235	93.866	—	77,778
Pass-through Georgia Institute of Technology	R21AG056781	93.866	—	746
Pass-through Georgia Institute of Technology	R21AG061687	93.866	—	43,969
Pass-through Georgia Institute of Technology	R21AG064309	93.866	—	8,550
Pass-through Georgia State University	R01AG062310	93.866	—	67,568
Pass-through Georgia State University	SP00013539-01,R56AGO	93.866	—	92,517
Pass-through Indiana University	U01AG057195	93.866	—	33,758
Pass-through Indiana University	U54AG054345	93.866	—	323,668
Pass-through M D Anderson Cancer Center	R01AG067419	93.866	—	47,126
Pass-through Mayo Clinic	R21AG062580	93.866	—	15,874
Pass-through Northwestern University	U2CAG057441	93.866	—	83,236
Pass-through Northwestern University	U2CAG060426	93.866	—	8,366
Pass-through Oregon Health and Science University	P30AG008017	93.866	—	40,428
Pass-through Oregon Health and Science University	R01AG056102	93.866	—	16,666
Pass-through Oregon Health and Science University	R01AG067546	93.866	—	12,067
Pass-through Rush University Medical Center	R01AG015819	93.866	—	282,487
Pass-through Univ of Texas Health Sciences Ctr	R01AG059993	93.866	—	9,684
Pass-through University of Alabama Birmingham	R01AG061800	93.866	—	657,285
Pass-through University of California San Diego	R01AG062387	93.866	—	274,897
Pass-through University of Florida	R01AG064786	93.866	—	140,073
Pass-through University of Florida	RF1AG057247	93.866	—	147,452
Pass-through University of Georgia	R01AG059260	93.866	—	12,680
Pass-through University of Minnesota	R21AG061372	93.866	—	8,817
Pass-through University of Rochester	R21AG066970	93.866	—	61,365
Pass-through University of Southern California	R01AG054424	93.866	—	80,164
Pass-through University of Southern California	U24AG057437	93.866	—	150,590
Pass-through University of Washington	U01AG016976	93.866	—	15,890
Pass-through University of Washington Saint Louis	RAG056639A	93.866	—	11,221
Pass-through University of Washington Saint Louis	U19AG032438	93.866	—	60,954
Pass-through University of Wisconsin-Madison	R01AG058680	93.866	—	24,421
Pass-through Washington University	R01AG067505	93.866	—	73,537
Pass-through Yale University	R33AG058926	93.866	—	90,794
Total CFDA No. 93.866			<u>7,163,210</u>	<u>34,122,653</u>
Vision Research	5R01EY025978-03 REVISED	93.867	18,210	36,822
Vision Research	5UG1EY013287-15	93.867	—	402
Vision Research	F31EY028855	93.867	—	30,114
Vision Research	K23EY030158	93.867	—	218,033
Vision Research	P30EY006360	93.867	—	520,578
Vision Research	R01EY014852	93.867	—	242,531
Vision Research	R01EY021592	93.867	—	491,636
Vision Research	R01EY027711	93.867	200,328	426,384
Vision Research	R01EY028450	93.867	51,321	481,562
Vision Research	R01EY028859	93.867	113,549	512,415
Vision Research	R01EY029594	93.867	10,185	229,433
Vision Research	R01EY029724	93.867	—	399,418
Vision Research	R01EY031042	93.867	—	191,953
Vision Research	R21EY028320	93.867	—	147,171
Vision Research	T32EY007092	93.867	166,306	234,174
Vision Research	UG1EY025553	93.867	—	(5,438)
Vision Research	5U10EY013287-12REVIS	93.867	—	23,008
Pass-through Georgia Institute of Technology	R01EY016435	93.867	—	38,967
Pass-through Johns Hopkins University	2003162709	93.867	—	65,097
Pass-through Morehouse School of Medicine	R01EY026291	93.867	—	53,472
Pass-through New England College of Optometry	R01EY025307	93.867	—	37,271
Pass-through University of Alabama Birmingham	R01EY028578	93.867	—	30,007
Pass-through University of California San Francisco	UG1EY023939	93.867	—	16,215
Pass-through University Of North Texas	R01EY030967	93.867	—	28,561
Pass-through Washington University	UG1EY025181	93.867	—	(278)
Total CFDA No. 93.867			<u>559,899</u>	<u>4,449,508</u>
Medical Library Assistance	G13LM013010	93.879	—	45,652
Medical Library Assistance	K01LM012924	93.879	—	121,278
Medical Library Assistance	R01LM013049	93.879	124,542	180,317
Medical Library Assistance	R01LM013323	93.879	—	259,035
Medical Library Assistance	R21LM013014	93.879	—	131,702
Pass-through University of Maryland, Baltimore	UG4LM012340	93.879	—	9,672
Total CFDA No. 93.879			<u>124,542</u>	<u>747,656</u>
Grants for Training in Primary Care Medicine and Dentistry	T0BHP28571	93.884	—	15,125
Pass-through Grady Memorial Hospital	T0BHP29995	93.884	—	191,450
Total CFDA No. 93.884			—	<u>206,575</u>
COVID-19 – Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	H7CHA37221	93.918	—	54,525
Total CFDA No. 93.918			—	<u>54,525</u>
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS004977-04	93.941	—	(333)
HIV Demonstration, Research, Public and Professional Education Projects	U01PS005112	93.941	—	50,212
HIV Demonstration, Research, Public and Professional Education Projects	U01PS005181	93.941	190,685	943,460
Total CFDA No. 93.941			<u>190,685</u>	<u>993,339</u>
COVID-19 – Geriatric Education Centers	T1MHP39056	93.969	—	77,575
Geriatric Education Centers	U1Q33070	93.969	269,503	775,831
Pass-through University Of New Mexico	3RJK7	93.969	—	199,270
Total CFDA No. 93.969			<u>269,503</u>	<u>1,052,676</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Preventive Health Services, Sexually Transmitted Diseases Research, Demonstrations, and Public Information and Education Grants:				
Pass-through University of Washington	NU62PS924588	93.978	\$ —	24,582
Total CFDA No. 93.978			—	24,582
International Research and Research Training	5D43TW007124	93.989	58,414	203,947
International Research and Research Training	D43TW009127	93.989	92,667	311,662
International Research and Research Training	D43TW010934	93.989	34,935	252,552
International Research and Research Training	D43TW011404	93.989	33,477	111,476
International Research and Research Training	R01TW010664	93.989	139,636	201,237
International Research and Research Training	U2RTW010114	93.989	94,760	168,294
Pass-through Addis Ababa University	R25TW011214	93.989	—	(65)
Pass-through Aga Khan University	D43TW010905	93.989	—	14,290
Pass-through Aga Khan University	G11TW010936	93.989	—	3,586
Pass-through Georgia State University	R01TW010666	93.989	—	31,789
Pass-through Natl Ctr for Tuberculosis and Lung Diseases	R21TW011157	93.989	—	57,891
Pass-through Universidad Peruana Cayetano Heredia	U01TW010107	93.989	—	6,321
Pass-through Vanderbilt University Medical Center	D43TW009337	93.989	36,340	75,039
Total CFDA No. 93.989			490,229	1,438,019
Contract	00HCVJCG-2018-25346	93.RD	—	63,053
Contract	200-2011-41278	93.RD	—	454,787
Contract	200-2017-92309	93.RD	—	(4,181)
Contract	75D30118C02645	93.RD	11,708	146,752
Contract	75D30118P01681	93.RD	—	9,856
Contract	75D30119C06635	93.RD	—	295,140
Contract	75D30119C06772	93.RD	—	185,231
Contract	75D30119P06734	93.RD	—	129,548
Contract	75D30120C09509	93.RD	30,931	47,820
Contract	75D30120C09811	93.RD	—	75,527
Contract	75D30120P07242	93.RD	—	44,662
Contract	75D30120P08620	93.RD	—	77,329
Contract	75D30120P09330	93.RD	—	11,783
Contract	75D30121C10084	93.RD	—	109,340
Contract	75D30121P11776	93.RD	—	168,793
Contract	HHS268201800013C	93.RD	—	9,441
Contract	HHS0100201900015C	93.RD	290,906	355,546
Contract	ISN 2020	93.RD	—	21,241
Contract	NFC-2020	93.RD	—	24,162
Contract	HHSN261201800003I	93.RD	—	2,909,508
Contract	HHSN61201800003I	93.RD	—	45,270
Contract	HHSN268201700205A	93.RD	—	3,071
Contract	75N94020D000009	93.RD	—	10,607
Contract	HHSN275201500001I	93.RD	—	132,740
Contract	75N93019C00058	93.RD	93,500	113,125
Contract	75N93020D000058	93.RD	—	3,575,390
Contract	75N93020P01395	93.RD	—	21,841
Contract	75N93021C00017	93.RD	—	165,021
Contract	HHNS272201300006C	93.RD	162,755	441,662
Contract	HHSN272201300018I	93.RD	—	29,787
Contract	HHSN272201300018I	93.RD	683,109	1,816,761
Contract	HHSN272201300018I/HHSN272	93.RD	—	118,585
Contract	HHSN272201400004C	93.RD	2,917,714	6,575,705
Contract	20FED2000031PSE	93.RD	—	3,433
Pass-through Ann & Robert H. Lurie Children's Hospital of Chicago	75D30119C06841	93.RD	—	28,306
Pass-through Children's Hospital of Philadelphia	75D30119C06345	93.RD	—	24,586
Pass-through Cincinnati Childrens Hospital	200-2012-53661	93.RD	—	17,622
Pass-through Georgia Institute of Technology	75D30120C09782	93.RD	—	2,908
Pass-through Georgia Institute of Technology	75F40120C00207	93.RD	—	42,585
Pass-through Hennepin Healthcare Research Institute	75R60220C00011	93.RD	—	9,921
Pass-through Hennepin Healthcare Research Institute	HHSN250201500009C	93.RD	—	1,290
Pass-through Kaiser Foundation Research Health Plan	200-2012-53583	93.RD	—	5,225
Pass-through Leidos Biomedical Research	HHSN261200800001E	93.RD	113,266	113,266
Pass-through Mayo Clinic	D30119C06088	93.RD	—	80,889
Pass-through Mount Sinai School of Medicine	06466933	93.RD	—	191,872
Pass-through Mount Sinai School of Medicine	75N93019C00051	93.RD	—	1,032,157
Pass-through Mount Sinai School of Medicine	N93019C00051	93.RD	—	871,337
Pass-through New England Research Institutes	HHSN268201200001I	93.RD	—	236
Pass-through NORC at the University of Chicago	8421.EMORY.01/MOD_0	93.RD	—	50,770
Pass-through NORC at the University of Chicago	HHSD2002013M53955B	93.RD	—	19,622
Pass-through NORC at the University of Chicago	HHSD2002013M54955B	93.RD	—	441,431
Pass-through Research Triangle Institute	HD036790	93.RD	—	149,515
Pass-through Rice University	OT2HL154977	93.RD	—	163,427
Pass-through Univ of Arkansas for Medical Services	75N91019D00024	93.RD	—	51,788
Pass-through University of Alabama Birmingham	HHSN272201300012I	93.RD	—	5,224
Pass-through University of Alabama Birmingham	HHSN272201300012I/75N93019F00013I	93.RD	—	182,272
Pass-through University of Chicago	75N92020D000018/75N92020F00001I	93.RD	—	118,162
Pass-through University of Georgia	N93019C00052	93.RD	—	73,119
Pass-through University of Mississippi	HHSN266201800010I	93.RD	—	66,713
Pass-through University of North Carolina Chapel Hill	2538	93.RD	—	67,970
Pass-through University of Washington	HHSN272201800008C	93.RD	—	60,810
Total CFDA No. 93.RD			4,303,889	22,092,931
U.S. Department of Health and Human Services Total			99,526,691	523,454,337
U.S. Agency for International Development:				
USAID Foreign Assistance for Programs Overseas	AID114A1700003	98.001	418,233	858,433
Pass-through Intl Aids Vaccine Initiative	AID-OAA-A-16-00032	98.001	—	735,660
Pass-through Natl Academy of Sciences	AID-391-A-17-00001	98.001	—	9,282
Total CFDA No. 98.001			418,233	1,603,375
U.S. Agency for International Development Total			418,233	1,603,375
Total Research and Development Cluster			106,930,727	557,646,619

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Major Programs:				
Student Financial Assistance Cluster (notes 2 and 3):				
U.S. Department of Education:				
Federal Work Study		84.033	\$ —	1,326,663
Federal Supplemental Education Opportunity Grant Program		84.007	—	1,735,492
Federal Pell Grant		84.063	—	8,056,644
Federal Direct Loan Program		84.268	—	84,479,954
Federal Direct PLUS Loan Program		84.268	—	54,461,489
Federal Perkins Loan Program		84.038	—	5,653,185
Total U.S. Department of Education			—	155,713,427
U.S. Department of Health and Human Services:				
Nursing Faculty Loan Program		93.264	—	984,274
Health Profession Student Loan Program		93.342	—	3,095,555
Nursing Student Loans		93.364	—	4,407,135
Total U.S. Department of Health and Human Services			—	8,486,964
Total Student Financial Assistance Cluster			—	164,200,391
U.S. Department of Agriculture:				
Special Supplemental Nutrition Program for Women, Infants, and Children: Pass-through Georgia Dept of Public Health	40500-041-20161820	10.557	—	(2,607)
Total CFDA No. 10.557			—	(2,607)
U.S. Department of Agriculture Total			—	(2,607)
U.S. Department of Commerce:				
Cluster Grants	ED20HDQ0200045	11.020	13,305	18,494
Total CFDA No. 11.020			13,305	18,494
U.S. Department of Commerce Total			13,305	18,494
National Endowment for Humanities:				
Promotion of the Humanities, Federal/State Partnership: Pass-through Georgia Humanities Council	SO-263604-19	45.129	5,000	10,000
Total CFDA No. 45.129			5,000	10,000
National Endowment for Humanities Total			5,000	10,000
U.S. Department of Veterans Affairs:				
Contract	36C24719C0118	64.CTR	—	(40,914)
Contract	36C24720C0163	64.CTR	—	297,739
Contract	36C24721C0077	64.CTR	—	355,142
Contract	36C24E19P0059	64.CTR	—	7,000
Total CFDA No. 64.CTR			—	618,967
U.S. Department of Veterans Affairs Total			—	618,967
U.S. Department of Education:				
Higher Education Emergency Relief Fund – COVID-19 Student		84.425E	—	5,963,970
Total CFDA No. 84.425E			—	5,963,970
Higher Education Emergency Relief Fund – COVID-19 Institutional		84.425F	—	15,554,943
Total CFDA No. 84.425F			—	15,554,943
U.S. Department of Education Total			—	21,518,913
U.S. Department of Health and Human Services:				
National Family Caregiver Support, Title III, Part E: Pass-through Atlanta Regional Commission	2001GAOAF C	93.052	—	17,280
Total CFDA No. 93.052			—	17,280
Global AIDS	NU2GGH001815	93.067	—	49,786
Total CFDA No. 93.067			—	49,786
Birth Defects and Developmental Disabilities – Prevention and Surveillance	6 NU50DD004932-04-01	93.073	—	553
Total CFDA No. 93.073			—	553
Maternal and Child Health Federal Consolidated Programs	UH7MC30772	93.110	94,013	632,826
Maternal and Child Health Federal Consolidated Programs	UH7MC30772-03-00	93.110	1,738	1,738
Pass-through Hemophilia of Georgia	H3024046	93.110	—	12,832
Pass-through Hemophilia of Georgia	H30MC24049	93.110	—	32,675
Total CFDA No. 93.110			95,751	680,071
Emergency Medical Services for Children: Pass-through Rhode Island Hospital	U03MC33155	93.127	—	92,484
Total CFDA No. 93.127			—	92,484
AIDS Education and Training Centers: Pass-through University of Washington	6 U1OHA33252-01-01	93.145	—	54,236
Total CFDA No. 93.145			—	54,236
Health Program for Toxic Substances and Disease Registry: Pass-through Amer Academy of Pediatrics	U61TS000237	93.161	—	(581)
Total CFDA No. 93.161			—	(581)
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security:	NU14GH001238	93.318	246,609	1,154,683
Total CFDA No. 93.318			246,609	1,154,683
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC): Pass-through Public Health Foundation Enterprises	NU50CK000539	93.323	—	389,739
Total CFDA No. 93.323			—	389,739

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Sickle Cell Treatment Demonstration Program: Pass-through Carolinas Healthcare System	U1EMC31108	93.365	\$ 32,589	111,952
Total CFDA No. 93.365			32,589	111,952
National and State Tobacco Control Program: Pass-through Kansas Department Of Health & Environment	NU58DP006823	93.387	—	58,000
Total CFDA No. 93.387			—	58,000
Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises:				
Pass-through CDC Foundation	NU1ROT000017	93.391	—	47,265
Pass-through Natl Network of Public Health Institutes	NU1ROT000004	93.391	64,220	78,542
Total CFDA No. 93.391			64,220	125,807
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health:				
Pass-through Natl Assoc of Chronic Disease Directors	6-NU38OT000286-01	93.421	—	11,669
Pass-through Natl Assoc of Chronic Disease Directors	NU38OT000286	93.421	—	67,462
Total CFDA No. 93.421			—	79,131
Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke:				
Pass-through Adcare Educational Institute	NU58DP006518	93.426	—	(1,433)
Pass-through Alabama Department of Public Health	NU58DP006527	93.426	—	50,000
Pass-through Maine Dept Of Health And Human Services	NU58DP006545	93.426	—	7,162
Pass-through Minnesota Department of Health	NU58DP006522	93.426	—	17,472
Pass-through Nebraska Department of Health and Human	NU58DP006548	93.426	—	9,500
Pass-through South Dakota Department of Health	NU58DP006526	93.426	—	170,349
Pass-through Tennessee Department of Health	NU58DP006552	93.426	—	45,084
Pass-through Wyoming Department of Health	NU58DP006551	93.426	—	26,412
Total CFDA No. 93.426			—	324,546
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke:				
Pass-through Kentucky Department for Public Health	NU58DP006612	93.435	—	77,187
Pass-through North Carolina Dept of Hlth and Human Services	NU58DP006635	93.435	—	1,322
Pass-through Utah Department of Health	NU58DP006609	93.435	—	23,650
Pass-through Wisconsin Department of Health and Family	NU58DP006607	93.435	—	11,664
Total CFDA No. 93.435			—	113,823
Coalition for a Healthier Community: Pass-through Georgia Dept of Public Health	NU58DP006623	93.453	—	17,636
Total CFDA No. 93.453			—	17,636
COVID-19 – COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured		93.461	—	19,610,436
Total CFDA No. 93.461			—	19,610,436
COVID-19 – Provider Relief Fund and American Rescue Plan (ARP) Distributions		93.498	—	143,739,531
Total CFDA No. 93.498			—	143,739,531
Children's Justice Grants to States: Pass-through Georgia Department of Human Services	42700-040-0000098036	93.643	—	99,952
Total CFDA No. 93.643			—	99,952
PPHF: Racial and Ethnic Approaches to Community Health Program financed solely by Public Prevention and Health Funds:				
Pass-through Georgia Dept of Public Health	NU58DP006580	93.738	—	40,765
Total CFDA No. 93.738			—	40,765
Preventive Health and Health Services Block Grant funded solely with Prevention and Public Health Funds (PPHF) :				
Pass-through Georgia Dept of Public Health	NB01OT009291	93.758	—	41,234
Total CFDA No. 93.758			—	41,234
Medical Assistance Program: Pass-through Georgia Department of Behavioral Health	4410-907000133937	93.778	—	3,427
Pass-through Georgia Department of Behavioral Health	H79T1081726	93.778	—	309,701
Total CFDA No. 93.778			—	313,128
Paul Coverdell National Acute Stroke Program National Center for Chronic Disease Prevention and Health Promotion: Pass-through Georgia Dept of Public Health	NU58DP006120	93.810	—	47,806
Total CFDA No. 93.810			—	47,806
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities: Pass-through Georgia Dept of Public Health	40500-033-16161809	93.817	—	(2,890)
Pass-through Georgia Dept of Public Health	U3REP150546	93.817	—	58,236
Total CFDA No. 93.817			—	55,346

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2021

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – National Ebola Training and Education Center	NU38CK000481	93.825	\$ —	841,478
National Ebola Training and Education Center	NU38CK000481	93.825	—	46,661
Total CFDA No. 93.825			—	888,139
HIV Emergency Relief Project Grants:				
Pass-through Fulton County	2 HA89HA00007-29-00	93.914	—	526,933
Pass-through Fulton County	2 HA89HA00007-31-00	93.914	—	397,491
Total CFDA No. 93.914			—	924,424
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	H76HA07848	93.918	—	619,413
Total CFDA No. 93.918			—	619,413
Assistance Programs for Chronic Disease Prevention and Control:				
Pass-through Ohio Department of Health	NU58DP006544	93.945	—	2,829
Total CFDA No. 93.945			—	2,829
Block Grants for Prevention and Treatment of Substance Abuse:				
Pass-through Georgia Department of Behavioral Health	B08TI010061-20; FY20 SAPT BG	93.959	—	70,069
Pass-through Georgia Department of Behavioral Health	B08TI083442	93.959	—	429,900
Total CFDA No. 93.959			—	499,969
Contract	1891136	93.CTR	—	4,390
Contract	200-2015-87862 00007	93.CTR	—	244,888
Contract	75D30120C07672	93.CTR	—	752,278
Contract	75D30120P08532	93.CTR	—	18,715
Contract	75D30120P09249	93.CTR	—	3,595
Contract	75D30121P10241	93.CTR	—	114,979
Pass-through Adcare Educational Institute	INTF4000M04502123189	93.CTR	—	6,364
Pass-through Assoc of State & Territorial Dental Directors	ASTDD072215/AMND 5	93.CTR	—	19,080
Pass-through Connecticut Department of Health	PO. DPHM1-0000068805	93.CTR	—	1,754
Pass-through Georgia Department of Community Health	2017001	93.CTR	—	226,336
Pass-through Georgia Dept of Public Health	40500-032-21192865/A	93.CTR	—	14,582
Pass-through Georgia Dept of Public Health	40500-CVD19-34	93.CTR	—	242,844
Pass-through Leidos Biomedical Research	75N91019D00024	93.CTR	122,150	265,896
Pass-through North Dakota State University	DTTAC2019	93.CTR	—	2,800
Total CFDA No. 93.CTR			122,150	1,918,501
U.S. Department of Health And Human Services Total			561,319	28,331,088
Total Expenditures of Federal Awards			\$ 107,510,351	916,081,396

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND
EXPENDITURES OF STATE OF GEORGIA AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2021

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
2 HA89HA00007-29-00	FULTON COUNTY	17RW2018A-MH, FY 18 Ryan White Part A	\$ 734,379	526,933
2017001	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Pro	802,062	226,336
2019-04-GA-1009	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	EASIL: Emory Antibiotic Stewardship to Improve Long-Term Care Lives	108,196	104,015
40500-036-16161809	GEORGIA DEPT OF PUBLIC HEALTH	Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	139,328	(2,890)
40500-036-21161799	GEORGIA DEPT OF PUBLIC HEALTH	Operation of the Statewide Georgia Comprehensive Cancer Registry	2,420,108	393,733
40500-041-20161820	GEORGIA DEPT OF PUBLIC HEALTH	Medical Foods For WIC Participants With Positive Inborn Errors of Metabolic Disord	120,579	(2,607)
40500-042-20203530	GEORGIA DEPT OF PUBLIC HEALTH	2020 Autism Spectrum Disorder Assessment Training Contract	56,100	41,234
40500-CVD19-32	GEORGIA DEPT OF PUBLIC HEALTH	Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	54,289	58,236
40500-CVD19-34	GEORGIA DEPT OF PUBLIC HEALTH	COVID-19 AAR	161,896	174,103
42700-040-0000088042	GEORGIA DEPARTMENT OF HUMAN SERVICES	2020 Summer Child Advocacy Program	70,457	3,000
42700-040-0000098036	GEORGIA DEPARTMENT OF HUMAN SERVICES	Summer Child Advocacy Program 2021	35,105	99,952
44100-906-0000156193	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2020-2021 Fetal Alcohol and Drug Screening project: MSACD	416,660	429,900
44100-9070000133937	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2019-2020 Emory Neuro Developmental Exposure Clinic (ENEC)	190,000	3,427
44100-9070000137642	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2019-2020 Fetal Alcohol and Drug Screening project: MSACD	83,323	70,069
44100-907-0000158746	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2020-2021 Emory Neuro Developmental Exposure Clinic (ENEC)	180,500	192,011
NU58DP006580	GEORGIA DEPT OF PUBLIC HEALTH	Evaluation of the REACH Grant	46,363	40,765
SO-263604-19	GEORGIA HUMANITIES COUNCIL	GA Humanities and the CARES Act Proposal	5,000	10,000
			<u>\$ 5,624,345</u>	<u>2,368,217</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2021

(1) Summary of Significant Accounting Policies

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University and its subsidiaries (the University) and is presented on the accrual basis of accounting. The Schedule presents all grants, contracts, and similar agreements entered into directly between agencies and departments of the federal government and subawards to the University from nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The Schedule also presents awards passed through from the University to other nonfederal subrecipient organizations. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

(2) Basis of Accounting

Expenditures for federal student financial assistance programs are recognized as incurred and include grants to students under the Federal Pell Grant and Federal Supplemental Educational Opportunity Grant Programs, student earnings under the Federal Work Study Program, and administrative cost allowances, where applicable. Expenditures for loans related to the Federal Direct Student Loan Programs (FDSLPL) are reported in the Schedule when disbursed.

New loans made during the fiscal year and loans from previous fiscal years for which the University has continuing compliance requirements to adhere to related to the Federal Perkins Loan Program are reported in the Schedule. Expenditures for other federal awards are recognized as incurred using the cost accounting principles contained in Uniform Guidance. Under these cost principles, certain types of expenses are not allowable or are limited as to reimbursement.

COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured (AL # 93.461) includes reimbursements for health care services rendered during the year ended August 31, 2021.

COVID-19 Provider Relief Fund (PRF) (AL # 93.498) includes reimbursements for lost revenues during the period from April 10, 2020 to June 30, 2020, based upon the PRF report that is required to be submitted to the HRSA reporting portal.

(3) Federal Loan Programs

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2021

the University obtains other assistance are the FDSLPL and revolving loan programs, such as the Federal Perkins Loan Program.

The loans advanced and related expenditures are as follows for the various student loan programs:

	<u>AL #</u>	<u>Amount</u>
Federal Direct Student Loan Programs:		
Student loans advanced:		
Subsidized Stafford Loan Program	84.268	\$ 6,529,824
Unsubsidized Stafford Loan Program	84.268	<u>77,950,130</u>
Total Direct Stafford Loan Program		84,479,954
Federal Direct PLUS Loan Program	84.268	<u>54,461,489</u>
Total Federal Direct Student Loan Programs		<u>\$ 138,941,443</u>

The Federal Perkins (Perkins) and Nurse Faculty and Student Loan Programs (Nursing) are administered directly by the University, and balances and transactions relating to these programs are included in the University's consolidated financial statements. The amounts presented on the Schedule include the Federal Perkins and Nurse Loans outstanding as of August 31, 2020. Perkins and Nursing loans outstanding at August 31, 2021 totaled \$4,788,817 and \$8,486,964, respectively. No Perkins loans were issued and \$299,228 Nursing loans were issued during the year ended August 31, 2021.

The University is responsible for the performance of certain administrative duties with respect to the FDSLPL. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2021. These loans are not included in the University's consolidated financial statements.

(4) Matching

Under the Federal Supplemental Educational Opportunity Grant Program, the University matched \$433,874 in funds awarded to students for the year ended August 31, 2021 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study Program, the University matched \$368,459 in total compensation to students for the year ended August 31, 2021 in addition to the federal share of expenditures included in the Schedule.

(5) Administrative Cost Allowance

The University recorded an administrative cost allowance of \$136,502 for the year ended August 31, 2021. This amount is included in the Schedule as federal expenditures under the Federal Work Study Program.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2021

(6) Indirect Costs

For the year ended August 31, 2021, the University did not elect to use the 10% de minimis indirect cost rate permitted by the Uniform Guidance.

UNIFORM GUIDANCE REPORTS



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Compliance For Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

The Board of Trustees
Emory University:

Report on Compliance for Each Major Federal Program

We have audited Emory University and its subsidiaries' (the University) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended August 31, 2021. The University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for the University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of the Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University's compliance with those requirements and performing such other procedures as we consider necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the University's major federal programs. However, our audit does not provide a legal determination of the University's compliance.

Opinion on Each Major Federal Program

In our opinion, Emory University and its subsidiaries complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2021.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance which is required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2021-001. Our opinion on each major federal program is not modified with respect to this matter.



The University's response to the noncompliance findings identified in our audit is described in the accompanying schedule of findings and questioned costs. The University is also responsible for preparing a corrective action plan to address each audit finding included in our auditors' report. The University's response and corrective action plan were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response or the corrective action plan.

Report on Internal Control Over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, we did identify a deficiency in internal control over compliance, described in the accompanying schedule of findings and questioned costs as item 2021-001, that we consider to be a significant deficiency.

The University's response to the internal control over compliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. The University is also responsible for preparing a corrective action plan to address each audit finding included in our auditors' report. The University's response and corrective action plan were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response or the corrective action plan.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

We have audited the consolidated financial statements of Emory University and its subsidiaries as of and for the year ended August 31, 2021, and have issued our report thereon dated December 20, 2021, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and the State of Georgia, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

KPMG LLP

Atlanta, Georgia
May 20, 2022

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2021

(1) Summary of Auditors' Results

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
 - Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (c) Noncompliance material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major program disclosed by the audit:
 - Material weaknesses: **No**
 - Significant deficiencies: **2021-001**
- (e) Type of auditors' report issued on compliance for major programs: **Unmodified**
- (f) Any audit findings, which are required to be reported under Section 2 CFR 200.516(a) of Uniform Guidance: **2021-001**
- (g) Major programs:
 - **Student Financial Assistance Cluster** – various AL numbers
 - **COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured** – AL# 93.461
 - **COVID-19 Provider Relief Fund** – AL# 93.498
 - **COVID-19 – Higher Education Emergency Relief Fund (HEERF) Student Aid Portion** AL# 84.425E and **HEERF Institutional Portion** AL# 84.325F
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee: **Yes**

(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with Government Auditing Standards

None

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2021

(3) Findings and Questioned Costs Relating to Federal Awards

Finding 2021-001: Eligibility

Federal Program

Student Financial Assistance Cluster (CFDA: 84.268)

Federal Agency

U.S. Department of Education

Federal Award Year

September 1, 2020 through August 31, 2021

Criteria or Requirement

The FSEOG program provides grants to eligible undergraduate students. Priority is given to Pell recipients who have the lowest expected family contributions. Federal funds are matched with institutional funds (34 CFR 676.21(a) and (c)). Certain minority-serving institutions may obtain a waiver of the matching requirement under 34 CFR 676.21(b). In addition to the requirements and limits, awards must be coordinated among the various programs and with other federal and nonfederal aid (need and non-need based aid) to ensure that total aid is not awarded in excess of the student's financial need or cost of attendance (34 CFR 668.42, FWS and FSEOG, 34 CFR 673.5 and 673.6; Direct Loan, 34 CFR 685.301). The maximum amount that can be awarded under the campus-based programs is equal to the student's financial need (COA minus EFC) minus aid from other SFA programs and other resources.

Per 2 CFR 200.303, the nonfederal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the nonfederal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award.

Condition Found, Including Perspective

1 student in a sample of 40 students was over awarded an FSEOG grant by \$1,032.

Possible Cause and Effect

The University has established certain automated controls for purposes of determining and packaging financial aid. The student was eligible for the FSEOG award at the time of award; however an institutional award was issued after initial packaging, which ultimately caused the over award (not captured in the EFC). Emory has a manual review over student accounts after the awarding period, which uses a quality assurance report highlighting trends and potential over awards. This review control was not operating with a level of precision to identify this over award.

Questioned Costs

Known questioned costs were \$1,032.

Statistical Validity

The sample was not intended to be, and was not, a statistically valid sample.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2021

Repeat Finding in the Prior Year

Not a repeat finding.

Recommendation

We recommend the University enhance the precision of the control around the review of its quality assurance reports to ensure compliance.

View of Responsible Officials

The quality assurance report is being modified to better identify problem payments, resulting in fewer potential hits to evaluate. Additionally, a three-stage review of the report is being implemented to ensure that any over-awards are corrected.